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Abstract 
Membrane transport proteins are the gatekeepers of the cell membrane, 
transporting compounds in and out of the cell. The organic anion transporting 
polypeptides (OATPs) are a family of transport proteins expressed in a variety 
of tissues, including absorptive / excretory cells of the liver and kidney. OATPs 
transport an array of endogenous and xenobiotic compounds including bile 
salts, thyroid hormones, stat ins and anti-cancer drugs. Therefore this protein 
family play an important role in cell homeostasis and drug disposition, and are 
I 
implicated in disease and drug-drug interactions. However there is little 
information available regarding the structural properties of OATPs, which 
would reveal how the proteins fold and bind to substrates. To help further this 
understanding, the topology and signature sequence of the hepatocyte specific 
isoform OA TP 1 B 1 have been investigated using a HEK293 T cell model. 
OA TP 1 B 1 was expressed in HEK293T cells and transport assayed using the 
substrate estrone-3-sulfate. Topology prediction programs were employed to 
map the transmembrane domains (TMs), which predicted a consensus of 
12TMs with internal amino (N) and carboxyl (C) termini. The topology was 
studied experimentally using a FLAG epitope system, whereby the FLAG 
epitope was inserted into the putative extracellular/intracellular and terminal 
regions of the protein. Detection of FLAG antibody binding was quantified by 
luminometry and visualised qualitatively using confocal microscopy. Results 
revealed that the predicted internal Nand C termini of the protein were 
external, in contrast to the predictions and current literature. A novel model has 
been generated from this data, encompassing these results and the current 
literature. 
All OATPs contain a conserved 13 amino acid signature sequence (D-X-RW-
(I,V)-GAWW-X-G-(F,L)-L) which spans the putative extracellular loop 3 and 
TM6, the function of which is not known. Six conservative mutations were 
made using site-directed mutagenesis; D251E, R253K, W254F, W258/259F 
and N261A. Kinetic, luminometric and immunofluorescence analysis revealed 
ii 
that all mutations except N261A reduced transport and expression on the 
membrane. The reduction in expression combined with the presence of 
structurally important arginine and tryptophan residues at the extracellular/TM 
interface indicate that this sequence may be important for membrane anchoring 
and/or protein folding. This knowledge of OA TP structure and function is 
imperative to the understanding the role of these proteins in the binding of 
endogenous and xenobiotic compounds. 
iii 
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1 Introduction 
1.1 Cell homeostasis and the plasma membrane 
The plasma membrane is essential for the homeostasis of all cells, by 
maintaining the integrity of the cell and its organelles. The membrane also 
protects the cell from the extracellular environment by allowing the selective 
movement of molecules (Alberts et al., 2002). These important features are 
I 
achieved by a dynamic membrane structure, comprising of an amphipathic fluid 
bilayer (Singer and Nicolson, 1972). The bilayer consists of two layers of 
phospholipids which have hydrophilic heads and hydrophobic tails (figure 1.1). 
This arrangement naturally maintains the membrane as the hydrophobic tails 
are attracted to one another and the hydrophilic heads attracted to the polar 
outside environments. The combination of glycoproteins, glycolipids, 
cholesterol and transmembrane proteins forms an organised communication 
network between the inside and the outside of the cell. 
Small molecules such as water and gases are able to diffuse across the 
membrane down a concentration gradient, without assistance from proteins or 
energy expenditure. However this process is slow and leads only to an 
equilibrium in concentration on either side of the membrane (Quastel, 1965). 
The transport process is therefore enhanced by a complex group of 
transmembrane proteins, known as transporters, which are responsible for the 
efficient and controlled transport oflarger, more lipophilic molecules across the 
bilayer. In fact 30% of all human genes code for membrane spanning proteins 
(Sciara and Mancia, 2012), indicating their diversity and prevalence in the 
genome. Some transmembrane proteins transport molecules simply by 
facilitating their diffusion, in a process that does not require energy. These 
passive or facilitated transporters transport solutes such as glucose and urea 
(Hediger et al., 2004). Other molecules may require A TP expenditure to drive 
the transport, often against the concentration gradient. This is known as primary 
active transport and is achieved by a combination of A TP-driven pumps and 
1 
channels. Transport can also be driven by electrochemical potential gradients 
such as Wand Na +, a process known as secondary active transport (Hediger et 
al., 2004). 
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Figure 1.1- Classical depiction of the cell membrane displaying the amphipathic phospholipid bilayer, containing cholesterol, 
transmembrane proteins and glycoproteins. 
Transmembrane proteins are classified into channel proteins, transporters and 
A TP-powered pumps (figure 1.2). Channel proteins are characterised as 
channels or pores with a hydrophobic or hydrophilic lining, to which water or 
ions may pass through rapidly (up to 108 per second). Transporters, however, 
undergo a conformational change, moving one molecule at a time, resulting in a 
slower movement of approximately 104 molecules per second (Lodish et al., 
2000). A TP-powered pumps utilise A TP hydrolysis to drive molecules against 
their concentration gradient. 
Transporters can function as uniporters; a single molecule transported down the 
concentration gradient, or as symporters; two or more moleculesJransported in 
the same direction, or as antiporters; exchange of one or more molecules for 
another (figure 1.2). Symporters and antiporters drive the molecule against the 
concentration gradient using various electrochemical gradients (Lodish et al., 
2000). 
1.2 Transport protein classification 
Transport proteins are classified by a transport classification (TC) system 
(Saier, 2000) similar to that of the enzyme classification (EC) system; however, 
unlike the EC system, the TC system is based upon both functional and 
phylogenetic information. This allows a classification based on many features, 
such as mechanism of transport, driving force and substrate specificities. The 
emergence of gene cloning combined with sequence analysis has revealed a 
number oftransporter families that were previously unidentified. Transporter 
information is now compiled into a web based Transporter Classification 
Database (TCDB) which contains over 400 transporter families (Saier et al., 
2006), also including transmembrane receptors such as the G-protein-coupled 
receptors. The Solute Carrier (SLC) superfamily contains the Organic Anion 
Transporting Polypeptides (OATPs) under the classification TC #2.A.60; TC2: 
Electrochemical potential driven transporters; A: Uniporters, symporters, 
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antiporters; 60: OATP-family. The driving force for OATP transport is, 
however, still under debate, as described in section 1.3.3. 
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Figure 1.2 - Depiction of channel proteins and transporters with different types 
of transport, including uniport, symport and antiport. 
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1.2.1 The solute carrier (SLC) superfamily 
The SLC superfamily contains a diverse collection of transporters which move 
"molecules across their electrochemical gradient, either by using energy from 
other ions or by diffusion" (Sreedharan et al., 2011). There are currently 55 
SLC families and more than 360 identified members (He et aI., 2009), 
comprising passive transporters, ion-coupled symporters and antiporters. The 
majority of SLC transporters are found in the cell membrane, however, there 
are some transporters present in organelle membrahes, including the SLC25 
mitochondrial transporter family (Palmieri, 2004) and the SLC18 vesicular 
amine transporter family (Eiden et al., 2004). The substrates transported are 
extremely diverse, including organic anions, cations, amino acids, 
oligopeptides, fatty acids, essential metals, hormones and vitamins, to name a 
few. This diversity ensures that a large number of endogenous compounds can 
be metabolised, along with many drugs, non-essential metals and environmental 
toxicants. The three main SLC families are the major facilitator superfamily 
(MFS), the amino acid-polyamine-organocation (APC) superfamily and the 
monovalent cation:proton antiporter/anion (CPA) transporter family. The MFS 
is one of the largest transporter families, encompassing single polypeptide 
secondary carriers (Pao et al., 1998). However, some MFS members also act as 
heteromers, requiring an accessory protein for complete function. For example 
members of the monocarboxylate (MCT) transporter family form heteromeric 
complexes with the plasma membrane glycoprotein CD147, facilitating MCT 
expression on the cell surface (Kirk et al., 2000). 
Transporter nomenclature is laid out by the Hugo Gene Nomenclature 
Committee (HGNC) (Seal et al., 2011). Families are grouped according to at . 
least 20% amino acid sequence identity (He et al., 2009). The root SLC is 
followed by a number representing the family, a letter representing the sub-
family and a number representing the isoform. The SLCa superfamily which 
codes for the OATPs is the only exception to this nomenclature system. The 
SLCa nomenclature stands for 'solute carrier organic anion transporter family,' 
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instead of SLC2l, as proposed by Hagenbuch and colleagues in 2004 
(Hagenbuch and Meier, 2004). This allows a species independent, 
evolutionarily divergent system with a numbering consistency. 
1.2.1.1 Uptake and efflux transporters ofthe SLC family 
The SLC family consists of both uptake and efflux proteins, i.e. transporters 
that transport into the cell and out of the cell, respectively. The uptake 
transporters for organic anions/cations include the SLCa family, SLC22 organic 
cation and organic anion transport families and the SLClO Na+ taurocholate 
family. These transporters are mainly located on the basolateral membrane of 
-
cells and transport substrates from the blood into the cell. As mentioned 
previously the SLCa family is grouped based on amino acid similarity. 
However the SLC22 family is grouped according to the substrate transported. In 
this way, the SLC22Al-3isoforms transport organic cations, whereas the 
SLC22A4-6 isoforms transport organic anions. The SLClO family in contrast is 
more varied; encompassing bile acid transporters such as the Na + taurocholate 
cotransporting polypeptide (NTCP) and also the sodium dependent organic 
anion transporter (SOAT) which transports steroid sulphates (Wu et al., 2009). 
Efflux proteins are also present in the SLC superfamily, such as the SLC30 zinc 
efflux transporters. This family transport zinc out of the cell and into 
intracellular compartments (Palmiter and Huang, 2004). Similarly, SLC38A3 is 
involved in the efflux of glutamine in the liver, kidney and brain (Wendel et al., 
·2008). An important example of uptake and efflux proteins working in unison 
to regulate substrate transport and maintain homeostasis is that of the 
hepatobiliary system; the regulation of bile salt transport, described in section 
1.5.1. 
1.3 The OATP superfamily 
Oatplal (Slcolal), the first Oatp cloned, was isolated from rat liver in 1994 
(Jacquemin et aI., 1994) and now more than 160 proteins have been predicted 
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in 25 species (Hagenbuch, 20 I 0). Mammalian OATPs with identities greater 
than 40% are classified into families (e.g. OATPI-6) and those with greater 
than 60% similarity are grouped into subfamilies (e.g. OATPIA) (Hagenbuch 
and Meier, 2004). Human OATPs are depicted with upper case letters, animal 
Oatps with lower case letters; however, they will be collectively referred to here 
as OATPs. Human and mouse/rat orthologues are not exact, as amino acid 
identities vary from 60-75% and tissue distribution and transport features can 
differ. It is thought that OA TP homologues probably emerged through gene 
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duplication on divergence from a common ancestor (Pizzagalli et al., 2002). 
This variation makes it difficult to examine cross species extrapolations and 
predict hepatic clearance. 
The phylogenetic relationship between mouse, rat, bovine, dog and human 
OATPs is shown in figure 1.3. OATPs have not been located in plants, fungi or 
bacteria, indicating their evolution after the formation of the animal kingdom. 
However the OA TPs are evolutionarily ancient, as an Oatp was identified in the 
liver of an ancient vertebrate, the small skate Raja erinacea (Cai et al., 2002a). 
The following sections in this chapter serve to introduce the current knowledge 
relating to the structure, function and regulation of OA TPs, as well as their role 
in disease and drug transport. 
1.3.1 The human OATPs 
1.3.1.1 Tissue distribution 
There are II human OATP members divided into 6 subfamilies (Obaidat et al., 
2012), as shown in table 1.1. The OA TP I group is the largest and best 
characterised, containing the subfamilies OATPIA, OATPIB and OATPIC. 
OATPIA2 is expressed in many tissues and transports a large range of 
substrates, which along with the liver specific expression ofOATPIBI and 
OATPIB3, suggests a role for OATPI in general detoxification. The other 
families have narrower substrate specificities; for example OA TP I C and 
OATP4A transport thyroid hormone (Hagenbuch, 2007) and OA TP2A 
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transports prostaglandins (Nomura et al., 2004). The least functional 
information is available for OATP5Al and OATP6Al. OATPIA2, OATPIBl, 
OATP I B3 and OA TP2B 1 are discussed in more detail in the following sections 
as they are the best characterised and most influential to drug interactions and 
disease. 
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OATP1B1 
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Figure 1.3 - Phylogenetic relationship between mouse (m), rat (r), bovine (b), 
dog (d) and human OATPs. Human hepatic OATPs are highlighted in red. 
Reproduced and adapted with permission of Elsevier Limited (Appendix VI) . 
(Geyer et at., 2004). 
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Table 1.1 - The six human OATP families and subfamilies with each member 
and tissue distribution 
Family Sub-family Members Tissue distribution Reference 
OATPI OATPIA OATPIA2 Ubiquitous (Kullak-Ublick 
et al., 1995) 
OATPIB OATP1Bl Liver specific (Hsiang et al., 
1999) 
OATPIB3 Liver specific (Konig et al., 
2000a) 
OATPIC OATPICI Brain, testis, ciliary (Gao etal., 
body epithelium 2005; Pizzagalli 
et al., 2002) 
OATP2 OATP2A OATP2Al Ubiquitous (Schuster, 1998) 
OATP2B OATP2Bl Ubiquitous (Kullak-Ublick 
et-al., 2001) 
OATP3 OATP3 OATP3Al Testes, brain, (Adachi et aI., 
heart, lung, spleen, 2003) 
peripheral blood 
leukocytes, thyroid 
gland 
OATP4 OATP4A OATP4Al Heart, placenta, (Fujiwara et al., 
lung, liver, skeletal 2001; 
muscle, kidney and Hagenbuch, 
pancreas 2007) 
OATP4C OATP4Cl Kidney-specific (Mikkaichi et 
al., 2004; 
Yamaguchi et 
al., 2010) 
OATP5 OATP5A OATP5Al Breast, fetal brain, (Bleasby et al., 
prostate, skeletal 2006; Kindla et 
muscle and thymus al., 2011 b) 
OATP6 OATP6A OATP6Al Testes, spleen, brain, (Lee et al., 
fetal brain and 2004; Obaidat et 
placenta al., 2012; 
Suzuki et al., 
2003) 
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1.3.1.2 OATPIA2 
OATPIA2 (SLCOlA2, previously OATP, OATP-A, OATPI, SLC2lA3) was 
the first human OATP to be cloned and consists of 670 amino acids (Kullak-
Ublick et al., 1995). The protein shares 67% and 81.7% amino acid identity 
with rat Oatplal and bovine Oatpla2 respectively. The gene SLCOlA2 is 
located on chromosome 12p12, along with OATPIB1, OATPIB3 and 
OATPICI (Pizzagalli et al., 2002). 
OATP 1 A2 is considered ubiquitous (Franke et aI., 2009), however, expression 
is established primarily on apical membranes in the liver, kidney, intestine, 
lung, testes and blood-brain barrier (Hagenbuch and Gui, 2008). The highest 
expression has been detected in the brain capillary endothelial cells and 
microvessels (Gao et al., 2000), suggesting an important role for the penetration 
of therapeutic drugs. In the kidney OATPIA2 is located in the distal tubule 
where it is most likely involved in the re-absorption of compounds (Lee et al., 
2005). Similarly the protein has a role in absorption from the duodenum, where 
it is co-localised with the A TP-binding cassette (ABC) efflux transporter 
ABCB I, at the apical membrane of villi (G laeser et al., 2007). In the liver 
OA TP 1 A2 is expressed in cholangiocytes, forming part of the hepatobiliary 
system. 
OATPIA2 transports the largest array of structurally diverse compounds 
including bile salts, steroid hormones, neutral and anionic peptides (van 
Montfoort et aI., 1999). It is also unique in the transport of bulky cations such 
as N-methylquinine (Kullak-Ublick et al., 2001). This diversity combined with 
the location within excretory organs such as the liver and kidney suggest a 
general role in drug disposition and clearance. 
1.3.1.3 OATPIBI 
OATPIBI (SLCOlBl, previously OATP2, OATP-C, LST-l, SLC2lA6) is 
specific to the basolateral membrane of hepatocytes, where it mediates uptake 
of a number of amphipathic compounds from portal blood (Hsiang et al., 1999). 
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OATPIBI consists of691 amino acids (Hsiang et al., 1999) and shares 64% 
amino acid identity with mouse and rat Oatp I b2, which are also expressed only 
on the hepatocyte basolateral membrane (Chen et al., 2008). OATPIBI is the 
main basolateral bile salt transporter but also transports bilirubin, hormones, 
cyclic and linear peptides, toxins and many drugs. Such drugs include 
antibiotics, statins and anti-cancer drugs. The localisation of OA TP I B I within 
the liver, combined with the transport of a range ofxenobiotic compounds, 
indicates a pivotal role in drug transport. Furthermore, a number of drug 
interactions have been associated with the transporter, particularly involving 
statins. This is further complicated by a number of single nucleotide 
polymorphisms (SNPs) which have also been associated with drug toxicity 
(discussed further in section 1.5). 
1.3.1.4 OATPIB3 
OATPIB3 (SLC01B3, previously OATP8, LST-2, SLC21A8) is a 702 amino 
acid protein, also specific to the basolateral membrane of hepatocytes and 
shares an 80% amino acid identity with OATPIBI (Konig et al., 2000b). In 
addition, OA TP I B3 shares 66% amino acid identity with rat Oatp I b2, also 
localised to the hepatocyte basolateral membrane (Meier-Abt et al., 2004). 
The transport of amphipathic compounds by OA TP 1 B3 is comparable to that of 
OATP I B I, while transporting bile salts and bilirubin to a lesser extent. 
OA TP I B3 has a broad overlapping substrate specificity with OA TP I B I, 
including the compounds phalloidin, valsartan and thyroxine (Hagenbuch and 
Gui, 2008). However in contrast to OATPIBI, OATPIB3 transports the 
intestinal peptide cholecystokinin octapeptide (CCK-8) (Letschert et al., 2005) 
and the opioid peptide deltorphin II (Kullak-Ublick et al., 2001). Transport of 
digoxin by OA TP 1 B3 is controversial. Some groups have reported digoxin 
transport (Kullak-Ublick et al., 2001; Reitman et al., 2011) but others do not 
detect OATPIB3 mediated transport (Kimoto et al., 2011; Taub et al., 2011). 
Neither OATPIBI nor OATPIB3 have so far demonstrated transport of organic 
cations. As well as having an important role in drug detoxification, OATPIB3 
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is up-regulated in many cancer cells, suggesting a role in cancer pathogenesis 
(section 1.4.2). 
1.3.1.5 OATP2Bl 
OATP2B1 (SLC02EJ, previously OATP-B, SLC2JA9) also consists of 702 
amino acids with rat Oatp2b I as the closest orthologue, containing 77% amino 
acid identity (St-Pierre et at., 2004). Unlike OATP1A2, OATP1BI, and 
t 
OATP1B3; OATP2BI is located on chromosome 11q13 (AI Sarakbi et at., 
2006). 
The highest expression ofOATP2BI is on the hepatocyte basolateral 
membrane, situated alongside OATPIBI and OATPIB3. However, expression 
is also detected in spleen, placenta, kidney, ovary, lung, heart, small intestine 
and brain (Kullak-Ublick et at., 2001). In relation to the other hepatocyte 
basolateral transporters, this protein has comparatively narrow substrate 
specificity; transport has only been shown for estrone-3-sulfate (E3S), 
bromosulfophthalein (BSP) and dehydroepiandrosterone sulphate (DHEAS) at 
pH 7.4. However it transports a number of additional substrates including 
taurocholate, statins and fexofenadine at acid pH (Hagenbuch and Gui, 2008). 
This suggests that pH affects the substrate and/or function of the protein, which 
is particularly relevant in the intestine where the local environment is around 
pH 6 (Fallingborg, 1999). 
The broad distribution of this protein throughout the body suggests that 
OA TP2B I may have an important role in the general absorption and 
distribution of compounds. 
1.3.2 OATP substrate specificity 
The OATPs transport a wide range of solutes, both endogenous and xenobiotic. 
OATP substrates are generally amphipathic molecules with molecular weights 
greater than 350 Daltons (Roth et at., 2011). The broad range includes bile 
acids, conjugated steroids, 
15 
thyroid hormones, linear and cyclic peptides, toxins as well as numerous drugs, 
including statins, sartans, antibiotics and anti-cancer drugs. Generally solutes 
are negatively charged, however some are neutral (digoxin) and even cationic 
(N-methylquinine) (Obaidat et al., 2012). In addition, many solutes are 
substrates for several OATPs, such as E3S and estradiol-17~-glucuronide 
(El7~G) which are often used as model substrates. However, other substrates 
are unique to a single transporter, such as CCK8, which is specific to 
OATPIB3 (Ism air et al., 2001). The transport of wide ranging endogenous and 
xenobiotic compounds indicates a pivotal role for OATPs in homeostasis and 
drug disposition. 
1.3.3 OA TP mechanism of transport 
OA TP transport has been established as chloride, sodium, potassium and A TP-
independent (Roth et al., 2011); however, the exact driving mechanism is still 
under debate. A central pore to which substrates physically translocate in a 
rocker-switch mechanism has been proposed (Meier-Abt et al., 2005) and is 
discussed further in section 1.3.4. 
OATPs transport bidirectionally and several studies have suggested that 
transport may occur via electroneutral exchange; whereby the uptake of organic 
anions is coupled to efflux. There is evidence for bicarbonate exchange in rat 
Oatplal, Oatpla4 and OATPIA2, OATPIB3, OATP2BI and OATP3AI 
(Leuthold et al., 2009; Satlin et al., 1997). However glutathione exchange was 
also shown for rat Oatp 1 a 1 and Oatp 1 a4 (Li et al., 1998). In addition, 
OATPIBI is not affected by bicarbonate (Leuthold et al., 2009) and both 
OA TP 1 Bland OA TP 1 B3 are not affected by glutathione (Mahagita et al., 
2007), suggesting that another mechanism is driving transport. This evidence is 
further supported by the amino acid identity the OA TPs share with the MFS; a 
transport family which use an ion gradient to drive transport (Pao et aI., 1998) 
(see section 1.3.4). 
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The pH can also affect OATP mediated transport. Studies have revealed that 
many rat and human OA TPs show increased transport activity when exposed to 
an acidic pH (Leuthold et at., 2009). This is particularly interesting for 
OATP2Bl, which is expressed in the small intestine, an organ that maintains a 
lower pH than other areas of the body. This may allow selectively increased 
transport of substrates and most likely affect drug absorption. Furthermore, the 
transport of some substrates is increased more than others when the pH is 
decreased (Nozawa et at., 2004a). The increased transport is caused by the 
I 
protonation of a conserved histidine residue at the extracellular end of 
transmembrane domain (TM) 3. This was shown in OATPIC1, an isoform 
which does not contain the histidine residue and is not pH dependent (Leuthold 
et at., 2009), as mutating the corresponding residue to histidine restored the pH 
dependency. 
Increasing the extracellular proton concentration will cause an outward driven 
flow of bicarbonate by its conversion into water and CO2, thus in tum possibly 
causing increased bicarbonate exchange. This may be the cause of the increased 
transport in acidic conditions. The effect of pH was further demonstrated by 
Martinez-Becerra and colleagues, who recently revealed that OATPIBI and 
OATPIB3 are electrogenic (Martinez-Becerra et at., 2011). The group used 
ionophores to assess changes in membrane potential. This is the first evidence 
of its kind to show that OA TPs are affected by membrane potential and may 
function via a proton pump. The group also confirmed that Oatplal is not 
affected by membrane potential, therefore supporting the evidence that it is an 
electroneutral exchanger. 
The current evidence for the driving force for OA TPs is not clear and it is likely 
that different mechanisms are involved for different transporters. Further 
studies are required to confirm the electrogenicity of OA TP 1 Bland OA TP 1 B3 
and other human isoforms. However it is likely that pH is somehow involved in 
the facilitation of substrate transport, possibly through the induction of a 
conformational change or as a driving force for protons or bicarbonate efflux. 
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1.3.4 OATP protein structure 
There is little high resolution structural knowledge of OATPs owing to the 
difficulties in purifying and crystallising transmembrane proteins. As a result, 
only 70 high resolution membrane protein structures exist compared to 
thousands of soluble protein structures (Nam et al., 2009). As an alternative, 
protein structure predictions are made using homology modelling and 
hydrophobicity analyses, which provide a theoretical framework for 
experimental determination. 
OATPs consist of 643-722 amino acids (Hagenbuch and Meier, 2004) and the 
majority expressed on plasma membranes of epithelial cells, however some 
OATPs are also expressed in T-lymphocytes (Janneh et al., 2008). There is 
currently no crystal structure, and in silico modelling has revealed a putative 
topology of 12TMs with amino (N) and carboxyl (C) termini facing the 
cytoplasmic space (figure 1.4) (Hagenbuch and Meier, 2004; Hanggi etal., 
2006; Noe et al., 1997; Roth et al., 2011). However, the 12TM topology has 
only been studied in rat Oatplal (Wang et al., 2008) and the orientation of the 
Nand C termini was not determined. The predictions are consistent with the 
notion that the OA TPs are related to the MFS, which mainly have 12TMs. 
Evolutionary conservation has been shown between rat Oatp I c 1 and the MFS 
(Westholm et al., 2010) and OATP and MFS protein sequences share high 
sequence identity when compared using the protein domain database Prosite 
(Sigrist et al., 2010) (data not shown). 
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Figure 1.4 - Model of an OATP displaying the putative 12TM topology. The 
signature region (highlighted in grey) is at extracellular loop 3 and TM domain 
6. N-glycosylation sites are indicated with a Y (Leuthold et al., 2009) 
(Copyright permission not required, see Appendix VI). 
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The OATPs are characterised by a signature region (D-X-RW-(l,V)-GAWW-
XG-(F,L)-L) located at the border between extracellular loop 3 and TM6 (figure 
1.4) which is conserved across all species (Hagenbuch and Meier, 2004). Of 
particular interest are three unusual conserved tryptophans; tryptophan residues 
are rare in proteins, with only 2-3 residues often observed across an entire 
sequence (Samanta et al., 2000). It is not known whether this sequence is 
required for functioning or membrane localisation. 
The large extracellular loop 5 of OATP2B 1 contains ten cysteine residues 
linked by disulphide bonds, found to be essential for OA TP2B 1 targeting to the 
cell surface (Hanggi et al. 2006). Mutations of just one residue resulted in the 
protein being retained intracellularly. These cysteine residues are conserved 
across many OATPs. Furthermore, the loop may not be positive (Meier-Abt et 
aI., 2005), suggesting a structural rather than substrate binding role. A 
homology has also been detected between this loop 5 and the kazal-2-type 
serine protease inhibitors, the role for which has not been elucidated. In fact, 
this homology was observed in 115 different OATPs (Barabote et al., 2006). 
Remarkably, the OA TPs are the only transmembrane proteins to show this 
homology (Svoboda et al., 2011a). In humans, the kazal-type serine protease 
inhibitors are involved in many physiological processes such as inflammation 
and development, by regulating proteinase activity (Zheng et al., 2006). 
G Iycosylation sites have been predicted for several rat and human OATPs, in 
extracellular loops 2 and 5 (figure 1.4). However, the sites have only been 
experimentally analysed in Oatp lal (Lee et al., 2003; Wang et al., 2008) and 
OATP1Bl (Yao et al., 2012). Oatp1al also contains a PDZ sequence (Wang et 
al., 2005a); a sequence known to interact with PDZ binding domain proteins. 
The 'PDZ' stands for the first letters of three proteins originally found to share 
the common structural domain (PSD95, Dlgl and zo-I). Proteins containing the 
domains are known to interact with the C-terminal of transmembrane proteins, 
ensuring their localisation at the cell surface (Brone and Eggermont, 2005). 
However, not all OATPs contain a PDZ sequence and thus must use a different 
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mechanism for membrane localisation. Phosphorylation sites have also been 
detected in Oatplal, suggesting a possible mechanism for trafficking to the cell 
surface (Choi et al., 2011). The role of glycosylation, membrane targeting and 
phosphorylation are further discussed in section 1.3.5. 
The amino acids in various TMs are important for targeting to the cell 
membrane and substrate transport. In a comparison of mouse, rat and human 
OATPs, TMs 1-6 and 11 showed the most amino acid conservation (50-70%) 
(Cai et al., 2002b). Four amino acids in TM2 ofoATPIBI when substituted, 
impaired the transport ofE3S (Li et aI., 2012). More specifically, E74 may be 
involved in stabilising the protein through a salt bridge, and 070 is important 
for substrate recognition. Removing the charge from both amino acids also 
affected substrate transport, indicating that the charge is important for attracting 
anionic substrates to the protein. TMs 8 and 9 ofOATPIBl are also involved in 
E3S transport; as when substituted the membrane targeting was not affected, 
but transport kinetics were altered (Miyagawa et al., 2009). Similar 
mutagenesis ofOATPIBl TMI0 showed that four amino acids present in the 
domain are required for E3S transport, and substitution completely abolished 
function (Gui and Hagenbuch, 2009). DeGorter and colleagues went further to 
identify three amino acids in TMl, TMI0 and extracellular loop 6 which are 
specific to the transport ofCCK-8 by OATPIB3 (OeGorter et al., 2012). This 
was shown by introducing the amino acids into OATPIB1, a transporter not 
previously capable of transporting CCK-8. Gui and colleagues also isolated 
amino acids in TMI0 important for OATPIB3 mediated CCK-8 transport (Gui 
and Hagenbuch, 2008). Molecular modelling suggested that these amino acids 
form hydrogen bonds with the substrate. 
It is clear that residues within certain TMs are essential for substrate transport. 
The layout of the TMs to form the tertiary structure was studied by Meier-Abt 
and colleagues, who put forward a model based on an alignment with the E.coli 
MFS proteins glycerol-3-phosphate and lactose permease (Meier-Abt et al., 
2005). The model, based on OATPIB3, revealed the protein to have a positive 
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electrostatic pore or 'binding pocket' formed by TMs 1,2,4,5, 7, 8, 10 and 11 
(figure 1.5). Charged residues were also identified and predicted to be involved 
in substrate interactions. The presence of a positive pore indicates a mechanism 
for facilitating the translocation of anionic compounds. A similar model with a 
putative pore was demonstrated for OATPICI, also through MFS comparison 
(Westholm et al., 2010). The positive residues predicted to be substrate exposed 
in this model have been studied by several groups. Amino acids R57, K361 and 
R580 are conserved within the OATPI family and are solvent exposed within 
the pore. Mutation of these residues in OA TP 1 B 1 affected surface expression 
and transport kinetics (Weaver and Hagenbuch, 2010). Comparative results 
were seen with the mutation of R580 in OA TP 1 B3 (Glaeser et al., 2010). Gui 
and colleagues also predicted L545 in TM 10 of OA TP 1 B 1 to be substrate 
exposed, through helical wheel modelling (Gui and Hagenbuch, 2009). 
Substitution of this amino acid reduced transport function, suggesting that it is 
involved in substrate interaction. 
OA TPs are able to transport a wide range of chemical structures, which may be 
explained by the presence of multiple binding sites. Several groups have 
reported through the observation ofbiphasic kinetics, the presence of two E3S 
binding sites in OATPIBI (Gui and Hagenbuch, 2009; Noe et al., 2007; 
Sharma et al., 2012). Atypical kinetics have also been shown for rat Oatplcl 
(Westholm et al., 2009a) and OATP2BI (Shirasaka et al., 2012), suggesting 
mUltiple binding sites. The presence of multiple binding sites in OATPs of 
different subfamilies suggests that this may be an inherent property of OA TPs. 
However the evidence is varying, as not all groups report biphasic properties. 
The presence of mUltiple binding sites is not unusual, as they have been found 
in other multispecific transporters, including Pgp (Aller et al., 2009). This 
property, however, complicates drug disposition experiments; as a drug may 
inhibit one binding site but not another. 
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Figure 1.5 - Predicted tertiary structure ofOATPlB3. TMs depicted as multi-
coloured cylinders, extracellular loop 5 in magenta, black dotted lines depict 
other extracellular loops. Red bars represent disulphide bonds modelled on the 
kazal-2-type serine protease inhibitors. Cyan circles depict modelled cysteine 
residues. Reproduced with permission of Springer Science + Business Media 
(Appendix VI) (Meier-Abt et ai., 2005). 
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1.3.5 OATP regulation 
OATP expression and function is tightly regulated by a complex network of 
transcription factors, cytokines and post-translational modifications. These 
regulate levels of expression and targeting of the protein to the membrane. 
Other factors can also indirectly affect regulation, including hormones, disease 
and xenobiotics. For example, sex steroid ho~ones are known to regulate the 
expression of mouse Oatps such as Oatp4cl, leading to gender specific 
expression patterns (Cheng and Klaassen, 2009). Disease is also known to 
affect expression, as shown by down-regulation ofOATPIBI, OATPIB3 and 
OATP2BI mRNA levels in hepatitis C patients (Ogasawara et al., 2010). 
Therefore many factors and pathways influence OATP expression: The known 
transcriptional and post-translational regulation pathways are briefly discussed 
here. 
1.3.5.1 Transcriptional regulation 
Transcriptional regulation of OA TPs allows protein expression to be adapted in 
response to the surrounding environment. OATPs have been associated with the 
cytokines and transcription factors; interferon-gamma (IFN-y), interleukin-I-
beta (11-1 P), interleukin-6 (11-6), tumour necrosis factor alpha (TNF -a), 
hepatocyte nuclear factor-Ia (HNF-Ia), aryl hydrocarbon receptor (AhR), 
constitutive androstane receptor (CAR) and the farnesoid-X-receptor (FXR) 
(Svoboda et al., 201Ia). 
The liver is under particular control by the hepatocyte nuclear factors (HNFs). 
OATPIBI and IB3 are under direct control by HNF-Ia; a transcription 
initiation site was located eight nucleotides upstream from the start of the 
OATPIBI sequence (Jung et al., 2001). Furthermore, mutation of this site 
hinders OA TP I B I promoter activity, indicating that it is required for 
expression. Additionally, unconjugated hyperbilirubinaemia may be caused by 
reduction in HNFla activity, leading to a reduction in OATPIBI levels (Jung 
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et at., 2001). Interestingly OATPIA2, which is expressed in liver 
cholangiocytes, does not contain an initiation site for HNFla, suggesting that 
this factor is involved only in hepatocyte specific regulation. 
OA TP expression can also be initiated by xenobiotics that are known ligand 
activators, as an important inductive response. Rifampicin is a ligand for the 
pregnane-X-receptor (PXR) and in the presence of rifampicin OATPIBI 
expression is increased, suggesting that PXR affects SLCOlBl gene expression 
I 
(Gui et at., 2008). FXR is also implicated in hepatic OATP regulation through 
bile acid activation. For example, SLCOlB3 is transactivated by FXR, causing 
an up-regulation in OATPIB3 (Eloranta and Kullak-Ublick, 2008). This may 
serve to ensure sufficient removal of endogenous and xenobiotic compounds, 
leading to decreased expression of other overlapping basolateral OATPs, such 
as OATPIBI and OATP2Bl. 
1.3.5.2 Post-translational regulation 
Post-translational regulation involving phosphorylation, glycosylation and 
protein-protein interactions ensures the correct targeting of transporters to the 
membrane. Protein phosphorylation is proposed to playa role in the targeting of 
OATP protein to the cell surface. Studies with rat Oatplal have shown that the 
protein undergoes serine phosphorylation at S634 and S635 in the presence of 
extracellular A TP (Glavy et at., 2000). This phosphorylation regulates the 
translocation ofthe protein between the plasma membrane and the intracellular 
vesicles, as mutation of the serines results in retention of the protein 
intracellularly (Choi et at., 2011). 
Protein kinase pathways allow for rapid regulation of OA TP expression on the 
membrane. Rat Oatplal (Guo and Klaassen, 2001), Oatpla4 (Guo and 
Klaassen, 2001) OATPIA2 (Zhou et aI., 2011) and OATP2Bl (Kock et at., 
2010) are all controlled by protein kinase C (PKC). Down-regulation of the 
OATP protein by intemalisation from the plasma membrane into endosomes is 
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induced by activation of PKC, in a clathrin-dependent process. The protein is 
then subjected to lysosomal degradation. OA TP2B 1 internalisation was further 
confirmed in an ex vivo placenta perfusion (Kock et al., 2010). In contrast, 
protein kinase A (PKA) controls the membrane trafficking ofOATPIBI 
through the Golgi complex and the vacuolar H+ -A TPase vesicle mediated 
membrane sorting pathway, to ensure plasma membrane localisation (Sun et al., 
2008a). 
The correct protein folding and localisation of OA TPs is also regulated by N-
glycosylation. N-Iinked glycosylation occurs at asparagines present in the 
following consensus sequence: Asn-Xaa-ThrISer, whereby Xaa can be any 
amino acid apart from proline or aspartic acid (Medzihradszky, 20(8). OA TPs 
are characterised by putative N-glycosylation sites at extracellular loops 2 and 
5, which are conserved across most species (section 1.3.4). In rat Oatplal, 
function and membrane targeting are affected by the level of glycosylation (Lee 
et al., 2003). These Oatplal glycosylation sites were identified as N124, Nl35 
and N492 (Lee et al., 2003; Wang et al., 2008). Absence of glycosylation in 
OATPIA2 also affects plasma membrane localisation (Lee et aI., 2005). 
Furthermore, glycosylation experiments with OATPIBI (Konig et al., 2000b), 
OATPIB3 (Konig et al., 2000a) and OATP2BI (Hanggi et aI., 2006) confirmed 
that all are glycosylated, and OATPIBI sites have recently been identified as 
Nl34, N503 and N516 (Yao et al., 2012). In addition, mutation in one of the 
three sites in OATP2B I impairs transport function (Hanggi et al., 2006). 
The correct functioning of the OATPs also relies on the accurate binding of the 
protein within the plasma membrane. Members of PDZ domain containing 
proteins have been shown to regulate plasma membrane anchoring and 
modulate function. Several human, rat and mouse OA TPs possess a C-terminal 
PDZ consensus sequence, and it has been demonstrated in rat Oatplal that 
binding to PDZKI is essential for plasma membrane localisation (Wang et al., 
2005a). PDZ proteins also interact directly with the C-termini of several human 
OATPs (table 1.2), however, whether the same mechanism is used for other 
OA TPs that do not contain PDZ consensus sequences is yet to be elucidated. 
26 
Table 1.2 - Human OA TPs known to contain a C-terminal PDZ sequence 
OATP C-terminal PDZ Reference 
amino acid sequence 
OATPIA2 KTKL (Obaidat et al., 2012) 
OATPICI ETQL (Kato et al., 2004) 
OATP2Bl DSRV (Wang et aI., 2005a) 
OATP3Al vI ESVL (Kato et al., 2004) 
1.4 OATPs and disease 
OA TPs are vital for cell homeostasis, and thus it might be expected that disease 
would result from mutations disrupting their activity. Until very recently, 
however, there was no direct link between OA TP impairment and disease, but a 
mutation in SLC02AI (OATP2Al) has been linked to the genetic disease 
primary hypertrophic osteoarthropathy (Zhang et al., 2012). The mutation 
inhibits OA TP2A 1 mediated prostaglandin E2 transport, causing the rare bone 
disease. OA TPs could be the cause of, or be affected by disease. For example 
inflammation caused by disease is linked to transporter impairment, as seen by 
the reduction ofOatp4al gene expression in adjuvant arthritis (Hanafy et al., 
2012). This is most likely caused by dysregulation. The main OATP linked 
diseases are hyperbilirubinaemia and cholestasis, which will be discussed in the 
following sections, as well as the role ofOATPs during cancer pathogenesis. 
1.4.1 Cholestasis and hyperbilirubinaemia 
OATPIBI and OATPIB3 are the major hepatocyte basolateral transporters for 
bile (see section 1.5.1 for the role ofOATPs in the hepatobiliary system), and 
deficiencies in these OATPs are the cause of hyper bilirubinaemia and 
cholestasis. 
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Cholestasis is characterised by a reduction of bile flow and subsequent 
accumulation in hepatocytes, which eventually leads to cirrhosis and liver 
failure. This can be caused by an obstruction of bile flow or lack of secretion 
from hepatocytes and cholangiocytes (Paumgartner and Pusl, 2008). OATP 
transporter down-regulation is likely to be one of the causes of cholestasis. This 
was shown by a decrease in OATPIA2 and OATPIB3 expression during 
intrahepatic cholestasis of pregnancy (Wang et af., 2012). This was also 
observed in rat Oatplal, which shares 67% amino acid identity with 
OA TP 1 A2. The down-regulation of one transporter can also affect another, as 
observed in patients with primary sclerosing cholangitis. Patients with this 
disease have both down-regulation of OA TP 1 Bland the ABC tran~porter 
multidrug resistance-associated protein 2 (MRP2). Down-regulation of 
OA TP 1 B 1 is caused by the impaired canalicular transport by MRP2, as a 
mechanism to reduce the transport of more organic anions into the hepatocyte 
(Oswald et af., 2001). This highlights the complex relationship between 
transporters and the importance of their regulation. 
Un-conjugated bilirubin is transported into the hepatocyte by OATPIBI and 
OATPIB3 where it is conjugated to make it soluble. Failure to transport 
bilirubin causes hyperbilirubinaemia, a build-up of bilirubin in the blood, 
leading to diseases such as jaundice. Mutations in OA TP 1 Bland OA TP 1 B3 
are the cause of human rotor syndrome, a genetically inherited 
hyperbilirubinaemia (van de Steeg et af., 2012). SNPs in SLCOIB3 similarly 
cause hyperbilirubinaemia, through the impairment of OA TP 1 B3 function 
(Sanna et af., 2009). Drug induced hyperbilirubinaemia is also caused through 
the inhibition ofOATPIB1, for example by indinavir, saquinavir, rifamycin 
and/or cyclosporine A (Campbell et al., 2004). It is likely this inhibition is also 
enhanced by the saquinavir and indinavir mediated inhibition ofUDP 
glucuronosyltransferases (UGTs) (Zhang et af., 2005). The UGTs are enzymes 
which catalyse the glucuronidation of bilirubin as part of the bilirubin 
elimination process, and thus inhibition causes bilirubin retention. 
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This evidence suggests a pivotal role ofOATPIBI and OATPIB3 in bilirubin 
transport and understanding their function may aid in understanding the 
pathogenesis resulting from transporter impairment. 
1.4.2 Cancer 
It is likely that OATPs playa role in, or are affected by cancer. The expression 
patterns of OA TPs are altered in cancer tissue and expression can be up-
regulated or down-regulated, as shown in table 1.3. Therefore transporters are 
expressed in cancer tissues that would not normally be associated with the 
transporter. This suggests a potential role for transporters maintaining or acting 
against cancerous tissues, possibly through a selective pressure in relation to 
drug resistance. However, there is stilllittIe evidence as to how OA TP 
regulation is linked to cancer. It is speculated that altered post-translational 
regulation is involved, as increased cytoplasmic staining ofOATPIA2 has been 
observed in breast cancer cells (Obaidat et at., 2012). It is also speculated that 
the down-regulation ofOATPIB3 in hepatocellular carcinoma is caused by 
hepatocyte nuclear factor-3p (HNF-3P), which is up-regulated (Vavricka et at., 
2004). 
Transporters may also adversely facilitate hormone dependent cancers, by 
transporting hormone precursors to cancerous tissue. For example OATPIA2 
and OA TP 1 B3 are over expressed in breast cancer tissues and transport the 
estrogen precursor E3S, which is required by the estrogen dependent cancer. 
OATPIB3 is particularly prominent, as it is normally liver specific, but is 
expressed in many cancer tissues (table 1.3). A new cancer specific OATPIB3 
mRNA isoform has even been identified; which contains a different 
transcription start site and an alternative promoter in intron 2 (Nagai et at., 
2012). OATPIB3 transports several anti-cancer drugs including methotrexate 
(Abe et at., 2001), and by further understanding transport by this cancer 
isoform, cancers may be better targeted with chemotherapeutics. 
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Table 1.3 - OATP expression patterns and regulation during cancer 
OATP Cancer tissue Up-regulated (t) Reference 
or down-regulated 
(1) 
OATPIA2 Prostate i (Arakawa et al., 2012) 
Pancreas i (Kounnis et aI., 2011) 
Breast i (Meyerzu Schwabedissen et al., 
2008) 
Bone i (Liedauer et al., 2009) 
OATPIBI Pancreas t (Kounnis et al., 2011) 
Liver ~ (Pressler et al., 2011) 
Colon i (Pressler et al., 2011) 
Ovarian i (Svoboda et al., 2011b) 
OATPIB3 Pancreas t (Kounnis et al., 2011) 
Colorectal t (Lockhart et al., 2008) 
Gastroinestinal t (Abe et al., 2001) 
Breast i (Muto et al., 2007) 
Testicular t (Pressler et al., 2011) 
Ovarian t (Svoboda et al., 2011b) 
Liver ~ (Vavricka et al., 2004) 
Prostate t (Hamada et al., 2008; Yang et al., 2011) 
OATPICI Bone t (Liedauer et aI., 2009) 
OATP2Al Bone t (Liedauer et al., 2009) ./ 
Liver i (WIeek et al., 2011) 
Breast t (WIeek et aI., 2008) 
OATP2Bl Bone t (Liedauer et aI., 2009) 
Liver ~ (Pressler et aI., 2011) 
Pancreas ~ (Pressler et al., 2011) 
Prostate t (Hamada et aI., 2008; Yang et al., 2011) 
Thyroid t (pressler et al., 2011) 
OATP3Al Bone t (Liedauer et al., 2009) 
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Liver i (Wlcek et al., 2011) 
Breast i (Kindla et al., 2011 b) 
OATP4Al Bone i (Liedauer et al., 2009) 
Liver i (Wlcek et al., 2011) 
OATP4Cl Bone i (Liedauer et al., 2009) 
OATP5Al Bone i (Liedauer et al., 2009) 
Small cell lung i (Olszewski-Hamilton et al., 2011) 
Liver i • (Wlcek et al., 2011) 
Breast i (Kindla et al., 2011 b) 
OATP6Al Lung, bladder, i (Lee et al., 2004) oesophagus 
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1.5 OATPs and drug disposition 
Xenobiotics require transport proteins to traverse cellular membranes, owing to 
their size, charge and lipophilicity. OA TPs transport a broad range of 
xenobiotics, ranging from antibiotics such as penicillin (Tarnai et al., 2000), the 
antifungal caspofungin (Sandhu et al., 2005) and many anti-retroviral protease 
inhibitors including saquinavir (Hartkoorn et al, 2010; Su et al., 2004), to 
chemotherapeutic agents including methotrexate (Badagnani et al., 2006) and 
cardiac drugs such as the cardiac glycoside digoxin (Kullak-Ublick et al., 
2001). Numerous statins such as pitavastatin (Hirano et al., 2006) are also 
transported by OATPs. The anti-histamine fexofenadine (Cvetkovic et al., 
1999), anti-diabetic drug glibenclamide (Satoh et al., 2005b) and the opioid 
receptor agonist deltorphin II (Gao et al., 2000) are also transported. Finally 
toxins including microcystin (Fischer et al., 2005) and the poison arsenic (Lu et 
al., 2006) are also processed through the liver by OATPs. In this way OA TPs 
retain a selective barrier to different drugs and ensure that all compounds can be 
metabolised to maintain homeostasis. 
Interestingly the preference for drug type can vary between transporters. For 
example, the angiotensin II receptor antagonists such as valsartan are taken up 
equally by OATPIBI and OATPIB3 (Yamashiro et al., 2006), however 
pitavastatin and rosuvastatin are transported preferentially by OA TP 1 B I, even 
though they are also substrates for the other basolateral transporters (Hirano et 
al., 2004). Similarly drugs belonging to the same class can be transported 
differently, for example valsartan and olmesartan can be transported by both 
OATPIBI and OATPIB3 but telmisartan is only transported by OATPIB3, 
even though they are both angiotensin II receptor agonists. 
The localisation of OA TPs in a wide range of cell membranes and their ability 
to transport a wide selection of drug compounds indicates important roles in the 
absorption, distribution, metabolism and excretion (ADME) ofxenobiotic 
compounds. For example, OATPs expressed in the intestine are involved in the 
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absorption of orally administered drugs and ubiquitously expressed OA TPs are 
involved in the distribution of drugs to the site of action, such as the blood brain 
barrier. OATPIA2, OATPIB1, OATPIB3 and OATP2Bl are part of the 
hepatobiliary system and are their relationship with the ADME of drug 
compounds is the most characterised (section 1.5.1). 
1.5.1 OATPs and hepatic drug disposition 
1.5.1.1 The hepatobiliary system 
Bile secretion is a process imperative to the excretion of waste compounds, 
including bilirubin and cholesterol, as well as many xenobiotics. Bile once 
produced in the liver is transported to the intestine, where it assists the 
breakdown and assimilation of lipids and lipid soluble nutrients (Zsembery et 
al., 2000). This process, known as the enterohepatic circulation, is primarily 
controlled by transporters (Kullak-Vblick et al., 2004). 
Generation of bile flow is a vectoral, ATP driven process which requires a 
number of transport proteins in the canalicular and basolateral membranes of 
hepatocytes. Compounds including bile salts are transported from portal blood 
into the hepatocyte on the basolateral membrane (figure 1.6) by OATPIBl, 
OATPIB3, OATP2Bl and NTCP. NTCP mediates mainly Na+-dependent 
conjugated and unconjugated bile salt transport into the hepatocyte. The non-
bile salt substrates BSP, thyroid hormone (triiodothyronine T3 and thyroxine 
T4) and E3S are also transported among others (Meier et al., 1997). OATPIBI 
is the predominant Na+-independent transporter of bile acids with OATPIB3 
transport to a lesser extent. OA TP2B 1 transports a number of endogenous and 
xenobiotic compounds and the bile acid taurocholate. Additionally the organic 
anion transporters (OATs, SLC22) and organic cation transporters (OCTs, 
SLC22) transport organic anions and type 1 organic cations into the hepatocyte 
(Chandra and Brouwer, 2004). Once inside the hepatocyte, substrates may be 
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metabolised by enzymes through biotransformation and/or transported into the 
bile canaliculi by the ABC transporters. 
Cholangiocytes are the epithelial cells of the bile ducts and also form a vital 
part of the hepatobiliary system. Cholangiocytes form only 3-5% of liver cells 
but they are responsible for up to 40% of the bile production, by adding fluid 
and electrolytes as well as reabsorbing substances (Arrese and Accatino, 2002). 
There is little experimental evidence to support the role ofOATPlA2 in the 
liver; however its expression on apical membranes of cholangiocytes suggest a 
contributing role to bile production by transporting substrates across the 
membrane into the canalicular lumen. 
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Figure 1.6 - Hepatocyte model displaying the major transporters involved in transport of solutes from portal blood into the hepatocyte and 
canalicular lumen. The OA TPs are highlighted with a red circle. BSEP = Bile salt export pump, MDR = Multidrug-resistance protein, MRP 
= Multidrug resistance-associated protein, BCRP = Breast cancer resistance protein. 
Biotransformation is the process whereby endogenous and xenobiotic 
compounds are chemically modified to make them more soluble for excretion 
(Boelsterli and Lim, 2007). The main studied enzyme group that catalyse phase 
I reactions through oxidation, reduction and peroxidation are the cytochrome 
P450 (CYP) enzymes (Gibson and Skett, 2001). 
Biotransformation is central to determining the fate of a drug as the compound 
enters this process before reaching the systemic circulation. Until transporters 
were better understood it was thought that the CYP enzymes were major 
determinants of drug disposition, however it is more likely that disposition is 
influenced by a combination of transporter, CYP enzyme and other regulatory 
processes. It is claimed that the uptake of compounds into the hepat<;>cyte can 
even be the rate limiting step in hepatic drug clearance; with the uptake of 
saquinavir, nelfinavir, and ritonavir into the hepatocyte exceeding their 
metabolism (Parker and Houston, 2008). These interactions between CYP 
enzymes and transporters are still not fully understood, particularly with regards 
to the OA TPs. However, it is likely that there is an important relationship, as 
substrate specificities frequently overlap. For example the ABC multidrug-
resistance protein 1 (MDRl) has an overlapping specificity with CYP3A for 
rifampicin. When MDRI and CYP3A are both exposed to rifampicin in vitro 
and in vivo, levels ofCYP3A are reduced (Schuetz et ai., 1996). 
The hepatic OA TPs have a major role in the bioavailability of drugs during first 
pass elimination. That is, increased uptake of drugs into the hepatocyte for 
biotransformation or bile production can decrease the availability of the drug in 
the systemic circulation. Conversely, decreased uptake results in systemic 
accumulation, causing toxicity. Owing to the position of OA TP 1 B 1, OA TP 1 B3 
and OA TP2B 1 on the hepatocyte basolateral membrane the majority of drug 
transporter interactions have been studied in these transporters, and a wealth of 
information has been gathered over the past decade. 
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1.5.2 OATP-drug interactions 
Transporter-drug interactions alter the function of the transporter and are 
responsible for the hepatotoxicities associated with drug administration. These 
interactions can be caused by drug-drug interactions (DDIs), genetic variability 
and environmental factors such as diet. In addition, it is likely that interactions 
occur between compounds that are both substrates for the CYP enzymes and 
OATPs, as well as other transporters. For these reasons, the International 
Transporter Consortium was set up in 2007, for the purpose of investigating the 
role of transporters such as OATPs, in drug safety and efficacy (Huang et al., 
2010). 
OA TPs are inhibited by a wide array of xenobiotic compounds, such as the 
majorOATPlBI inhibitors displayed in table 104. These include anti-fungals, 
antibiotics, anti-cancer drugs and statins. Many are inhibitors for several 
OA TPs, such as the immunosuppressant cyclosporine A, a potent inhibitor of 
OATPIBI, OATPIB3 and OATP2BI function (Kalliokoski and Niemi, 2009). 
This transporter inhibition alters the pharmacokinetics of the drug, affecting the 
ADME properties and inducing toxicity and/or disease. For example, 
OA TP I B I is the main bilirubin transporter in the liver, and inhibition by 
indinavir, saquinavir, cyclosporine A and/or rifamycin causes drug induced 
hyperbilirubinaemia (Campbell et al., 2004). One mechanism for the reduction 
of transporter expression may be through the drug induced modulation of 
regulation pathways. For example spironolactone and dexamethasone are PXR 
ligands, reducing the mRNA expression of several mouse Oatps (Cheng et al., 
2005). Inhibition may also be caused by the competitive inhibition of a 
substrate, by the inhibitor acting as a substrate itself (Westholm et al., 2009b). 
Inhibition can however be to varying degrees, as shown by the varying ICso 
values observed in table 104. The ICso or half maximal inhibitory concentration 
is the concentration required to inhibit transporter activity by 50% (Sebaugh, 
2011).A detailed review of the hepatic OATP inhibitors has been published 
recently (Karlgren et al., 2012). 
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Table 1.4 - Major inhibitors of OATP 1 B 1 with corresponding ICso values. 
Reproduced and adapted with permission from John Wiley & Sons (Appendix 
VI) (Kalliokoski and Niemi, 2009) 
Class Inhibitor ICso (f.1M) Reference 
Angiotensin receptor Telmisartan 
0.436 (Hirano et al., 
II antagonists 2006) 
Valsartan 
8.96 (Hirano et al., 
2006) 
Clarithromycin 8.26- 96 (Hirano et al., 
2006) 
Erythromycin 11.4 - 217 (Hirano et al., 
2006) 
Antibiotics Rifampicin 
0.477-17 (Vavricka et al., 
2002) 
Rifamycin SV 
0.171-2 (VavriCka et al., 
2002) 
Roxithromycin 
153 (Seithel et al., 
2007) 
Telithromycin 
121 (Seithel et al., 
2007) 
Irinotecan Unknown (Nozawa et al., 
2005) 
Anti-cancer SN-38 
Unknown (Nozawa et al., 
2005) 
Paclitaxel 0.03 (Gui et al., 
2008) 
Anti-convulsants Carbamazepine 188 (Gui et al., 
2008) 
Glibenclamide 0.746 (Hirano et al., 
2006) 
Pioglitazone Unknown (Nozawa et al., 
2004b) 
Anti-diabetics Repaglinide 
2.2 (Bachmakov et 
al., 2008) 
Rosiglitazone 
6.0 (Nozawa et al., 
2005) 
Troglitazone 
1.2 (Gui et aI., 
2008) 
Troglitazone Unknown (Nozawa et al., 
sulphate 2004b) 
Anti-fungals Caspofungin Unknown (Sandhu et al., 
2005) 
Clotrimazole 9.0 (Gui et al., 
2008) 
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Ketoconazole 19.2 (Hirano et at., 
2006) 
Indinavir 5.84-18.4 (Campbell et aI., 
2004) 
Anti-retrovirals Nelfinavir 0.93 (Tirona et at., 
2003) 
Ritonavir 
0.71- (Tirona et at., 
0.781 2003) 
Saquinavir 
1.2 -1.56 (Campbell et aI., 
2004) 
Cardiac glycosides Digoxin 31.7 (Hirano et at., 
• 2006) 
Endocrine drugs Metyrapone Unknown (Gui et at., 
2008) 
Mifepristone 3.3 (Gui et ai., 
2008) 
Immunosuppressants Cyclosporine 0.2 - 2.2 (Shitara et ai., 
2003) 
Tacrolimus 
0.611 (Hirano et ai., 
2006) 
Atorvastatin 0.87 (Hsiang et ai., 
acid 1999) 
Atorvastatin 2.6 (Chen et ai., 
lactone 2005) 
Gemfibrozil 4.0-72 (Noe et ai., 
2007) 
Gemfibrozil-l- 22.6-24 (Shitara et ai., 
O-glucuronide 2004) 
Lipid lowering Lovastatin 6.1 (Hsiang et at., 
1999) 
Lovastatin acid 4.0 (Chen et ai., 
2005) 
Lovastatin 28 (Chen et ai., 
lactone 2005) 
Pravastatin Unknown (Hsiang et ai., 
1999) 
Simvastatin 
Unknown (Hsiang et aI., 
1999) 
Simvastatin acid 3.6 
(Chen et ai., 
2005) 
Simvastatin 9.7 (Chen et at., 
lactone 2005) 
Other Hyperforin 0.82 (Tirona et at., 
2003) 
Sildenafil 
1.5 (Treiber et ai., 
2007) . . ... 
ICso- Inhibitor concentratIOn producmg 50% mhlbltIon by the transporter 
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1.5.2.1 Drug-drug interactions (DDIs) 
DDIs are characterised by the effect of one drug on another, when administered 
concomitantly. This can be the competitive or non-competitive inhibition of a 
drug by the transport of another, or the induction of the transporter by another 
drug. For example, the OATPIBI and OATPIB3 mediated transport of the 
endothelin receptor agonist bosentan is inhibited when co-administered with 
cyc1osporine A and rifampicin (Treiber et al., 2007). Transporter induction is 
less well characterised in the OATPs but has been observed in the ABC 
transporters and the P450 enzymes (Lin, 2003), suggesting it may also occur 
with the OA TPs. In addition to direct inhibition/induction, allosteric induced 
modulation of transport may also assist in the mechanism ofDDIs. This indirect 
modification of transport was shown recently, whereby non-steroidal anti-
inflammatories (NSAIDs) inhibited the mediated transport ofOATPlBl and 
OATPIB3, even though they themselves were not substrates of the transporters 
(Kindla et al., 2011a). 
Herbal and other alternative non-prescribed medicines also have DDI effects. 
Alternative medicines are popular and past clinical studies have quoted >50% 
of participants using at least one non-prescribed alternative medicine 
(MacLennan et al., 2002). A number of herbal compounds have been studied to 
observe their potential inhibitory effects on OATP2BI. Bilberry, echinacea, 
green tea, banaba, grape seed, ginkgo, and soybean potently inhibited 
OA TP2B 1 mediated uptake of E3S (Fuchikami et al., 2006). OATP2B 1 is 
expressed in intestinal epithelial cells as well as hepatocytes, suggesting that 
herbal medicines of this nature may reduce OATP2Bl mediated oral drug 
absorption as well as metabolism and excretion. 
DDIs are further enhanced by the multispecific overlapping nature of the 
OA TPs, ABCs and CYP enzymes for substrates. Many compounds that are 
inhibitors for the OA TPs are also inhibitors for the ABC transporters and the 
CYP enzymes. Therefore the vectoral process of drug transport, metabolism 
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and elimination is affected by interactions associated with each step. For 
example, OATPIBI mediated transport of the anti-cancer drug gimatecan is 
completely inhibited by the breast cancer resistance protein (BCRP) inhibitor 
valspodar (Oostendorp et al., 2009). This increases the level of complexity 
when assessing the effects of drugs administers concomitantly. There are 
several important OATP DDIs associated with the cholesterol lowering drugs 
statins, which are discussed below. 
1.5.2.1.1 Statin interactions 
The hepatic OA TPs are crucial determinants of statin clearance, as the site of 
action is within the hepatocyte, through the inhibition of 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase. Therefore the inhibition of stat in 
transporting OA TPs on the hepatocyte membrane reduces the cholesterol 
lowering effect of the statin. A number ofDDIs have been associated with 
statins; whereby another drug inhibits the transporter mediated uptake ofthe 
statin. This has led to clinically relevant cases of myotoxicity, a condition 
characterised by muscle breakdown from the toxicity of stat in accumulation. 
OATPIBI is the most studied and main hepatocyte basolateral transporter for 
statins. The most potent is the inhibition of OATP 1 B 1 mediated cerivastatin 
transport by cyclosporine A (Shitara et al., 2003) and gemfibrozil (Shitara et 
al., 2004). Cyclosporine A is also an inhibitor ofMDRl and CYP3A4 
(Kalliokoski and Niemi, 2009). Therefore uptake and efflux transporters as well 
as metabolising enzymes are inhibited, resulting in a damaging effect on the 
disposition of other drugs. Cyclosporine A inhibition of pravastatin (Regazzi et 
a1., 1993) and simvastatin (Vlahakos et a1., 2002) transport was also confirmed 
in vivo. In fact cerivastatin was removed from the market in 2001 owing to 
cases of rhabdom yo lysis, a condition causing severe muscle breakdown and 
kidney failure from toxic products in the blood (Psaty et a1., 2004). The 
consequences of these DDIs highlight the detrimental effects of these 
interactions on patient health. 
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1.5.3 Environmental drug interactions 
It is well established that fruit juices have an impact on orally absorbed drugs 
by enhancing the systemic exposure during first pass metabolism. The 
furanocoumarins in citrus juices inhibit the CYP3A4 enzymes (Paine et al., 
2006) and fruit juices also affect transporter function. Juices from grapefruit, 
apple and orange inhibited the OATP2B I (Satoh -et al., 2005a) and OATPIA2 
(Adachi et al., 2003; Dresser et al., 2002) mediated absorption ofE3S and 
fexofenadine respectively. This inhibition was most likely caused by 
flavonoids, which are present in many fruit juices and herbal medicines. 
Flavonoids were found to directly inhibit OATPIBI uptake ofDHE~S (Wang 
et al., 2005b) and OATPIA2 and OATP2Bl mediated uptake ofatorvastatin 
(Mandery et al., 20 I 0). As these transporters are expressed in the intestine and 
the liver, there is the strong potential for altered ADME of drugs in the presence 
of fruit juices. 
1.5.4 Genetic variation and drug transport 
SNPs in the SLea gene sequence alter the OA TP protein sequence, often 
reducing transport function and affecting the ADME ofxenobiotic compounds. 
Influential SNPs can be in coding and non-coding regions (Trevino et al., 
2009). Many polymorph isms that reduce transport function have been identified 
in OATPIA2 (Lee et al., 2005), OATPIBI (Chigutsa et al., 2011), OATPIB3 
(Chew et al., 2011) and OATP2BI (Nozawa et al., 2002). However the in vitro 
and in vivo associations with drug interactions have been most extensively 
studied in OATPIB1. 
Initially 14 non-synonymous SNPs were located in OA TP 1 B I (Tirona et al., 
2001); eight of which conferred decreased transport activity. Now more than 40 
have been located (Niemi et al., 2011) (figure 1.7). These variations can affect 
protein expression on the membrane (Kameyama et al., 2005) or the functional 
processes of the transporter (Iwai et al., 2004). The variations are widely 
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distributed around the world and haplotypes (frequently occurring collections of 
SNPs) are associated with populations in Africa, Middle East, Americas, 
Europe and Oceana (Chigutsa et al., 2011; Pasanen et al., 2008). The SNP 
521 T>C is one of the most prevalent and associated with altered 
pharmacokinetics of several drugs. One such altered is lopinavir, an anti-
retroviral drug used in combination for the treatment of human 
immunodeficiency virus (HIV). Individuals with the SNP were shown to have 
significantly higher plasma concentrations of lopinavir, suggesting that , 
impaired transport of the drug into the hepatocyte was the cause (Hartkoom et 
al., 2010; Kohlrausch et a!., 2010; Schipani et al., 2012). This SNP also has 
implications for statin clearance. SNP 521 T>C reduced the hepatic uptake of 
atorvastatin, pitavastatin, pravastatin, rosuvastatin (Romaine et al., 2010) and 
simvastatin (Brunham et al., 2011), also elevating plasma levels. 
Genetic variation is another important mechanism for the adverse effects 
associated with drug ADME. It is attractive to consider that this knowledge of 
genotype may in the future indicate a patient's response to drug therapy. 
43 
EXTRACELLULAR 
F73L 
V82A 
TlOA 
CYTOPLASM 
D462G C48SF G488A 1499V 
E667G 
Figure 1.7 - Predicted topology ofOATPIB 1 highlighting the broad range of 
SNPs. Reproduced with permission from the American Society for 
Pharmacology and Experimental Therapeutics (Appendix VI) (Niemi et ai., 
2011). 
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The presence of the many drug interactions associated with OA TPs highlights 
the importance of characterising these transporters for future drug development 
studies. OATPs are part of a complex network of transporters and enzymes 
which work together to move and metabolise drugs. Furthermore, interactions 
associated with each of these components can have a detrimental or synergistic 
effect on another component. 
DDIs could, however, be used advantageously to improve the bioavailability of , 
a drug. This has been utilised previously for the delivery of penicillin, whereby 
the antibiotic was co-administered with probenecid. Probenecid reduced the 
urinary excretion of penicillin, thus improving its bioavailability (Frisk et al., 
1952). More recently, it was also found that the protease inhibitors ritonavir and 
saquinavir have a positive interaction. By co-administering ritonavir with 
saquinavir in HIV patients, the oral bioavailability of saquinavir was increased 
(Hsu et al., 1998). The mechanism is likely to be from the ritonavir mediated 
inhibition of CYP3A4; a P450 enzyme which metabolises saquinavir into an 
inactive form (Kempf et al., 1997). It could be that such interactions could be 
utilised in a similar way with OA TP compounds. 
Similarly, the SNPs that impair transport function are well characterised for 
OATPIBI but less so for the other hepatic OATPs. Analysis of genetic 
variation in this manner may in the future change the way drugs are 
administered, by assessing an individual's genotype prior to administration. 
Understanding the structural and functional characteristics of OA TPs is 
fundamental to understanding the properties of drug disposition. 
1.6 Choice of model system 
The choice of model system for studying the characteristics and kinetics of 
transport proteins is crucial to gaining an accurate insight to transporter 
function. There is literature to support the use of several systems for OATP 
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transport, including Xenopus laevis oocytes (St-Pierre et al., 2002), primary 
hepatocytes (Nakai et al., 2001), mammalian cell lines (Gui and Hagenbuch, 
2008) and cell line membrane vesicles (St-Pierre et al., 2002). 
Primary human hepatocyte studies are useful for studying the entire cellular 
environment as they maintain cellular characteristics and regulatory pathways. 
Influx and efflux by transporters has been demonstrated this way (Jigorel et al., 
2005). However, by analysing a complete endogenous cell, specific families or 
individual transporter characteristics cannot be isolated. In order to study the 
structural characteristics and because of the overlapping substrate specificities, 
OA TPs need to be studied in isolation. Therefore X laevis oocytes and cell 
lines are more favourable models for studying specific OA TP proper:ties. 
X laevis oocytes and a human embryonic kidney 293T (HEK293T) cell line 
were evaluated as potential models for investigating the OA TPs, which is 
discussed further in chapter 3. Primary rat kidney membrane vesicles were also 
investigated as a novel method for measuring endogenous Oatp transport. 
1.6.1 Transmembrane protein topology prediction analysis 
The experimental determination ofthe structure and orientation of a 
transmembrane protein is facilitated by the prediction of the TMs and 
extracellular loops. This is known as the 'topology;' defined by the orientation 
of the Nand C termini within the membrane, as well as the number and 
orientation ofTMs (Sonnhammer et al., 1998). There are various topology 
prediction programs available to predict these features with algorithms based on 
hydrophobicity analysis, statistical models and multiple sequence alignment 
(Zhou and Zhou, 2003). Hydrophobicity analysis is the most frequently utilised 
tool for topology prediction and is based on the hydrophobicity of amino acids. 
Amino acids present within the cell membrane are hydrophobic to match the 
hydrophobic phospholipid tails, and thus collections of hydrophobic amino 
acids can be predicted as intramembrane domains. The hydrophobicity of 
amino acids is organised into a scale; the more hydrophobic the amino acid, the 
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more positive on the scale it becomes. This can be displayed on a hydropathy 
plot, as shown in figure 1.8. 
1.6.2 Site directed mutagenesis 
Site directed mutagenesis (SDM) is a useful tool for assessing the structural and 
functional properties of a protein, when a crystal structure is not available. A 
single amino acid is mutated to determine the importance for protein folding, 
membrane targeting andlor substrate binding, which cad be identified by 
quantifying levels of protein on the membrane and altered transport kinetics. 
The method is used frequently for the structural analysis of transmembrane 
proteins, including the OA TPs. For example the positive amino acids within the 
putative pore ofOATPIBI (Weaver and Hagenbuch, 2010) and the cysteine 
residues in loop 5 of OA TP2B 1 (Hanggi et al., 2006) were characterised using 
this method. 
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Figure 1.8 - Hydropathy plot of OATP 1 B 1 displaying] 2 predicted TM 
segments; regions of hydrophobic amino acids show as positive on the 
hydrophobicity scale (green bars). Obtained from the SVMtm protein 
prediction server (Nugent and Jones, 2009). 
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1.7 Aims 
The aim ofthis thesis was to further elucidate the structure and function of 
any/all of the functionally influential OATPs; OATPIA2, OATPIBI, 
OA TP 1 B3 and OA TP2B I. These four hepatic OA TPs have important roles in 
the ADME of compounds and have been implicated in disease and clinically 
relevant DDIs. Little is known about the exact topology ofthe OATPs and the 
function of their structural features, such as the 13 amino acid signature 
sequence region. The aim therefore was to determine the topology of one or 
more of the hepatic OATPs, as well as determine the importance of the 
signature sequence for membrane expression and transporter function. More 
specifically these aims included: 
• To establish a suitable in vitro expression system for the expression 
of OA TPs, and use this system for further studies. The expression systems 
included X laevis oocytes, HEK293T cells and rat kidney plasma membrane 
vesicles. Transport was measured using the model substrate E3S and wild type 
(WT) values obtained (chapter 3). 
• To develop in silico topology models for each OATP using a range 
of topology prediction programs, to predict the amino acid locations of the 
TMs, extracellular loops, Nand C termini and signal peptide sequence (chapter 
4). 
• To experimentally determine the number ofTMs and orientation of 
the Nand C termini, by inserting FLAG epitope tags into the predicted 
extracellular loops and termini, based on the topology predictions. The tagged 
proteins were to be detected on the membrane quantitatively using luminometry 
and qualitatively using confocal microscopy. Maintenance of function would be 
confirmed by comparing transport kinetics for E3S with the WT protein 
(chapter 4). 
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• To determine the importance of residues within the signature 
sequence region for substrate transport and membrane expression using SDM 
of one of the previously tagged isoforms. The effect of the mutation was to be 
determined through transport experiments, luminometry and confocal 
microscopy. Values would be compared to those ofthe tagged WT protein 
(chapter 5). 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless stated 
otherwise 
2.1.2 Bacterial cells 
Escherichia coli: XLI-Blue Subcloning Grade Competent Cells (Agilent 
Technologies, Stockport UK; cat # 200130). 
2.1.3 Mammalian cells 
Human Embryonic Kidney 293T/17 cells (LGC Standards, Middlesex UK; 
A TCC # CRL-11268). 
2.1.4 eDNA clones 
SLCOlA2: Source Bioscience, Nottingham UK; Accession # BC042452, 
A TCC Image clone # 4820050 
SLCOlBl: Autogen Bioclear, Wiltshire UK; Accession # BC114376, ATCC 
Image clone # 40037364 
SLCOlB3: Invitrogen, Paisley UK; Accession # BC141525, ATCC Image 
clone # 100014510 
SLC02Bl: Source Bioscience, Nottingham UK; Accession # BC041095, 
ATCC Image Clone # 5752976 
2.1.5 Vectors 
pGem-T (Ampicillin resistance): Promega, Southampton UK; cat # A3600 
pXT7 (Ampicillin resistance): Gift from S.L Alper (Kurschat et a/., 2006) 
pcDNA3.1/Hygro(-) (Ampicillin resistance): Life Technologies Ltd, Paisley 
UK; cat # V875-20 
pCI-neo (Ampicillin resistance): Prom ega, Southampton UK; cat # E1841 
2.1.6 Enzymes 
All restriction enzymes were purchased from New England Biolabs (Hitchin, 
UK) 
Plu DNA polymerase (Promega, Southampton UK) 
Easy-A high-fidelity peR cloning enzyme (Agilent Technologies, Stockport 
UK) 
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Antarctic phosphatase (New England Biolabs, Hitchin UK) 
T4 DNA ligase (New England Biolabs, Hitchin UK) 
T7 enzyme mix (Life Technologies, Paisley UK) 
Turbo DNase solution (Life Technologies, Paisley UK) 
2.1. 7 Antibiotics 
Ampicillin sodium salt (Sigma, Dorset UK) 
Gentamycin sulphate (Sigma, Dorset UK) 
Penicillin/Streptomycin solution (Sigma, Dorset UK) 
Amphotericin B (Sigma, Dorset UK) 
2.1.8 Antibodies 
Monoclonal ANTI-FLAG M2-Peroxidase (HRP) mouse antibody (Sigma, 
Dorset UK; cat # A8592) 
Monoclonal ANTI-FLAG M2 mouse antibody (Sigma, Dorset UK; cat # 
F1804) 
Anti-mouse JgG-FITC rabbit antibody (Sigma, Dorset UK; cat # F9137). 
2.1.9 Isotopes 
eH] E3S (54.3Cilmmol, Perkin Elmer, MA USA; cat # NET203250UC) 
eH] D-phenylalanyl-L-glutamine (l7.4Cilmmol custom synthesised, 
Cambridge Research Biochemicals, Stockton-on-Tees UK) 
2.2 Molecular biology methods 
2.2.1 Polymerase chain reaction (peR) 
2.2.1.1 Primer design 
Primers were designed in order to sequence a region of a gene, flank the gene 
for amplification or mutate a region of interest (mutagenic primers). Mutations 
included single base pair mutations and FLAG epitope tag insertions. Flanking 
and sequencing primers were designed to conform to a length of 18-22 base 
pairs, minimum 40% GC content, 55-60°C Tm and terminate in one or more C 
or G bases where possible. Mutagenic primers were between 30-60 base pairs 
and T m > 78°C. The mutation was contained in the middle of the primer with 
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approximately 20 base pairs of gene sequence each side of the mutation. 
Primers were constructed with a restriction site before the start/after the stop 
codons with at least 3 bases each side for efficient restriction digestion. 
Restriction sites in sequences were located using NEBcutter (Vincze et al., 
2003). Primers were checked for hairpins, dimers and complementarity using 
OligoCalc (Kibbe, 2007) and efficient alignment checked using GeneDoc 
(Nicholas et al., 1997). Primers were ordered from Fisher Scientific 
(Loughborough UK). 
2.2.1.2 peR reaction 
Polymerase chain reactions (PCRs) were facilitated with the high fidelity 
enzyme Plu DNA polymerase (Promega, Southampton UK) unless otherwise 
stated. Reactions were prepared according to the product datasheet and 
summarised in table 2.1. Aliquots of assembled dNTPs were stored at -20°C 
prior to reaction assembly. Primers were reconstituted in nuclease free dH20 to 
50 picomoles (pmol) according to the manufacturer's instructions and also 
stored at -20°C. 
Table 2.1- Reaction components for a single PCR reaction using Plu DNA 
polymerase 
Reaction components Volume h1l) 
DNA template (50-I OOn g/J,.l I) I 
P{u lOX reaction buffer 5 
dNTPs (lOnM each) I 
Forward primer (-50pmol) I 
Reverse primer (-50pmol) I 
Plu DNA polymerase (2-3U/J,.ll) 0.5 
Nuclease free dH20 40.5 
TOTAL 50 
Temperature and cycling conditions were based on a 'ramp' approach (personal 
communication, Dr Imogen Sparkes, Oxford Brookes University, Oxford UK), 
whereby the annealing temperature was gradually decreased every 5 cycles to 
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provide a range of temperatures for different primers to anneal. This reduced 
the level of annealing temperature optimisation for each primer designed. The 
thermal cycling conditions are summarised in table 2.2. The extension 
temperature is optimal for the polymerase used (68-72°C) and extension time 
depends on the size ofthe gene to be amplified (l min per kb). 
Table 2.2 - Thermal cycling conditions for Plu polymerase reaction utilising a 
'ramp' based approach 
Step Temperature (oC) Time (mins) Number of cycles 
1 95 1 1 
94 0.2 
2 63 1 -5 
72 llkb 
94 0.2 
3 55 1 5 
72 llkb 
94 0.2 
4 45 1 5 
72 llkb 
5 4 00 -
2.2.2 Purification ofPCR and template DNA 
The QIAquick PCR purification kit (Qiagen, Hilden Germany) was used to 
purify PCR products and restriction enzyme digested DNA (section 2.2.3) up to 
10kb. Purification was performed according to the manufacturer's instructions. 
Briefly, 5 volumes of buffer PB supplied in the kit were added to 1 volume of 
DNA. The total volume was added to a purification column and DNA bound to 
the membrane by centrifuging at 13,OOOrpm for 1 minute. All further 
centrifugation steps were performed at 13,OOOrpm. The eluate was discarded 
and 750~1 buffer PE supplied with the kit added to the column. The column was 
centrifuged as above. The eluate was discarded and column centrifuged once 
more to remove residual ethanol. The column was then transferred to a clean 
1.5ml tube and 50~1 nuclease free dH20 added directly to the membrane. The 
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membrane was left for 1 minute before centrifuging. Purified DNA was stored 
at -20°C. 
2.2.3 Restriction digestion 
Restriction digests were performed to create compatible cohesivelblunt ends for 
a gene/vector ligation. A generic restriction digest is displayed in table 2.3. 
Typically, IJ.lg DNA was digested for 1 hour at 37°C. Bovine serum albumin , 
(BSA) was required for specific enzymes described by the manufacturer and 
prevented adhesion of the enzyme to tubes and pipette surfaces. 
Double digests were also performed with two restriction enzymes 
simultaneously. High fidelity enzymes were purchased where possible for this 
purpose, which displayed 100% activity in the same buffer. Digests with 
incompatible enzymes were conducted sequentially, by digesting with one 
enzyme at a time and purifying the template in between. 
Table 2.3 - Typical single enzyme restriction digest reaction 
Reaction components Volume (Jil) 
Template DNA (1 J.lg/J.lI) 1 
lOX NEBbuffer 5 
100X BSA (if required) 0.5 
Restriction enzyme 0.5 
Nuclease free dH20 43 
TOTAL 50 
2.2.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate nucleic acids by size 
following a PCR or restriction digest reaction. Typically, 1 % agarose gels were 
prepared with Hi-Pure Low EEO agarose (Biogene Ltd, Cambridge UK), Tris-
Borate-EDTA (TBE) buffer (Invitrogen, Paisley UK) and ethidium bromide 
solution (lOmg/ml) (Sigma, Dorset UK). Approximately lOOng DNA was 
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combined with 6X blue/orange loading dye (Promega, Southampton UK) and 
loaded one sample per well. A lkb ladder (Promega lkb DNA ladder, 
Southampton UK or NEB I kb DNA ladder, Hitchin UK) was loaded 1:5 with 
blue/orange loading dye (Promega, Southampton UK) in the first and last wells. 
Gels were run in TBE buffer at -95V for 45 minutes or until the ladder had 
separated thoroughly. Gels were visualised using a UV transilluminator (UVP, 
Cambridge UK) and photographed using a Uvitec- camera with hood 
(Cambridge, UK). When DNA band excision was required, gels were run at 
-75V to avoid shearing of DNA ends. The DNA bands were then quickly 
removed from the gel by scalpel, to avoid the introduction of mutations by the 
UV light. 
2.2.5 DNA gel extraction 
Specific DNA bands were excised from 1 % agarose gels and purified using a 
QIAquick gel extraction kit (Qiagen, Crawley UK). Briefly, 3 volumes of 
buffer QG supplied with the kit was added to I volume of excised gel slice 
(lOOmg gel- 100~1 buffer QG). The tube was heated to 50°C and vortexed to 
dissolve the agarose. The solution was then added to a spin column and 
centrifuged for 1 minute at 13,OOOrpm. The eluate was discarded and the 
column was washed by adding 750~1 buffer PE supplied with the kit and 
centrifuging as above. The eluate was discarded and the column centrifuged for 
an additional minute to remove residual ethanol. The column was transferred to 
a clean tube and 50~1 nuclease free dH20 added for 1 minute. The tube was 
centrifuged to elute the DNA and was stored at -20°C. 
2.2.6 Vector dephosphorylation 
DNA vectors were dephosphorylated with antarctic phosphatase (NEB, Hitchin 
UK) following restriction enzyme digestion, to remove 5' phosphates and 
prevent vector re-Iigation. Antarctic phosphatase can be 1 00% heat inactivated 
in 5 minutes and thus requires no further purification prior to ligation. 
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Reactions were assembled as per table 2.4 and incubated for 15 minutes at 
37°C. The enzyme was then heat inactivated for 5 minutes at 65°C. 
Table 2.4 - Reaction components for antarctic phosphatase treatment of DNA 
vectors 
Reaction components Volume (Ill) 
Purified vector DNA (-I/lg) 44 
lOX reaction buffer 5 
Antarctic phosphatase (5/l1) 1 
TOTAL 50 
2.2.7 DNA ligation 
Vector and gene restriction fragments were ligated using T4 DNA ligase (NEB, 
Hitchin UK). Gene (insert) fragments were routinely ligated 3:1 with vector 
fragments as recommended in the manufacturer's instructions. The amount of 
insert DNA required for a ligation was calculated with the equation displayed in 
figure 2.1. 
Length of insert (bp) 
Insert (ng) = N x ( -------------------------) x vector (ng) 
Length of vector (bp) 
Figure 2.1- Equation for calculating the amount of insert DNA required for a 
particular insert to vector ratio (N). 
Reactions were assembled according to table 2.5. Negative controls contained 
vector DNA and dH20 in place of gene fragments to assess for vector re-
ligation. Reactions were incubated overnight at 16°C then stored at 4°C until 
transformation into E. coli cells (section 2.2.8). 
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Table 2.5 - Components of a DNA ligation reaction 
Reaction components Volume btl) 
Vector DNA 4* 
Insert DNA 4* 
lOX T4 DNA ligase reaction 1 
buffer 
T4ligase (400UIIlI) 1 
TOTAL 10 
* Volumes were calculated accordmg to molar ratios and varied per reaction. 
2.2.8 Transformation of DNA into E. coli cells 
XLI blue subcloning grade E. coli cells (section 2.1.2) were used to transform 
whole plasmid and ligated plasmid DNA. Cells were thawed on ice and 50111 
aliquots made per transformation reaction. Approximately 50ng plasmid DNA 
or 5111 of ligation reaction (section 2.2.7) were added to the cells followed by 
heat shocking at 42°C for 45 seconds. Tubes were incubated on ice for 2 
minutes prior to the addition of9001l1 Super Optimal Broth with Catabolite 
repression (SOC) medium (Invitrogen, Paisley UK), prewarmed to 42°C. Tubes 
were incubated at 37°C while shaking for 30 minutes. Cells were centrifuged at 
3500rpm, 25°C for 5 minutes and the supernatant replaced with IOOIlI fresh 
SOC medium. The total volume was spread on LB agar (Sigma, Dorset UK) 
plates containing IOOIlg/ml ampicillin (section 2.1.7). Plates were incubated 
overnight at 37°C and transformants screened by cracking method (section 
2.2.9). Positive colonies were grown overnight at 37°C in 5ml LB broth (Sigma, 
Dorset UK) followed by the generation of glycerol stocks (section 2.2.10). 
DNA was isolated and purified by a miniprep (section 2.2.11). DNA was 
quantified using a spectrophotometer (section 2.2.12) and stored at -20°C. 
2.2.9 DNA cracking 
E.coli bacterial colonies were screened to check for positively ligated DNA. 
The DNA cracking method (Personal communication, Dr Isabel Bermudez-
Diaz, Oxford Brookes University, Oxford UK) allows for rapid screening of 
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colonies prior to miniprep and sequencing. The method involves the lysis of 
bacterial cells to release the plasmid DNA, which is then visualised 
immediately using agarose gel electrophoresis (section 2.2.4). Approximately 
12 colonies were screened per plate. Cracking buffer stock was made according 
to table 2.6 and stable at room temperature for 6 months. The stock was 
assembled by dissolving sucrose in the dH20 by heating to 65°C (without 
boiling), followed by the addition of the other components. Lysis buffer was 
prepared fresh by combining cracking buffer stock with 6X loading dye , 
(Promega, Southampton UK) in a 1 in 10 dilution. 
Table 2.6 - Components of the cracking buffer stock 
Components Amount/volume 
Sucrose 25g 
5MNaOH 5ml 
10% SDS 2.5ml 
dH20 42.5ml 
TOTAL 50ml 
Individual colonies were collected from agar plates with a pipette tip and placed 
in 20~1 dH20 by pipetting up and down 10-20 times. The tip was then 
transferred to a corresponding tube containing 200~1 LB broth with 100~glml 
ampicillin. Following this 7~llysis buffer was added to the bacterialldH20 
solution and the total volume immediately loaded on a 1 % agarose gel. The 
sample DNA band patterns were compared with that of negative (vector only) 
and positive (vector with insert) controls. Sample bands that matched the 
pattern of the positive control were chosen as positive colonies and the 
bacteriallLB broth solutions grown while shaking overnight in 5ml LB broth 
with 100~glml ampicillin at 37°C. Glycerol stocks were then made; the DNA 
purified by miniprep and sent for sequencing to confirm the presence ofthe 
insert. 
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2.2.10 Plasmid glycerol stocks 
Glycerol stocks are a reliable method for long term storage of bacterial cells 
which contain a specific plasmid of interest. Stocks were generated by 
combining Iml E. coli overnight culture with 250JlI autocIaved 80% glycerol in 
dH20 and stored immediately at -80°C. Stocks were regenerated by placing a 
sample ofthe stock in 5ml LB broth with antibiotic and grown overnight at 
37°C while shaking. 
2.2.11 Isolation and purification of DNA from E. coli 
Overnight cultures were prepared by picking E. coli colonies from agar plates, 
from DNA cracking or from glycerol stocks and placing in 5ml LB broth plus 
antibiotic. Cultures were grown overnight at 37°C while shaking. Following 
incubation Iml culture was reserved for glycerol stocks ifrequired (section 
2.2.10). DNA was isolated from the remaining culture using the miniprep 
purification system (section 2.2.11.1). High quality and highly concentrated 
DNA required for cell transfections was isolated using a maxiprep purification 
system (section 2.2.11.2). Purified DNA was visualised using agarose gel 
electrophoresis and quantified by spectrophotometer. 
2.2.11.1 Miniprep DNA purification 
DNA was isolated from E. coli cultures using the Wizard Plus SV Minipreps 
DNA Purification System (Promega, Southampton UK) which yielded -1.5Jlg 
total purified DNA. This DNA was used for PCR reactions and restriction 
digestions. 
Overnight culture was centrifuged at 3500rpm for 10 minutes to generate a cell 
pellet. All further centrifugation steps were conducted at 13,OOOrpm and all 
solutions were provided in the kit. The supernatant was discarded and the pellet 
thoroughly resuspended in 250111 resuspension solution. The total volume was 
transferred to a 1.5ml tube, 250111 cell lysis solution added and the tube inverted 
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several times. This was followed by the addition of 1OJ.l1 alkaline protease 
solution, the tube inverted and then incubated at room temperature for 5 
minutes. Then 350J.l1 neutralisation solution was added, the tube inverted and 
centrifuged for 10 minutes. The supernatant was placed in the supplied columns 
and centrifuged for 1 minute. The eluate was discarded and 750J.l1 column wash 
solution added to the column. This was centrifuged for 1 minute and the eluate 
discarded. The column was then centrifuged for a further 2 minutes to remove 
any residual ethanol. , 
The column was transferred to a clean 1.5ml tube and 100J.l1 sterile dH20 placed 
directly on the membrane. The column was centrifuged for a further minute to 
elute the DNA. It was then stored at 4°C for -3 days or -20°C for long term 
storage. 
2.2.11.2 Maxiprep DNA purification 
The Pureyield™ plasmid maxiprep system (Promega, Southampton UK) was 
used to isolate DNA for HEK293T cell transfections, as the system produces 
DNA of a high yield and quality. It also includes an endotoxin removal wash 
step which reduces the amount of protein, RNA and endotoxins in the sample. 
An E. coli cell sample containing the plasmid of interest was taken from a 
glycerol stock and grown overnight at 37°C in 5ml LB broth with 100J.lg/ml 
ampicillin. The total volume was added to 245m! LB broth with antibiotic in a 
500ml conical flask overnight at 37°C whilst shaking. The culture was 
centrifuged at 20,000rpm for 10 minutes at room temperature to pellet the cells. 
The supernatant was discarded and the pellet thoroughly resuspended with 
12ml resuspension solution. This was followed by the addition of 12ml cell 
lysis solution and the tube inverted several times. The solution was incubated at 
room temperature for 5 minutes. Then 12ml neutralisation solution was added 
and the tube inverted 10-15 times. The tube was then centrifuged for 30 
minutes at 20,000 rpm. A blue column was placed in a white column supplied 
with the kit and placed on a Vac-Man® laboratory vacuum manifold (Promega, 
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Southampton UK). Vacuum was applied to the manifold using a Laboport 
vacuum pump (KNF Neuberger Inc, Witney UK). The supernatant was 
dispensed into the blue column and drawn through the blue and white column 
using the vacuum. The blue column was discarded and 5ml endotoxin removal 
wash drawn through the white column by vacuum. Then 20ml column wash 
was drawn through the white column. The vacuum was applied for a further 5 
minutes to remove any residual ethanol from the membrane. A sterile 1.5ml 
tube was placed in the supplied elution device and placed on the manifold under 
the column to elute the DNA. Iml nuclease free dH20 was placed directed on 
the membrane and drawn through the column. The purified DNA was sent for 
sequencing and stored in aliquots at -20°C. 
2.2.12 DNA quantification 
DNA and RNA were quantified using the NanoDrop ND 1000 
spectrophotometer (Thermo Fisher Scientific, Loughborough UK) at the 260nm 
absorbance. The spectrophotometer was normalised with 2J.lI dH20 before 
measuring 2J.lI DNA sample. Units were reported as ng/J.lI and purity was 
assessed using the 260/280nm ratio. 
2.2.13 DNA sequencing 
Purified miniprep/maxiprep DNA was sequenced by Sanger sequencing, 
conducted by the Oxford division of Source Bioscience (Nottingham, UK). 
DNA at a concentration of -1 OOng in 5 J.lI aliquots were sent with 3.2pmol 
custom primers. The beginning of the gene was sequenced using the stock T7 
primer, the centre and end ofthe gene were sequenced with custom primers 
(table 2.8), to ensure the gene was completely sequenced. Resultant sequences 
were aligned using CiustalW2 (Larkin et al., 2007). 
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2.2.14 DNA constructs 
DNA cloning was required to sub-clone genes into different vectors, introduce 
FLAG epitope tags and make single base mutations. An overview of the 
cloning method is displayed in figure 2.2, with a list of constructs generated in 
table 2.7. Primers are listed in table 2.8. The molecular biology methods 
employed in section 2.2 are those described previously unless otherwise stated. 
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1) Gene amplified in a PCR 
reaction (section 2.2.1.2) 
4) PCR purified 
restriction digested DNA 
(section 2.2.2) 
5) Vector treated with Antarctic 
phosphatase to prevent ends from re-
ligating (section 2.2.6). 
8) Colonies screened by cell 
cracking method (section 2.2.9) 
to check for positive colonies 
9) Positive colonies 
grown overnight. 
2) PCR purified DNA template 
... (section 2.2.2). 
J 
3) Restriction digested flanking regions 
of gene and corresponding sites in 
vector (section 2.2.3). 
6) Ligated linearised gene and 
~ vector DNA overnight (section 
2.2.7) 
7) Transformed E. coli cells with 
ligated DNA and colonies grown 
on agar plates overnight (section 
2.2.8) 
10) Glycerol stocks made (section 
2.2.10) and DNA isolated and 
purified by miniprep (section 
2.2.11.1) 
I 
11) DNA sent for sequencing to 
confirm presence of the gene (section 
2.2.13). 
Figure 2.2 - Flow chart displaying procedures for sub-cloning a gene from one 
vector to another 
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Table 2.7 - Plasmid constructs generated 
Plasmid Vector Gene Epitope 
pGem vector sub-cloning 
pGem-TISLCOlA2 pGem-T SLCOlA2 None 
pGem-TISLCOlBl pGem-T SLCOlBl None 
pGem-TISLCOlB3 pGem-T SLCOlB3 None 
pGem-TISLC02Bl pGem-T SLC02Bl None 
pXT7 vector sub-c1onin2 
pXT7/SLCOlA2 pXT7 SLCOlA2 None 
pXT7/SLCOlBl pXT7 SLCOlBl None 
pXT7 ISLCO 1 B3 pXT7 SLCOlB3 None 
pXT7/SLC02Bl pXT7 SLC02Bl None 
pel-neo vector su b-c1onin2 
pCI-neo/SLCOlA2 pCI-neo SLCOlA2 None 
pcDNA3.lIHY2ro(-) vector sub-c1onin2 
pcDNAISLCOlA2 pcDNA3.lIHygro( -) SLCOlA2 None 
pcDNAISLCOlBl pcDNA3.1/Hygro(-) SLCOlBl None 
pcDNAISLCOlB3 pcDNA3.1/Hygro(-) SLCOlB3 None 
pcDNA3.1IHygro(-) FLAG c1onin2 
pcDNAISLCOlBl-FI-FI3 pcDNA3.1/Hygro( -) SLCOlBl FLAG 1-13 
(FI-F13) 
pcDNA3.1IHygro(-) mutagenesis c1onin2 
pcDNAISLCOlBl-F4- pcDNA3.1/Hygro( -) SLCOlBl F4 
D251E 
pcDNAISLCOlBl-F4- pcDNA3.1/Hygro( -) SLCOlBl F4 
R253K 
pcDNAlSLCO 1 Bl -F4- pcDNA3.1/Hygro( -) SLCOlBl F4 
W254F 
pcDNAISLCO 1 Bl -F4- pcDNA3.1/Hygro( -) SLCOlBl F4 
W258/259F 
pcDNAISLCOlBl-F4- pcDNA3.1/Hygro(-) SLCOlBl F4 
N261A 
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Table 2.8 - List of primers used in sequencing, sub-cloning and mutagenesis: 
highlighting the restriction enzyme (yellow), Kozak sequence (pink), FLAG 
epitope insertion (blue) and site-directed mutation (green) 
Primer Restriction Sequence (5'-3') 
en~me 
DNA sequencing primers 
SLCOlA2 central gene - AGATGATCTGATCATAACTCCCA 
primer C 
-' 
SLCOlA2 end of gene - GGACTAGAGACTAATGCTGACA 
primer 
SLCOlBl central gene - CCTTGTGTCTGGACTATTCTCC 
primer 
SLCOlBl end of gene - GTCTCCAGAACAGAAATTACTC 
primer 
SLCO 1 B3 central gene - CACTATCATTGCATGTGCTG 
primer 
SLCOlB3 end of gene - GTAACTGGTCTCCAGAACAG 
primer 
SLC02Bl central gene - GAAAGGTCTTAGCAGTCAC 
primer 
SLC02Bl end of gene - TTCTACACCAACTGCAGC 
primer 
pXT7 vector sub-cloning 
pXT7 ISLCO lA2-F KpnI TTTTTTGGTACCAACATGTTTCT 
GTTGGC 
pXT7/SLCOlA2-R EagI AAAAAACGGCCGTCATTAGAAA 
ACAACATAC 
pXT7 ISLCO 1 Bl-F KpnI TTTTTTGGTACCCAATCATGGAC 
CAAAATCAAC 
pXT7/SLCOlBl-R EagI AAAAAACGGCCGTCCCTTAACA 
ATGTGTTTC 
pXT7/SLCOlB3-F AvrIl TTTTTTCCTAGGACCATGGACCA 
AC 
pXT7/SLCOIB3-R Xbal AAAAAATCTAGACTAGTTGGCA 
GCAGCAT 
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vector sub-c1onin 
pcDNAlSlcJ 5al(PepTl) XhoI 
-FLAG-F 
pcDNAlSlcJ5al(PepTI) KpnI 
-FLAG-R 
pcDNAlSLCO IA2-F XhoI 
pcDNAlSLCOIA2-R KpnI 
pcDNAlSLCOIBI-F XhoI 
pcDNAlSLCOIBI-R KpnI 
pcDNAlSLCOIB3-F XhoI 
pcDNAlSLCOIB3-R KpnI 
SLC01Bl FLAG cion in 
pcDNAlSLCOIBI-FI (N 
I-F 
pcDNAlSLCOIBI- FI XhoI 
(N terminal) primer 2 -
F 
pcDNAlSLCOIBI-F2 -
F 
pcDNAlSLCOIBI-F2 -
R 
pcDNAlSLCOIBI-F3 -
F 
pcDNAlSLCOIBI-F3 -
R 
pcDNAlSLCOIBI-F4 -
F 
pcDNAlSLCOIBI-F4 -
R 
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TTTTTTCTC 
AATGTCT 
AAAAAAGGTACCTCACATCTGT 
GTCTG 
TCTGTTG 
CCAACATCAAC 
AAAAAAGGTACCCTAGTTGGCA 
GCAGCATTGTC 
GATAAAATTTGATTAATTAAAC 
ACTTGTCGTCGTCGTCCTTATAA 
TCAGTGGATAAGGTTGATGTTG 
pcDNAlSLC01Bl-F5 -
F 
pcDNAlSLC01Bl-F5 -
R 
pcDNAlSLC01Bl-F6 -
F 
pcDNAlSLC01Bl-F6 -
R 
pcDNAlSLC01Bl-F7 -
F 
pcDNAlSLC01Bl-F7 -
R 
pcDNAlSLC01Bl-F8 -
F 
pcDNAlSLC01Bl-F8 -
R 
pcDNAlSLC01Bl-F9 -
F 
pcDNAlSLC01Bl-F9 -
R 
pcDNAlSLC01Bl-FIO -
F 
pcDNAlSLC01Bl-FlO -
R 
pcDNAlSLC01Bl-Fll -
F 
pcDNAlSLC01Bl-FI1 -
R 
pcDNAlSLC01Bl-F12 -
F 
CTTTTGACGTTGTTACAAG 
AAGCCTATAGTGTTTTACAAC 
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pcDNAlSLC01Bl-F12 -
R 
r-~~~~~~~+--------+ 
pcDNAlSLC01Bl-F13 
AAGTAGACCCTTGAAAATGACT 
TGTCGTCGTCGTCCTTATAATCT 
GTGGAATTATATGTCCTAC 
(C terminal) - Primer 1 
R 
pcDNAlSLC01Bl-F13 
(C terminal) - Primer 2 
R 
SLCOIBI re 
pcDNAlSLC01Bl-F4-
D251E-F 
pcDNAlSLCO 1 Bl-F4-
D251E-R 
pcDNAlSLC01Bl-F4-
R253K-F 
pcDNAlSLCO lBl-F4-
R253K-R 
pcDNAlSLCO 1 Bl-F4-
W254F-F 
pcDNAlSLC01Bl-F4-
W254F-R 
pcDNAlSLC01Bl-F4-
W258/259F - F 
pcDNAlSLCO 1 Bl-F4-
W258/259F - R 
pcDNA-SLCOl Bl-F4-
N261A-F 
pcDNAlSLCO 1 B l-F4-
N261A-R 
KpnI 
F = forward primer, R = reverse primer 
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esis 
GGATAACTGCTA GA 
TGGGTTGG 
CCAACCCATCGAGACTCAGTAG 
GAGTTATCC 
ACTCCTACTGA 
TGGAGCTTGG 
CCAAGCTCCAACCCATTTAGAAT 
CAGTAGGAGT 
CTACTGA GA 
GCTTGGTGG 
CCACCAAGCTCCAACAAATTTA 
GAATCAGTAG 
CGATGGG 
TAATTTCCTTGTG 
CACAAGGAAATTAAGGAAGAAA 
GCTCCAACCCATCG 
TTGGAGCTTGG 
CTTGTGTCTGGACT 
~~~~~ AGTCCAGACACAAGGA 
2.2.14.1 Cloning SLeD genes into pXT7 vector 
The SLCO genes were sub-cloned into the pXT7 vector (section 2.I.S) to 
facilitate expression in X laevis oocytes. 
The genes were cloned either side of X laevis untranslated beta globin regions 
which were recognised by the X laevis translation machinery (figure 2.3). 
SLCOlA2, SLCOlBl, SLCOlB3 and SLC02Bl ,,:,ere first cloned into a pGem-
T vector before sub-cloning into pXT7. Primers were generated to include 
flanking restriction enzymes, which could be used to digest the gene out of the 
pGem vector and into pXT7. SLCOlA2 and SLCOlBl were cloned with KpnI 
and Eag!. SLCOlB3 was cloned with AvrIl and XbaI, SLC02Bl with AvrIl and 
EagI (table 2.8). The DNA template was amplified by PCR using the Easy-A 
polymerase (Agilent Technologies, Stockport UK). This high fidelity enzyme 
generated 3' -A overhangs which facilitated cloning into the pGem vector with 
T -overhangs. The reaction was assembled as per table 2.9 and cycling 
conditions as per table 2.10. 
Table 2.9 - Components for the Easy-A PCR reaction 
Reaction components Volume (,.t1) 
SLCO DNA template (lOOng/,.tI) 1 
Easy-A lOX reaction buffer S 
dNTPs (lOnM each) 1 
Forward primer (-SOpmol) 1 
Reverse primer (-SOpmol) 1 
Easy-A DNA polY111_erase (SUhtl) O.S 
Nuclease free dH20 40.S 
TOTAL 50 
Table 2.10 - Thermal cycling conditions for Easy-A DNA polymerase based 
PCR 
Step Temperature Time Number of cycles 
1 9SoC 2min 1 
9SoC 40 sec 
2 (Tm-SOC) 30 sec 30 
nOc 1 min / kb 
3 nOc 7min 1 
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Beta globin. 
Ampicillin 
resistance 
T7 Promoter 
pXT7 
3kb 
Flanking restriction enzyme 
SLCOgene 
1-2kb 
Beta globin 
Flanking 
restriction 
enzyme 
Figure 2.3 - pXT7 vector with SLCa gene sub-cloned and displaying the X 
laevis beta globin regions. Designed with 'A Plasmid Editor' (Davis, 2012). 
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The PCR product was confirmed on an agarose gel, then purified before 
ligating into the pGem-T vector (table 2.11). Ligated products were 
transformed into E. coli cells and positive colonies identified by cracking. 
Glycerol stocks were then made and the DNA isolated by miniprep. Positive 
colonies were further confirmed by sequencing. 
The four SLCO genes were sub-cloned from pGem-T into pXT7 by restriction 
digestion and ligation. Digests with KpnI and EagI were performed sequentially 
as the buffers were not compatible. The template was PCR purified between 
digests. The other digests were performed as double digests. Illg pXT7 vector 
DNA was also digested with corresponding enzymes. The SLCO and pXT7 
digested DNA bands of the correct size were then excised from an agarose gel 
and purified. The vector was dephosphorylated before ligation of the gene into 
the vector. The ligation was transformed into E. coli cells and plated on agar 
overnight. Glycerol stocks were made and plasmid DNA isolated by miniprep. 
Plasmids containing the gene were confirmed by restriction digestion with 
NdeI, an enzyme which cut once within pXT7 but not in the gene. Those 
visualised as the correct size on an agarose gel were confirmed by DNA 
sequencing (all methods as described in section 2.2). 
Table 2.11- Reaction assembly for a pGem-T ligation reaction 
Reaction components Volume btl) 
2X Rapid ligation buffer 5 
PCRproduct 3 
pGem-T vector (50ng/J..Ll) 1 
DNA ligase 13 U/J,l l) 1 
TOTAL 10 
2.2.14.2 Cloning SLeO genes into pcDNA3.1/Hygro(-) vector 
SLCOlA2, SLCOlBl, SLCOlB3 and rabbit SlcJ5al(PepTI)-FLAG (positive 
control) were cloned into pcDNA3.I/Hygro(-) (section 2.1.5) to facilitate 
expression in HEK293T cells. The vector contains the human cytomegalovirus 
immediate-early (CMV) promoter which allows high level constitutive 
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expression in mammalian cells. The primers were designed with a flanking 
restriction enzyme followed by the Kozak consensus sequence (GCCACC) 
upstream of the start codon, which is known to initiate translation in eukaryotes 
(Kozak, 1991) (table 2.8). SLCOJA2, SLCOJBJ, SLCOJB3 and S/cJ5aJ-FLAG 
were cloned individually into the vector with the restriction enzymes ){llOl and 
Kpnl (figure 2.4). 
The genes were amplified with Pfu polymerase in a PCR reaction then 
confirmed on an agarose gel. The product was PCR purified before digesting , 
the total volume with both enzymes in a double digest as displayed in table 
2.12. 
Table 2.12 - Components of a double restriction digest for cloning SLCO genes 
into pcDNA3.1/Hygro(-) 
Reaction components Volume btl) 
PCR product 43.5 
lOX NEB buffer 4 5 
100X BSA 0.5 
Xhol (20U/IlI) 0.5 
Kpnl High fidelity (20U/Ill) 0.5 
TOTAL 50 
The pcDNA3.1IHygro( -) vector was digested simultaneously; 1 J.lg DNA in a 
double digest as above. The PCR product and vector were then PCR purified 
and the vector dephosphorylated. The product was ligated into the vector before 
transforming into E. coli cells. Positive colonies were screened by cracking, 
confirmed by DNA sequencing and stored as glycerol stocks. Large quantities 
of DNA were isolated by maxiprep and used for HEK293T cell transformations 
(all methods as described in section 2.2). 
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pcDNA3.1/Hygro{-) 
5.6kb 
CMV Promoter 
T7 Promoter 
1 Xhol 
Gene 
Figure 2.4 - pcDNA3.lIHygro(-) vector containing a gene with XhoI and KpnI 
flanking restriction enzymes~ displaying the features of the vector. Designed 
with' A Plasmid Editor ' (Davis, 2012). 
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2.2.14.3 Cloning SLCOlA2 into the pCI-neo vector 
The SLCOlA2 gene was cloned into the pCI-neo vector (section 2.1.5) 
following poor expression ofpcDNAlSLCOlA2 in HEK293T cells. The pCI-
neo vector is a similar mammalian expression vector containing the mammalian 
CMV promoter but also contains a chimeric intron which flanks the gene 
(figure 2.5). In HEK293 cells this has been shown to increase gene expression 
by 20-fold (Brondyk, 1994). The primers containing the flanking enzymes XhoI 
and KpnIfrom the pcDNA3.1I Hygro(-) cloning (section'2.2.14.2) were used to 
sub-clone SLCOlA2 into pCI-neo. 
The pcDNA3.lISLCOlA2 plasmid and pCI-neo vector were simultaneously 
restriction digested with XhoI and Kpnl Both digests were then PCR purified 
and the pCI-neo vector was dephosphorylated. SLCOlA2 was then ligated into 
the vector before transforming into E. coli cells. Positive colonies were 
screened by cracking, confirmed by DNA sequencing and stored as glycerol 
stocks. Large quantities of DNA were isolated by maxiprep and used for 
HEK293T cell transformations (all methods as described in section 2.2). 
75 
Ampicillin 
resistance 
CMV promoter 
Chimeric Intron 
pel-neo 
5.4kb 
T7 Promoter 
Xhol 
Kozak 
SLC01 A2 gene 
1.2kb 
Figure 2.5 - pel-neo vector containing SLCOIA2 with XhoI and KpnI flanking 
restriction enzymes and displaying the features of the vector. Designed with 'A 
Plasmid Editor' (Davis, 2012). 
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2.2.14.4 Cloning FLAG epitope regions into SLCOIBI 
The FLAG epitope consisting of 8 amino acids (DYKDDDDK) was cloned 
separately into the N-terminus, C-terminus and putative internal and external 
loops ofpcDNNSLC01Bl (figure 2.6). The epitope regions once cloned could 
be detected using luminometry (section 2.5.2.3) and immunofluorescence 
(section 2.5.2.4). 
Primers were designed containing the 24 base epitope DNA sequence (table , 
2.8). Those at the Nand C termini were placed immediately after the start 
codon and before the stop codon as separate clones. Two PCR methods were 
used, as described below, using Pfu polymerase, 10% dimethyl sulfoxide 
(DMSO) and the ramp cycling method. 
A two stage primer method was used to insert the FLAG sequence into the N 
and C termini, owing to the length of the sequence to be inserted. Two primers 
were designed for each terminal, each containing half of the FLAG sequence. 
One primer was used to amplify the first part of the FLAG sequence, the 
product PCR purified, then placed in a second PCR reaction with the primer 
containing the second part of the FLAG sequence. The flanking forward and 
reverse primers used to clone SLC01Bl into pcDNA3.l/hygro(-) (section 
2.2.14.2) were used for the opposite end of the gene. 
An overlap-PCR method (Heckman and Pease, 2007) was used for cloning the 
FLAG epitope into all other internal and external loops. Two fragments were 
generated; from the beginning ofthe gene to the end ofthe FLAG epitope, and 
the beginning of the FLAG epitope to the end of the gene (figure 2.7). 
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Figure 2.6 - Depiction ofOATPlBl predicted topology with 12TMs and internal and external loops with FLAG epitope insertions. 
FLAG pl'lme .. fo"Wal'(l 
> 
> Pl'Unel' reve .. se 
--------- FLAG tpltopt ~<"";"---
BtgbmlIlg of gtIlt < Elld of gtllt 
FLl\G pl'Une .. l'evel'St 
Figure 2.7 - Principle of the overlap-PCR method, Two PCR fragments were 
generated, from the beginning of the gene to the end of the FLAG, and from the 
beginning of the FLAG to the end of the gene, 
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The two fragments were visualised by DNA gel electrophoresis then PCR 
purified. The DNA fragments were then quantified and 50ng. each combined 
with the original forward and reverse primers in another PCR reaction. This 
produced the full gene product with the epitope region in the correct location. 
The full gene products from the two stage and overlap PCR were then excised 
from an agarose gel and purified before restricting the total volume with XhoI 
and KpnI in a double digest. The pcDNA3.1/hygro(-) vector was 
simultaneously digested. The PCR product and vector were then PCR purified 
and the vector dephosphorylated. The product was ligated into the vector before 
transforming into E. coli cells. Positive colonies were screened by cracking, 
confirmed by DNA sequencing and stored as glycerol stocks. Large quantities 
of DNA were isolated by maxi prep and used for HEK293T cell transformations 
(methods as described in section 2.2). 
2.2.14.5 Mutagenesis of the signature sequence region in SLCOIBI 
The 13 amino acid OA TP signature sequence is highly conserved between 
species but its function is not known. The importance of the signature sequence 
region in SLCOIBI (DSRWVGAWWLNFL) was determined by SDM of the 
highly conserved amino acids (table 2.13). The amino acid changes were made 
with mutagenic primers (table 2.8) and introduced to pcDNNSLCOIBI-F4 
using the overlap-PCR and cloning method described in section 2.2.14.4. 
Confirmation of the mutation was obtained by DNA sequencing (section 
2.2.13). 
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Table 2.13 - Site-directed mutations in the signature sequence of SLeOlEl. 
The amino acids in bold were mutated 
Name Original protein sequence Mutated protein sequence 
D251E DSRWVGA WWLNFL ESRWVGAWWLNFL 
R253K DSRWVGAWWLNFL DSKWVGA WWLNFL 
W254F DSRWVGA WWLNFL DSRFVGA WWLNFL 
W258/259F DSRWVGAWWLNFL DSRWVGAFFLNFL 
N261A DSRWVGAWWLNFL DSRWVGAWWLAFL 
2.3 Xenopus laevis oocyte methods 
The X laevis oocyte model is an established method for expressing transport 
proteins. Oocytes were removed from frogs and prepared before micro-injection 
with cRNA for the transport protein of interest. Transport function was assessed 
by radioactive substrate transport experiments. 
2.3.1 Preparation and maintenance of oocytes 
Oocytes were harvested from female African clawed X laevis frogs (European 
Xenopus Resource Centre, Portsmouth University, Portsmouth, UK) as 
approved by the Oxford Brookes University Animal Research Committee, in 
accordance with the guidelines of the 1986 Scientific Procedures Act of the 
United Kingdom. Frogs were anesthetised on 1: 1 ice/water mix for 30-45 
minutes before sacrificing by decapitation. An incision was made on the 
posterior ventral side and ovary lobes were removed, by sterile scalpel and 
forceps. 
Ovaries once removed were treated to remove the follicular membrane (section 
2.3.1.1). Oocytes were stored pre and post-injection in Barths's solution (table 
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2.14) at 17.5°C. The solution was stored at 4°C and O.4J.lM sterile filtered before 
use. 
Table 2.14 - Composition of Barth's solution for X laevis oocytes 
Component Concentration 
NaCl 88mM 
KCl ImM 
MgS04 0.82mM 
CaN03 0.33 mM 
NaHC03 2.4mM 
CaCh 0.41 mM 
HEPES (adjusted to pH 7.6 with 15mM 
10M NaOH) 
Sodium pyruvate* 5mM 
-
Gentamycin sulphate salt* 501lg/ml 
* Added after the pH of the solutIOn had been set. 
2.3.1.1 Oocyte defolliculation 
Oocytes were defolliculated to facilitate micro-injection. Ovary lobes were 
separated into approximately 5mm sections using forceps, then incubated in 
1 mglml collagenase from Clostridium histolyticum (Sigma, Dorset UK), in 
calcium free solution (table 2.15) on a tube roller. The oocytes were incubated 
at room temperature for 45 minutes then fresh collagenase solution exchanged 
and incubated for a further 45 minutes. Following defolliculation oocytes were 
washed five times with calcium free solution and then five times with Barth's 
solution (table 2.14). Oocytes were maintained in Barth's solution at 17.5°C for 
24 hours prior to micro-injection. Barth's solution was exchanged daily and 
dead oocytes removed. 
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Table 2.15 - Components of calcium free solution 
Component Concentration Jml\'Q. 
NaCI 80 
KCI 2 
MgCh 1 
HEPES (adjusted to pH 7.6 with 5 
10M NaOH) 
2.3.2 cRNA synthesis 
cRNA was synthesised in preparation for oocyte micro-injection. The pXT7 
vector DNA containing the SLCO gene of interest was grown fresh from a 
glycerol stock and isolated using the miniprep method (section 2.2.11.1). The 
plasmid was linearised and purified (section 2.3.2.1) then used as template 
DNA for cRNA synthesis (section 2.3.2.2). The newly synthesised cRNA was 
further purified using an RNA specific clean up kit prior to micro-injection. 
2.3.2.1 Plasmid linearisation and purification 
The pXT7/SLCO plasmid was linearised with NdeI (NEB, Hitchin UK), a 
restriction enzyme present only in the vector, downstream of the gene to be 
transcribed. This process ensured that specifically the gene and not the entire 
plasmid were transcribed into cRNA. The restriction digest was assembled as 
shown in table 2.16, overnight at 37°C. 
Table 2.16 - Components of a restriction digest in preparation for cRNA 
synthesis 
Reaction components Volume/amount 
Template DNA 10H 
lOX NEBbuffer lO~1 
NdeI (20U/lll) llll 
Nuclease free dH20 Up to lOO1l1 
TOTAL lO0.l!1 
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The linearised DNA was purified using the Qiagen PCR purification kit 
(section 2.2.2) and then assembled into a cRNA synthesis reaction (section 
2.3.2.2). 
2.3.2.2 cRNA synthesis reaction 
cRNA synthesis was performed using the Ambiori® mMessage mMachine T7 
kit (Life Technologies, Paisley UK). All RNA experiments were conducted in a 
dedicated RNA work area and the area and equipment cleaned for RNases using 
RNaseZap (Life Technologies, Paisley UK). All reactions were performed with 
Ambion® RNase free consumables (Life Technologies, Paisley UK). The 
reaction was set up as listed in table 2.17. All components except for the lOX 
reaction buffer were thawed on ice and the reaction buffer and NTP/CAP were 
vortexed before use. The reaction was assembled at room temperature and 
incubated for 3 hours at 37°C. 
Table 2.17 - Components of a cRNA synthesis reaction 
Reaction components Volume btl) 
Purified template DNA 6 
2XNTP/CAP 10 
lOX Reaction buffer 2 
T7 Enzyme Mix 2 
TOTAL 20 
Following cRNA synthesis 1 III TURBO DNase solution (2UIIlI) was added to 
the reaction to remove any remaining DNA template. The tube was incubated 
for a further 15 minutes at 37°e. 
2.3.2.3 cRNA purification 
The newly synthesised cRNA was purified using the RNeasy Mini Kit (Qiagen, 
Crawley UK). Purification was conducted at room temperature and all mixing 
steps were performed by pipetting rather than vortexing. In addition, all 
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centrifugation steps were performed at 13,OOOrpm. The cRNA was adjusted to 
1 00~1 with 80~1 Ambion® nuclease free dH20 (Life Technologies, Paisley UK) 
and 350~1 buffer RL T was added to the tube. Then 250~1 100% molecular 
grade ethanol (Sigma, Dorset UK) was added and mixed. The entire volume 
was transferred to an RNeasy mini spin column placed in a collection tube and 
centrifuged for 15 seconds. The collection tube was replaced after each 
centrifugation step to reduce contamination. Then 500~1 buffer RPE was added 
and the column centrifuged for 15 seconds. A further 500~1 buffer RPE was ,. 
added to the column before centrifuging for 2 minutes. The column was then 
centrifuged for a further 1 minute to remove residual ethanol before placing in 
an RNase free 1.5ml tube and 30~1 DNase free water added directly to the 
membrane. The column was incubated for 1 minute before centrifuging for 1 
minute to elute the RNA. 
RNA was quantified using a spectrophotometer (section 2.2.12). Typical cRNA 
recoveries were between 1-3~g/~1. The RNA was visualised on a 1 % agarose 
gel (section 2.2.4). RNA was stored at -80°C and maintained on ice throughout 
use. 
2.3.3 Oocyte micro-injection 
Oocytes following collagenase treatment at approximately 1 mm diameter and 
with a healthy appearance were selected for micro-injection. Injections were 
achieved with a Nanoject II injector (Drummond Scientific, c/o Alpha 
Laboratories Ltd, Eastleigh UK) under a Leica MZ6 light microscope (Wetzlar, 
Germany). Oocytes were injected using disposable glass capillary needles made 
with a PC-l 0 puller (Narishige, London UK). Needles were filled with mineral 
oil before filling with cRNA to facilitate injection. Approximately 30 oocytes 
per experimental condition were injected with 27ng cRNA into the vegetal pole 
of the oocyte (figure 2.8). The animal pole was avoided to reduce the likelihood 
of damaging the nucleus. Water-injected and/or non-injected oocytes were used 
as controls. Injected oocytes were transferred to a new dish with fresh Barth's 
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solution. Oocytes were incubated for 72 hours at 17.SoC, with Barth's solution 
changed and dead oocytes removed daily. 
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cRNA injection 
Animal pole 
X laevis oocyte 
Figure 2.8 - Schematic diagram of aX laevis oocyte displaying the vegetal 
and animal poles. cRNA was injected into the vegetal pole. 
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2.3.4 Oocyte transport experiments 
Transport by OA TP expressing oocytes was determined by measuring the 
radioactive substrate eH]E3S. At 72 hours post-injection 5 healthy oocytes per 
experimental condition (including control non-injected and water-injected 
oocytes) were selected and placed in freshly made uptake solution (table 2.18). 
All stages of the experiment were conducted at room temperature. 
Table 2.18 - Components of uptake solution for oocyte transport experiments 
Component Concentration (mM) 
NaCI 95 
KcI 2 
CaCh I 
MgCh I 
HEPES (adjusted to 20 
pH 7.4 with O.SM 
TRIS) 
After approximately 30 minutes in uptake solution the oocytes were transferred 
to uptake solution containing 37nM eH] E3S (Perkin Elmer, MA USA), 5 
oocytes per 100J,l1. Oocytes were incubated for various time points. Individual 
oocytes were then washed sequentially five times in Iml 0.12M NaCI before 
being transferred individually to a flexible 96 well microplate (Perkin Elmer, 
Cambridge UK). Oocytes were lysed with the addition of SOJ,l1 2% SDS and 
placed on a plate shaker for I hour at room temperature. Following lysis 200J,l1 
scintillation fluid (Optiphase Supermix, Cambridge UK) was added per 
oocyte/well and a plate sealer added (Perkin Elmer, Cambridge UK). The plate 
was placed on a plate shaker for I hour before counting in a Microbeta Trilux 
1450 liquid scintillation and luminometry counter (Perkin Elmer, Cambridge 
UK). eH]E3S was detected as counts per minute (cpm) at 1 minute per well. 
The counting protocol was standardised to radioactive controls to account for 
quenching agents. The efficiency was 41.4% which resulted in 49.9 
cpmlfemtomol (fmol). Sample counts were converted to fmol and reported as 
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fmol/oocyte. Data were expressed as the mean ± standard error (SE) and data 
analysis were performed as discussed in section 2.7. 
2.4 HEK293T cell culture methods 
HEK293T cells were also utilised for OATP expression. Cells were transiently 
transfected with the SLea gene using an electroporation method and transport 
function was assessed by radioactive substrate transport ~xperiments. 
2.4.1 Maintenance of HEK293T cells 
HEK293T cells (section 2.1.3) were routinely grown in 75cm2 flasks with 10ml 
complete media (table 2.19) and incubated at 37°C with 5% CO2. Fresh media 
was exchanged every 2 days or when the media changed colour. Cells were 
grown in complete media unless stated otherwise. 
Table 2.19 - Components of complete media for HEK293T cells 
COI1!~onents VolumeJm!l 
Dulbecco's modified eagles media 500 
(Life Technologies, Paisley UK) 
Fetal bovine serum (Heat inactivated) 50 
(Life Technologies, Paisley) 
Penicillin-Streptomycin solution, 100X 5 
L-Glutamine,200mM 5 
Non-essential amino acid solution, 100X 5 
Amphotericin B solution, 250~g/ml 0.5 
2.4.1.1 Routine sub-culturing of HEK293T cells 
HEK293T cells were sub-cultured after -3 days or when cells reached 70% 
confluence. Cells were not grown further than passage 15 to ensure 
maintenance of phenotype and high protein expression. The media was 
removed and the flask washed with 10ml cell culture grade phosphate buffered 
saline (PBS) (Sigma, Dorset UK). This PBS was used for all further cell culture 
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methods unless stated otherwise. Cells were detached from the plate by 
incubating with 5ml 0.05% trypsin-EDTA (Life Technologies, Paisley UK) in 
PBS for 5 minutes at 37°C. The flask was then knocked by hand to dislodge 
cells and confirmed by visualising on a Motic AE31 inverted light microscope 
(Wetzlar, Germany). 5ml pre-warmed complete media was added to the cell 
suspension and the total volume was centrifuged at 1300rpm for 5 minutes. The 
supernatant was discarded and the pellet resuspended in I Oml complete media. 
This was split 1110 (-lxlO7 cells175cm2 flask) between 75cm2 flasks containing 
10ml pre-warmed complete media. 
2.4.1.2 Cryopreservation of HEK293T cells 
Cell stocks at passage numbers -2-6 were maintained in liquid nitrogen for long 
term storage. Stocks were prepared by growing HEK293T cells until confluent 
and sub-cultured as described in section 2.4.1.1. The cell pellet was 
resuspended in Iml complete media including 5% DMSO (Sigma, Dorset UK) 
as a cryoprotective agent. The cell suspension was placed immediately in a 
sterile cryogenic vial and stored in an isopropanol chamber overnight at -80°C. 
The vials were then transferred to liquid nitrogen for long term storage. 
2.4.1.3 Thawing cryopreserved HEK293T cells 
Working HEK293T cell stocks at low passage number were generated from 
cryopreserved stocks stored in liquid nitrogen. Individual cryovials were 
removed from liquid nitrogen and thawed rapidly in a water bath pre-warmed to 
37°C. Immediately after all ice in the solution had thawed the vial was 
transferred to a 50ml tube and centrifuged for 5 minutes at 1300rpm. The 
supernatant was removed and the pellet resuspended in I ml pre-warmed media. 
The total volume was then transferred to a 25cm2 flask with 5ml pre-warmed 
media. Cells were sub-cultured into 75cm2 flasks after 24 hours or when the 
cells were attached and -60-80% confluent. Once in 75cm2 flasks cells were 
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sub-cultured once more to ensure the working stocks were stable before 
conducting experiments. 
2.4.2 HEK293T cell experiments 
2.4.2.1 HEK293T cell transfections 
Cell transfection experiments were conducted in order to deliver the SLea gene 
into cells. Cells transfected with the SLea gene then translated the gene into 
protein on the membrane. Transfection was achieved using the Amaxa® cell 
line nuc1eofector® kit V (Lonza, Preston UK), specific for HEK293T cells. The 
kit is based on an electroporation method and is compatible with the Amaxa 
nuc1eofector II device (Lonza, Preston UK; model # AAB-l 00 1). The method 
involved removing the cells from the flask, electroporating the cells, then 
plating the cells in plates or dishes specific to the experiment required. Before 
electroporation, plates and/or dishes were required to be coated with poly-D-
lysine (section 2.4.2.1.1). 
2.4.2.1.1 Coating plates with poly-D-Iysine 
Transport experiments were conducted in 12 well cell culture plates (Appleton 
Woods Ltd, Birmingham UK), immunofluorescence experiments were 
conducted in 12 well plates with 15mm glass coverslips (Bioquote, York UK) 
and luminometry experiments were conducted in 35mm x 10mm dishes 
(Coming, Ewloe UK). Cover slips were prepared by individually soaking in 
100% ethanol for 1 minute before air drying and placing in 12 well plates with 
sterile tweezers. Before plating cells, each surface required coating with poly-
D-Iysine to facilitate cell adherence. Poly-D-Iysine solution (Millipore, Watford 
UK) was used at a concentration ofO.lmg/ml diluted in PBS. For 12 well plates 
800llllwell was added, for 35mm dishes Imlldish was added. Plates/dishes were 
incubated at 4°C for 3-72 hours then washed once with PBS before use. 
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2.4.2.1.2 HEK293T cell transfection method 
The cell transfection method using the kit and device mentioned in section 
2.4.2.1 is the same for transport, immunofluorescence and luminometry 
experiments. The plates/dishes previously coated with poly-D-Iysine (section 
2.4.2.1.1) were prepared by adding transfection media (table 2.20) then sealed 
with micropore surgical tape for sterility. Volumes are stated in table 2.21. The 
plates/dishes were then pre-warmed to 37°C in the incubator. 
Table 2.20 - Components oftransfection media for HEK293T cells 
Components Volume (ml) 
Dulbecco's modified eagles media 500 
(Life Technologies, Paisley UK) 
Fetal bovine serum (Heat inactivated) 50 
(Life Technolol2;ies, Paisley) 
L-Glutamine,200mM 5 
Non-essential amino acid solution, 100X 5 
Table 2.21- Volumes ofHEK293T transfection media and cell suspension 
required per plate/dish type 
Plate type Volume of Final volume of cell Number of 
transfection suspension added wells per 
media required to plate/dish (,..,1) cuvette 
(ml) 
12 well~late 3 100 6 
12 well plate 3 100 6 
with cover 
slips 
35mm dish 2 150 4 
A 75cm2 flask containing cells at 80-90% confluence was washed with 10ml 
PBS. The flask was then incubated with I Oml accutase (Millipore, Watford 
UK) for 5 minutes at 37°C. Accutase is a cell detachment solution found to 
cause less stress to cells before transfection than trypsin. Cells were dislodged 
as described in section 2.4.1.1. 5ml pre-warmed 37°C transfection media was 
added to the cell suspension and the total volume was centrifuged at 1300rpm at 
room temperature for 5 minutes. The supernatant was discarded and the pellet 
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resuspended in 500J.lI transfection media. The cell density was measured by 
removing 10J.lI and combining with 10J.lI 0.4% trypan blue solution (Sigma, 
Dorset UK) then counted using a standard glass haemocytometer. 
The cells were then divided into aliquots of 1 x 106 cells as required per 
cuvette. Each aliquot was centrifuged 1 646rpm at room temperature for 10 
minutes. The supernatant was completely removed and the pellet resuspended 
in lOOJ.lI nucleofector solution provided in the kit. Then 5J.lg maxiprep purified 
plasmid DNA was added to each cell aliquot and the total volume added to a 
• 
cuvette. Each cuvette was electroporated under program Q-OOI of the 
nucleofector device. Following electroporation 500J.lI transfection media was 
added directly to the cuvette and the entire volume transferred to a 1.5ml tube. 
Aliquots of the cell suspension were transferred to the prepared plates. The 
volumes required per plate type and number of wells filled per cuvette are 
displayed in table 2.21. Micropore tape was placed around the edges of the 
plates before incubating for 72 hours. Transfection media was exchanged 50% 
for complete media after 24 hours. 
2.4.2.2 IIEK293T cell transport experiments 
OA TP radioactive transport experiments were conducted using eH]E3S. 
HEK293T cells transfected with the SLea gene or vector alone in 12 well 
plates were removed from the incubator at 72 hours post-transfection 
(approximately 80% confluence). The media was aspirated and the wells 
washed three times with 1 ml freshly made uptake solution (table 2.22) pre-
warmed to 37°C. 
93 
Table 2.22 - Composition of uptake solution for HEK293T cell transport 
experiments 
Component Amount (mM) 
NaCI 142 
KCI 5 
KH2P04 I 
MgS04 1.2 
CaCh 1.5 
Glucose 5 
HEPES (Adjusted with TRIS to 12.5 
pH 7.3) 
Cells were then incubated in O. I J.1M eH]E3S (Perkin Elmer, Witney UK) in 
300J.11 uptake solution for 3 minutes at 37°C. The transport was stopped by the 
addition of Iml ice cold uptake solution per well. Each well was washed a 
further three times with ice cold uptake solution before the addition of200J.11 
1% SDS/O.5M NaOH. The plate was then placed on a plate shaker at room 
temperature for I hour. Transport experiments were quantified by liquid 
scintillation counting and protein quantification. For liquid scintillation 
counting 50J.11 of the celllSDSINaOH solution was removed and placed in a 
flexible 96 well microplate (Perkin Elmer, Witney UK). Then 200J.11 
scintillation fluid (Optiphase Supermix, Perkin Elmer, Witney UK) was added 
per well and a plate sealer added (Perkin Elmer, Witney UK). The plate was 
placed at room temperature on a plate shaker for 1 hour before counting in a 
Perkin Elmer 1450 Microbeta Trilux liquid scintillation and luminometry 
counter (Witney, UK). 
Cell transport experiments were performed with at least 3 well replicates and 
eH]E3S detected by liquid scintillation counting as disintegrations per minute 
(dpm) at 20 minutes per well. The protocol was standardised to radioactive 
controls to account for quenching agents and determine the efficiency of the 
counter. The efficiency was 35.5% which resulted in 42.8 dpmlfmol. Sample 
counts were converted to fmol/pmol, then adjusted to (fmol/pmol)/mg protein 
in the sample using a BCA protein quantification method (section 2.4.2.2.1). 
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Data were displayed as mean ± SE. Data analysis and transport kinetics were 
performed as discussed in section 2.7. 
2.4.2.2.1 Protein quantification 
HEK293T protein was quantified using a BCA protein assay kit (Merck, 
Feltham UK), conducted in a 96 well flat bottom plate. BSA (BDH 
Biochemicals, Poole UK) standards were calculated as shown in table 2.23, 
• 
with 1 % SDS/O.5M NaOH as diluent. The standards were added in triplicate, 
25~Vwell. As a blank control25~1 diluent was also added in triplicate. 25~1 of 
each sample was also added to the plate, diluted if necessary to ensure the 
absorbance results were within the range of that of the standards. 
Working BCA reagent was prepared by adding 4~14% cupric sulphate to 200~1 
BCA reagent per sample. A mastermix was made and 200~1 working reagent 
added per well. The plate was mixed on a plate shaker at room temperature for 
1 minute then incubated at 60°C for 15 minutes. 
The plate was left to cool to room temperature then measured on a Benchmark 
microplate reader (Biorad, Hemel Hempstead UK) at 490nm. Absorbances 
were corrected for interactions by the diluent through subtracting the blank 
absorbances from the sample and standard absorbances. A standard curve was 
generated by plotting the corrected standard absorbances against BSA 
concentration. Sample protein amounts were calculated from the equation 
generated from the standard curve. 
Table 2.23 - BSA standards required for BCA protein quantification 
Tube Volume ofBSA (Ill) Volume of diluent Final concentration 
(1 % SDS/O.5M (mg/ml) 
NaOn) btl) 
1 100 (from 10mg/ml 900 1 
stock) 
2 800 (from tube 1) 200 0.8 
3 750 (from tube 2) 250 0.6 
4 666 (from tube 3) 334 0.4 
5 500 (from tube 4) 500 0.2 
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2.4.2.3 HEK293T celiluminometry 
Luminometry was used to detect OA TP protein present in the membranes of 
HEK293T cells. To summarise; the FLAG epitope was cloned into putative 
extracellular and intracellular regions of the protein (section 2.2.14.4) and an 
anti-FLAG antibody was used to detect the epitope on the membrane. Cells 
expressing OA TPs with putative internal FLAG epitopes were pemeabilised to 
allow the antibody into the cell. The antibody was HRP conjugated and thus 
with the addition of a substrate light was produced, which could be detected 
quantitatively using a luminometer. 
The following method is adapted following personal correspondence with Dr 
Kevin Paavola, Emory University, USA (Paavola et al., 2011). OA TP 
transfected HEK293T cells grown in 3Smm dishes as described in section 
2.4.2.1.1 and 2.4.2.1.2 were used for experiments 72 hours post-transfection, or 
when the cells reached 100% confluence. 
The dishes were placed on ice, media removed and washed twice with PBS. 
Cells were then fixed to the dishes at room temperature with Im14% 
paraformaldehyde (Agar Scientific, Essex UK) in PBS for 30 minutes. For cells 
requiring pernleabilisation, the above fix solution was supplemented with 
0.2S% Triton-XI 00 (Sigma, Dorset UK). Dishes were then washed twice with 
PBS. 
Blocking was performed with 2% Marvel skimmed milk (Premier Foods, Herts 
UK) buffer in PBS for 30 minutes at room temperature. Primary monoclonal 
mouse HRP-conjugated anti-FLAG antibody (Sigma, Dorset UK) was 
immediately added, 1 ml at I: 1000 dilution in milk buffer. Dishes were 
incubated for 2 hours at room temperature. Cells were then washed twice with 
milk buffer and once with PBS. The PBS remained in the dish ready for 
Iuminometry experiments. 
PBS was replaced with 1 ml substrate (Pierce Protein Research Products , 
Loughborough, UK), which was added to the dish for IS seconds before 
analysing in a TD-20/20 luminometer (Turner Designs, c/o R.S Aqua Ltd, 
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Alton UK). Luminometry readings were taken with a 5 second delay and 30 
second measurement. Protein was quantified using the BCA protein assay kit as 
described in section 2.4.2.2.1. Substrate was removed and the dishes washed 
once with PBS. 1 ml 1 % SDS / 0.5M NaOH was added per dish and the fixed 
cells removed from the bottom of the dish by scraping with a plate scraper. The 
cells were lysed using a plate shaker overnight, then 25Jll of each sample was 
removed for protein quantification. 
Luminescence was displayed as luminescence/mg protein in relative light units , 
(RLU) by normalising raw luminescence values to the protein content in each 
dish. Sample values were displayed as mean ± SE and data analysis performed 
as described in section 2.7. 
2.4.2.4 HEK293T cell immunofluorescence 
An immunofluorescence technique was used to visualise OA TP protein in the 
membranes of HEK293T cells, under a confocal microscope. Detection was 
achieved using an anti-FLAG antibody which recognised the external FLAG 
eptiope region in the protein, coupled to a fluorescein isothiocyanate (FITC) 
secondary antibody which fluoresced at 488nm. The nuclei were also stained 
for visualisation. Cells expressing OA TPs with putative internal FLAG epitopes 
were pemeabilised to allow the antibody into the cell. The following method is 
optimised from the anti-FLAG antibody manufacturer's instructions (Sigma, 
Dorset UK). 
SLea transfected HEK293T cells grown on cover slips in 12 well plates as 
described in section 2.4.2.1.1 and 2.4.2.1.2 were used for experiments 72 hours 
post-transfection. All steps were performed at room temperature with coverslips 
remaining within the wells unless otherwise stated. 
Wells were washed with Iml PBS then cells fixed by the addition of Im14% 
paraformaldehyde, 4% sucrose (BDH Biochemicals Ltd, Poole UK) in PBS for 
15 minutes. For cells requiring permeabilisation, the above fix solution was 
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supplemented with 0.25% Triton-XI 00 (Sigma, Dorset UK) in PBS. Wells 
were then washed with Iml PBS twice at 5 minute intervals. 
Wells were blocked with ImllO% BSA in PBS for 30 minutes at 37°C. The 
blocking solution was removed and Iml primary monoclonal mouse anti-FLAG 
antibody (Sigma, Dorset UK) at 1 :2000 dilution in 5% BSAfPBS was added to 
the wells. Incubation was for 2 hours at 37°C. Wells were washed with Iml 
PBS three times at 5 minute intervals. Then I ml anti-mouse IgG-FITC rabbit 
secondary antibody (Sigma, Dorset UK) in a 1: 1000 dilution with 5% 
BSAfPBS was incubated for 45 minutes at 37°C. Wells were washed three 
times with I ml PBS at 5 minute intervals. 
Before mounting, wells were incubated with 4',6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) (Sigma, Dorset UK), a nucleic acid stain that 
fluoresces at 504nm. Wells were incubated with Imllllg/ml DAPI in dH20 for 
2 minutes. Wells were then washed three times with Iml PBS and the last wash 
left on the plates. The cover slips were then removed from the wells with 
tweezers and mounted face down over a drop of polyvinyl alcohol mounting 
media containing 1,4-diazabicyclo[2.2.2Joctane (DABCO) (Sigma, Dorset UK) 
on a standard glass slide. Nail varnish was used to seal the edges of the cover 
slip and the slides stored in the dark overnight at 4°C. Slides were visualised on 
a confocal microscope within 7 days of mounting. 
A Zeiss LSM 510 META was used for confocal microscopy. The blue 
fluorescence of DAPI was excited with a 405 nm diode laser and detected after 
passing through a 420-480 nm band-pass filter. The green fluorescence of FITC 
was excited with the 488 nm line of an argon ion laser and detected after 
passing through a 505-530 nm band-pass filter. Pinhole diameter and gain 
settings varied based on brightness of stain emission on a sample-to-sample 
basis. 
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2.5 Membrane vesicle methods 
Membrane vesicles are useful for studying the overall transport and inhibition 
of endogenously expressed membrane proteins. This method has been adapted 
from a personal communication with Dr David Meredith (Oxford Brookes 
University, Oxford UK). Rat kidney membrane vesicles were used to study 
endogenous Oatp transport. 
2.5.1 Preparation of membrane vesicles 
Kidneys were removed from female Wistar rats (HarIan UK Ltd, Oxon UK) 
following euthanasia in house and placed on ice. The connective tissue, fat and 
medulla were removed with a scalpel and the remaining cortex tissue cut into 
small pieces. Suspension solution (table 2.24) was heated until the ethylene 
glycol tetraacetic acid (EGTA) was dissolved and cooled to 4°C before use. The 
tissue was transferred to 100ml suspension buffer and homogenised on ice 
using an IKA T1 0 basic homogeniser (IKA, c/o Labsource, Manchester UK). 
Table 2.24 - Components of suspension solution for membrane vesicles 
Component Concentration 
Mannitol 300mM 
EGTA 5mM 
TRIS-HCI 12mM 
KOH (Adjust pH to 7.4) 10M 
Once fully homogenised 12mM MgCb was added to the solution and the 
volume incubated for 15 minutes on ice. A series of centrifugation steps were 
then conducted, as described in figure 2.9. Suspension buffer was diluted two 
fold with dH20 and the membrane pellet re-suspended in experimental buffer 
(table 2.25) was stored at -80°C. 
99 
Table 2.25 - Components ofthe experimental buffer for membrane vesicle 
experiments 
Component Concentration (ml\1l 
NaCI 100 
Mannitol 20 
MgS04 0.1 
HEPES (Adjusted with 80 
TRIS to pH 7.4) 
Membrane aliquots were thawed on the day of vesicle uptake experiments. The 
protein in the sample was quantified using a Bradford's assay (Bradford, 1976). 
BSA standards were assembled as shown in table 2.26. Absorbance was 
measured by adding 2.9ml protein assay dye (Biorad, Hemel Hempstead UK) to 
100J.ll sample/standard and read at 595nm in a Jenway 6505 UV 
spectrophotometer (Bibby Scientific Limited, Staffordshire UK). Blank control 
absorbances were measured with 100J.ll dH20 and 2.9ml Bradford's reagent. 
Table 2.26 - BSA standards required for Bradford's protein quantification 
Tube Volume ofBSA (Ill) Volume of diluent Final concentration 
JdH2Q1 btl) (J.l2/ml) 
I 50 (from IOmg/ml 950 500 
stock) 
2 500 (from tube I) 500 250 
3 400 (from tube 2) 600 100 
4 500 (from tube 3) 500 50 
5 200 (from tube 4) 800 10 
Each membrane preparation yielded -200J.lg/ml protein. The membrane sample 
was diluted to allow for 50J.lg/well protein. The total volume was drawn 
through a Iml syringe with a 25 gauge needle (Terumo Medical Corporation, 
Renfrewshire UK) 15 times to form the membrane vesicles. 
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Rat kidney membrane homogenate 
Pellet 
(Discard) 
Supernatant 
(Discard) 
Supernatant 
, 
3000g /15 min / room 
temperature 
I 27,000g / 30 min /4oC 
• 
Pellet - 100ml diluted suspension 
buffer & 12mM MgC12 15 min on ice 
/ 
I 
3000g / 15 min / 
Pellet 
(Discard) 
, room temperature 
Supernatant 
/ I 27,000g 130 min 1 
Pellet , room temperature 
(Discard) 
Supernatant 
(Discard) 
Pellet - 30ml 
experimental buffer 
/ 27,000g / 30 min / 
room tern perature , 
./ Pellet - 500111 experimental 
/ buffer 
Supernatant 
(Discard) 
Figure 2.9 - Flow chart representing the centrifugation steps required to isolate 
membrane vesicles. 
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2.5.2 Membrane vesicle transport experiment 
The transport of eH]E3S into rat kidney vesicles endogenously expressing rat 
Oatplal and Oatp4cl was quantified using a membrane vesicle uptake 
experiment. This involved incubating the vesicles with eH]E3S, capturing the 
vesicles on a filter membrane and measuring the radioactivity contained within 
them. 
A Multiscreen HTS filter plate (Millipore, Watford UK) was prepared by 
adding 100111 experimental buffer (table 2.25) per well and incubating the plate 
on ice. Experimental buffer was pre-warmed to 37°C. 50llg membrane vesicles 
were combined with 37nM eH]E3S or 37nM eH]E3S + 200llM E3S (control) 
in experimental buffer to a total of 50111 (table 2.27). The plate was incubated 
for 30 minutes at 37°C. The reaction was stopped by the addition of2001l1 ice 
cold wash solution (table 2.28) per well. 
Table 2.27 - Layout of the membrane vesicle assay plate 
Tim 1 I 2 I 3 I 4 5 I 6 7 I 8 I 9 I 10 I 11 I e 12 
A 0 Vesicles + 37nM [ H]E3S Vesicles + 37nM [",H]E3S + 200llM 
min E3S 
B 1 Vesicles + 37nM ['>H]E3S Vesicles + 37nM [",H]E3S + 200llM 
mm E3S 
C 5 Vesicles + 37nM [JH]E3S Vesicles + 37nM [JH]E3S + 200llM 
mm E3S 
D 10 Vesicles + 37nM [JH]E3S Vesicles + 37nM [JH]E3S + 200llM 
mm E3S 
E 20 Vesicles + 37nM ['>H]E3S Vesicles + 37nM [",H]E3S + 200llM 
min E3S 
F 30 Vesicles + 37nM [",H]E3S Vesicles + 37nM [JH]E3S + 200llM 
min E3S 
G nfa nfa nfa 
H nla 37nM [JH]E3S 37nM [JH]E3S nla 
control + 200llM E3S 
control 
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Table 2.28 - Components of wash solution for membrane vesicle uptake 
experiments 
Component Concentration -(mM) 
NaCI 150 
MgS04 50 
Mannitol 30 
TRIS (Adjusted with 5 
MES to pH 5.5) 
The total volume was transferred to the prepared filter plate and the solution , 
filtered using a Multiscreen HTS vacuum manifold (Millipore, Watford UK). 
The wells were washed a further 5 times with 200~1 ice cold wash solution 
before drying at 50°C for 15 minutes. The vesicles were released from the 
filters by incubating with 200~1 scintillation fluid (Optiphase Supermix, Perkin 
Elmer, Witney UK) for 10 minutes at room temperature. The vesicle solution 
was filtered into a 96 flexible well plate (Perkin Elmer, Witney UK) and a plate 
sealer added (Perkin Elmer, Witney UK). Radioactivity was counted using a 
Perkin Elmer 1450 Microbeta Trilux liquid scintillation counter (Witney UK). 
Vesicle experiments were performed with 6 well replicates and eH]E3S 
detected by liquid scintillation counting as counts per minute (cpm) at varying 
time points (table 2.27). The protocol was standardised to radioactive controls 
to account for quenching agents and determine the efficiency ofthe counter. 
The efficiency was 35.5% which resulted in 42.8 cpmlfmol. Sample counts 
were converted to fmol, then adjusted to fmollmg membrane protein. Data was 
displayed as mean ± SE and data analysis was performed as discussed in 
section 2.7. 
2.6 In silico modelling 
2.6.1 Topology modelling 
Protein sequences corresponding to the cDNA clones described in section 2.1.4 
were obtained from the National Center for Biotechnology Information (NCBI) 
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website (http://www.ncbi.nlm.nih.gov). Sequences were submitted to 16 
topology prediction programs and 9 signal peptide prediction programs online 
(section 4.2.1 and appendix I-V for the list of programs and results). 
2.6.2 OATPIBI homology modelling 
Homology modelling was performed by submitting the OATPIBl protein 
sequence (obtained as described in section 2.6.1) to the Phyre2 protein fold 
recognition server (www.sbg.bio.ic.ac.uklphyre2). 
2.7 Data analysis 
Sample values for transport and luminometry experiments were displayed as 
mean ± SE, with outliers removed using a Grubb's test (Graphpad Prism 5, 
Version 5.04 for Windows, California USA, www.graphpad.com). Statistical 
significance (P<0.05) between controls and sample data were determined using 
a two tailed unpaired Student's t-test (Graphpad Prism 5) and a two tailed one 
sample t-test for normalised values (Sigmaplot 11.0, Systat Software, San Jose, 
CA). The data was tested for normality using the D'Agostino-Pearson omnibus 
K2 normality test (Graphpad prism 5). Transport kinetics calculations were 
performed as described in section 2.7.1. 
2.7.1 Transport kinetics 
OA TP 1 B 1 transport in HEK293T cells was characterised using Michaelis-
Menten kinetics. The Michaelis constant or Km denotes the affinity of a 
substrate for a transporter and is defined as the substrate concentration at which 
the transport rate is half of the maximum (Simon, 1998). The maximum rate at 
a saturating substrate concentration is known as the maximum rate, or V max. 
This is a useful measure ofthe rate at which a substrate is transported. These 
features are calculated by the Michaelis-Menten equation, as shown in figure 
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2.10. In this way, v is the initial rate of reaction, [S] is substrate concentration, 
V max is the maximum rate of reaction and Km is the Michaelis constant 
(Stenesh, 1998). 
An apparent Km and V max for OA TP transport was derived by inhibiting a set 
concentration of eH]E3S substrate with increasing concentrations of unlabelled 
E3S substrate. Therefore the transport of eH]E3S into the oocyte/cell was 
inhibited by the unlabelled substrate, although the total concentration of 
substrate entering the system was increased. Only the O"A TP mediated transport 
was used to determine the kinetics, by the removal of background non-injected 
oocyte / pcDNA vector uptake. The Michaelis-Menten equation was rearranged 
to account for the total fraction of substrate entering the cell (figure 2.11), as 
only the radioactive fraction was measured. In the equation Vtot is the total 
velocity and [S*] is the radioactive substrate concentration. The Vtot was 
calculated for each concentration and the residual squares calculated by 
subtracting the Vtot from the V, then squared. The sum of the residual squares 
was then used to calculate best fit values to determine an apparent Km and V max 
(Sakoda and Hiromi, 1976). The equation was then used to plot the values as a 
Michaelis-Menten curve (Sigmaplot 11.0, Systat Software, San Jose, CA). WT 
OA TP transport kinetics were compared to mutant OA TPs to determine any 
change in affinity following SDM. 
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'~nax [S] 
'\"= 
(Km + [S]) 
Figure 2.10 - Michaelis-Menten equation, describing the relationship between 
the initial rate of reaction (v), substrate (S), Km and V max. 
"tot - Vmnx (S + S*) 
Km+S+S* 
Figure 2.11- Rearrangement of the Michaelis-Mention equation to account for 
the radioactive and unlabelled substrate. ,1 
106 
3 Choice of expression system 
3.1 Introduction 
There are several methods available for the in vitro expression of OA TPs. 
Owing to the difficulties of transporter crystal structure determination, in vitro 
expression systems are one of the main techniques used to study transporters. 
The aim of this project was to explore the structural characteristics ofOATPs 
and therefore a model system was needed to express OA TPs and their mutants 
in isolation. X laevis oocytes and cell lines have been used most extensively as 
over expression systems, to assess the effects of mutations on transport and 
membrane targeting. Therefore these systems were assessed and validated for 
OA TP transport. A primary rat plasma membrane vesicle method was also 
investigated as a novel way to detect endogenous transport of compounds 
known to be OA TP substrates. 
3.1.1 X laevis oocyte model 
The X laevis oocyte system is an established method for the expression of 
membrane proteins (Gurdon et al., 1973), including OATPs (Geyer et al., 2004; 
Leuthold et al., 2009). Oocytes are approximately 1-1.2mm in diameter 
(Heikkila et al., 2007), thus large enough to permit direct micro-injection of 
RNA into the cytoplasm or nucleus (figure 3.1). A mature oocyte also contains 
high volumes of expression machinery such as ribosomes and RNA 
polymerases, ensuring that a high level of expression occurs. However, oocyte 
quality and expression levels can vary considerably between oocyte batches. 
SLCOlA2, SLCOlEl, SLCOlE3 and SLC02El were sub-cloned into the X 
laevis specific vector pXT7 and transport assessed using X laevis oocytes (refer 
to methods section 2.3). 
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A B 
Figure 3.1- Photographs of X laevis oocytes A) in ovaries removed from the 
frog and B) individually before micro-injection. Scale bar = I cm 
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3.1.2 HEK293T cell model 
Cell culture is also an established method for studying the characteristics of 
transport proteins and is a simple and reproducible technique. Cell lines 
minimise whole animal studies and can be manipulated to focus on precise 
experimental conditions. Therefore like the X laevis model, the system is 
useful for analysing the kinetic parameters of specific proteins. The advantage 
of cell line models compared to X laevis oocytes lies in the ease of culture. 
Oocytes require extensive preparation and individual oocytes are not as high 
throughput as plates of cells. In addition the generation of RNA requires an 
extremely sterile environment and consumables, whereas cell culture requires 
plasmid DNA which can be easily generated using large scale DNA isolation. 
However, the transfection of DNA into cells cannot be as easily controlled as 
with the direct micro-injection of oocytes - transiently transfected mammalian 
cells are a heterogeneous population oftransfected and non-transfected cells. 
Many cell lines have been used to express OA TPs, including the human 
hepatoblastoma HepG2 (lung et al., 200 I), Henrietta Lacks (HeLa) (Tirona et 
al., 2001), chinese hamster ovary (CHO) (Hanggi et al., 2006) and HEK293 
cells (Fischer et al., 2010). 
HEK293T cells (figure 3.2) were the chosen cell line for comparison with the 
X laevis model. This cell line is suitable for specific OA TP protein expression 
as endogenous expression of the transporters is low, unlike in a hepatocyte cell 
line (Kullak-Ublick et al., 1996). HEK293T cells are engineered from their 
original HEK293 counterparts by the addition of the SV40 large T-antigen. It 
has been shown that when transfecting HEK293T cells with a vector containing 
an SV40 origin of replication, the SV40 T-antigen induces replication of the 
plasmid (Mahon, 2011). The mammalian vector pcDNA3.1/Hygro(-) (to which 
the OATPs were sub-cloned, section 2.2.14) contains this SV40 origin of 
replication. Therefore this cell line exhibits a high level of protein expression. 
Cells were transiently transfected as expressed proteins could be analysed after 
several days and the process amenable to mutagenesis studies. The transfection 
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method was performed by nucleofection (Lonza, Preston, UK), an 
electroporation method chosen for the specially adapted HEK293 transfection 
kit (see methods section 2.5). 
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Figure 3.2 - Bright field image ofnon-transfected HEK293T cells obtained by 
confocal microscopy_ Scale bar = lOO~M_ 
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3.1.3 Vesicular transport model 
Vesicular transport assays form another model which can be explored for the 
functional analysis of transport proteins. The method involves forming enclosed 
vesicles from crude plasma membrane extract, adapted from an original method 
involving purified' inside-out' vesicles from red blood cells (Steck et al., 1970). 
This is where the inside of the membrane faces outwards, following incubation 
in alkaline buffer. Inside out vesicles are now commercially available for 
vesicular transport assays, in order to study a specific transporter of interest, 
such as the ABC efflux transporters (Krumpochova et al., 2012). 
Membrane vesicles are useful for studying the overall transport and inhibition 
of endogenously expressed membrane proteins, however there are very few 
studies conducted with OA TPs. 'Right side out' vesicles (Palmgren et al., 
1990) are required to study the uptake of OA TPs, whereby the extracellular side 
of the membrane remains facing the extracellular environment (figure 3.3). 
Previously, vesicles have been prepared from HEK293 cell membranes over-
expressing OA TP2B I (Sai et al., 2006), but this has not been conducted with 
primary tissues. 
Primary rat kidney membrane vesicles were investigated as a tool for 
characterising endogenous OA TP expression. Little is known about the 
functioning of OA TPs in the kidney and it is likely that they play an important 
role in the absorption and elimination ofxenobiotics. In humans, there are 
several OA TPs that are expressed (table 3.1), however, the localisation of most 
is unknown. In the rat kidney several Oatps are also localised (table 3.1), 
although only Oatp I a I and Oatp4c I are homologues to the human OA TP I A2 
and OA TP4C I. Interestingly it is not known as to whether rat Oatp4c I is 
localised to the basolateral membrane of proximal tubule (PT) cells (Mikkaichi 
et al., 2004), or to the apical membrane (Kuo et al., 2012), as both have been 
reported. It is likely, however, that the human homologue is present on the 
same membrane. OA TP4C I is kidney specific and rat Oatp4c I is 
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predominantly expressed in the kidney. Both transport the cardiac glycoside 
digoxin, and therefore could be the main influence on digoxin elimination from 
the kidney (Mikkaichi et al., 2004). 
Oatp lal and Oatp4c1 both transport E3S (Kuo et al., 2012; Yang et al., 2009), 
like their human homologues (Kullak-Ublick et al., 1995; Yamaguchi et al., 
2010). To gain an insight into E3S transport by these transporters in the kidney, 
vesicles were isolated from rat kidney cortex, containing the PT and distal 
• 
tubule (DT) (see methods section 2.4). Because rat Oatplal shares 67% amino 
acid identity with OA TP I A2 (Westholm et al., 2008) and Oatp4c I shares 
80.4% amino acid identity with OATP4CI (Kuo et aI., 2012), it is likely that 
these transporters may playa similar role in the kidney. Therefore approximate 
correlations between rat and human transport could be made. Transport, if 
detected, could provide physiologically relevant knowledge of drug uptake 
systems in the kidney, and be a useful screening tool for the transport and 
inhibition of novel compounds. 
The results in this chapter include the E3S transport results by OATPIA2, 
OATPIBI, OATPIB3 and/or OATP2BI using X laevis oocytes and HEK293T 
cells. Rat kidney membrane vesicles were also evaluated as a tool for detecting 
endogenous OATP expression. The most reliable and reproducible method was 
then used for future experiments. 
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Figure 3.3 - Schematic representation of a ' right side out' vesicle, whereby 
vesicles are produced with the extracellular part of the membrane facing the 
extracellular environment. 
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Table 3.1 - Human and rat OA TPs expressed in the kidney 
OATP Localisation within the kidney Reference 
Rat 
Oatplal Apical membrane: PT (Weaver et al., 20 I 01 
Oatpla3 VI Apical membrane: PT _(Saito et al., 19961 
Oatpla3_ V2 Apical membrane: PT, cortical (Masuda et al., 1999) 
collecting duct 
Oatpla5 Unknown (Sekine et al., 2006) 
Oatpla6 Unknown lSekine et al., 2006) 
Oatp4cl Basolateral: PT IApical: PT (Kuo et al., 2012; 
Mikkaichi et al., 20041 
Human 
I 
I, 
OATPIA2 
: Apical: DT (Lee et al., 2005) 
OATP2AI Unknown (Sekine et al., 200(fr 
OATP2BI Unknown (Sekine et al., 2006) 
OATP3AI Unknown lSekine et al., 200(fr 
OATP4AI Unknown (Sekine et al., 2006) 
OATP4Cl Basolateral: PT (Mikkaichi et al., 
'20041 
PT: ProxImal tubule, DT: DIstal tubule 
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3.2 Results 
3.2.1 X laevis oocyte transport results 
The X laevis oocyte model was used to express OATPIA2, OATPIB 1, 
OA TP 1 B3 and OA TP2B 1. Controls were initially established and the 
experiment validated using a positive control. The transport experiment was 
then optimised to maximise transport. 
3.2.1.1 Establishment of controls 
Initial transport experiments were conducted with non-injected and water-
injected controls. This was to determine ifthere was a significant difference 
between the background radioactivity entering the water injected oocytes 
compared with those not injected. The transport experiment was conducted 72 
hours post-injection and oocytes incubated in eH]E3S for 1 hour unless 
otherwise stated. Uptake into the water-injected oocytes was not significantly 
increased from the non-injected (figure 3.4). Therefore future experiments were 
conducted with only non-injected oocyte controls. 
3.2.1.2 Initial OA TP transport results 
The OA TP clones purchased were contained within different vectors. SLCO lA2 
was contained within pBluescriptR, SLCOIBI in PCR-BluntlI-TOPO, 
SLCOIB3 in pENTR223.l and SLC02Bl in pCMV-Sport6. Initially 
pBluescriptRlSLCOlA2 cRNA was synthesised and injected to confirm 
detectable transport in oocytes. Uptake ofOATPIA2 was not significant from 
the non-injected controls (figure 3.5 A). 
To validate the transport experiment, cRNA for the rabbit peptide transporter 
PepTl (SlcJ 5al) in the X laevis vector pXT7 was injected into oocytes from 
the same frog as SLCOIA2. PepTl has been successfully expressed in oocytes 
. " in the same lab (pieri et al., 2008). Uptake of the substrate eH]D-phenylalanyl-
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L-glutamine (D-Phe-L-Gln) was significant for PepT1 but not for eH]E3S into 
OATPIA2 (figure 3.5 B). 
As it was possible that the pBluescriptR vector did not facilitate suitable 
expression of the gene, the four OATP genes were also sub-cloned into pXT7 
(section 2.2.14.1); a vector that facilitates X laevis expression (Dominguez et 
al., 1995). The pXT7 vector contains X laevis untranslated ~-globin regions 
that are detected by the oocyte's expression machinery 
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Figure 3.4 - Uptake of e H]E3S into non-injected and water-injected oocytes. 
Each bar is the mean ± SE of 10 individual experiments with 5 oocyte 
replicates. 
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Figure 3.5 - A) Uptake of eH]E3S into non-injected and 
pBluescriptRlSLCOlA2 cRNA injected oocytes. Each bar is the mean ± SE of3 
individual experiments with 5 oocyte replicates. B) Uptake of eH]E3S into 
non-injected and pBluescriptRlSLCOlA2 cRNA injected oocytes, with eH]D-
Phe-L-Gln into non-injected and pXT7/S1cJ 5al cRNA injected oocytes from 
the same frog. Data are representative of one experiment with 5 oocyte 
replicates. Asterisks (*) indicate a significant increase using an unpaired 
Student's t-test (P<O.05). 
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3.2.1.3 Transport by OATPs cloned into the pXT7 vector 
The four SLCO genes cloned into the pXT7 vector were synthesised into cRNA 
and injected into oocytes. Uptake experiments were performed 72 hours post-
injection, following a one hour incubation in eH]E3S. Transport of eH]E3S 
was significant from the non-injected controls for OA TP 1 A2, OA TP 1 B3 and 
OA TP2B 1 (figure 3.6). Transport was variable for OA TP 1 B 1 and only 
significant over four individual experiments, resulting in no significant 
difference when compared overall. Optimisation was performed for OA TP 1 A2, 
OA TP 1 B3 and OA TP2B 1 owing to the variability observed with OA TP 1 B 1. 
3.2.1.4 Optimisation of X laevis transport experiments 
Attempts were made to optimise transport and decrease variability in X laevis 
oocytes. The optimal incubation time for maximal transport was determined by 
performing a time course with oocytes in radioactivity. Oocytes injected with 
pXT7/SLCOIA2, pXT7/SLCOIB3 and pXT7/SLC02Bl cRNA were incubated 
from 30 minutes to 6 hours in eH]E3S (figure 3.7). Transport increased with 
time but did not plateau within 6 hours. Linear transport was recorded between 
approximately 2-6 hours and significant from non-injected controls between 4 
and 6 hours, thus future experiments were performed at 4 hour time points. 
Transport experiments were performed at 3 and 4 days post-injection, to 
determine if transport or expression could be increased with an extra day; 
however, there was no significant increase (figure 3.8). Furthermore, oocyte 
membranes were more susceptible to rupture following the increased time post-
injection. 
Oocyte transport experiments were variable and depended on the quality of the 
oocytes week by week. This is highlighted in figure 3.9, whereby transport 
variability for OA TP2B 1 is displayed over several experiments. Over time the 
oocyte method for expressing OATPs did not reveal itself to be reliable. 
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Figure 3.6 - Uptake of eH]E3S into non-injected and pXT7/SLC01A2, 
pXT7/SLC01Bl , pXT7/SLCOIB3 and pXT7/SLC02BI cRNA injected 
oocytes. Each bar is the mean ± SE of 4-1 3 individual experiments with 5 
oocyte replicates. *Unpaired t-test P<O.05 . 
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Figure 3.7 - Mediated uptake ofeH]E3S into pXT7/SLC01A2, 
pXT7/SLC01B3 and pXT7/SLC02Bl cRNA injected oocytes. Non-injected 
control uptake was subtracted. Each point is the mean ± SE of 3-6 experiments 
with 5 oocyte replicates. *Unpaired t-test P<O.05 (colour coded). 
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Figure 3.9 - Inter-assay variability of eH] E3S mediated uptake into 
pXT7/SLC0 2Bl cRNA injected oocytes. Non-injected oocyte controls were 
subtracted. Each bar is the mean ± SE of one experiment with 5 oocyte 
replicates. *Unpaired t-test P<O.05. 
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3.2.2 HEK293T cell experiment results 
HEK293T cells were evaluated as another method for studying the 
characteristics of OA TPs. SLC01A2, SLCO 1 B1 and SLC01 B3 were sub-cloned 
from the pXT7 vector into the mammalian expression vector 
pcDNA3.1/Hygro(-) (section 2.2.14.2). The transfection and transport 
experiments were optimised for maximum transport. 
3.2.2.1 Optimisation of HEK293T cell transfection 
The HEK293T cell transfection method was validated through the detection of 
cell expressed green fluorescent protein (GFP), using a confocal microscope. 
GFP is a useful visual guide to transfection efficiency as cells produce the 
protein in the cytoplasm, allowing the fluorescence to be visualised. HEK293T 
cells were transiently co-transfected with 2J.lg pmaxGFP® vector provided in 
the transfection kit (Lonza, Preston UK) and 5J.lg pcDNA empty vector. An 
assumption was made that the GFP fluorescence detected was equal to the 
potential expression observed of an OATP cloned into the pcDNA vector. Cells 
were incubated for 7 days post-transfection. GFP expression was detected as in 
situ fluorescence after 24 hours and up to 7 days (figure 3.10). Control non-
transfected cells did not express GFP. This provided a time frame for plasmid 
expression by the transiently expressing cells. 
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Figure 3.10 - Confocal microscopy images displaying HEK293T cells in situ at 
24 hours and 7 days post-transfection. Cells were co-transfected with 
pmaxGFP@ and pcDNA vector. Non-transfected cells were plated as a control. 
A) GFP only (488nm) B) bright field only C) overlay of both images. Scale bar 
= 200llm. 
127 
3.2.2.2 Optimisation ofOATPIBl transport in HEK293T cells 
OATPlBl was initially optimised in HEK293T cells with the aim that the 
experimental conditions could then be used as a basis for optimising the other 
transporters. The optimal incubation time for protein expression and transport 
were selected and the kinetics determined. 
3.2.2.2.1 Optimisation ofOATPIBl transport up to 72 hours post-
transfection 
Substrate uptake experiments were performed on OA TP 1 B 1 expressing 
HEK293T cells at 24, 48 and 72 hours post-transfection, to determine the 
optimal incubation time for detecting transport. Expression of G FP was 
detected up to 7 days post-transfection (section 3.2.2.1), suggesting that 
transport proteins may also be expressed for up to 7 days. Cells were incubated 
in eH]E3S for 1 minute, an approximate linear time range as described 
previously (Weaver et aI., 2010). Incubation time was studied subsequently 
(section 3.2.2.2.2). Transport of eH]E3S increased with time (figure 3.11) and 
was significantly increased from the pcDNA vector control at 48 and 72 hours. 
Future uptake experiments were performed at 72 hours post-transfection and an 
exact linear time range was subsequently determined. 
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Figure 3.11- Uptake of eH]E3S into pcDNAISLC01Bl and pcDNA vector 
transfected HEK293T cells at 24, 48 and 72 hours post-transfection. Each bar is 
the mean ± SE of one experiment with 6 well replicates. *Unpaired t-test 
P<O.05 . 
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3.2.2.2.2 Optimisation of the linear time frame for OATPIBI transport 
In order to detect the maximum transport by OATPIBI expressing HEK293T 
cells the transport experiments should be conducted when the transport into the 
cell is linear. Therefore OA TP I B I transfected cells at 72 hours post-
transfection were incubated in eH]E3S for various time points. Uptake 
experiments were performed at 0.5, 1,2,5, 10 and 20 minutes (figure 3.12). 
Uptake into the cells increased up until 5 minutes, then decreased. The linear 
range was between 2-5 minutes and therefore subsequent experiments were 
performed with 3 minute incubations in radioactivity. 
3.2.2.2.3 Determination of OATPIBI transport kinetics 
The kinetics of eH]E3S transport into OA TP I B I expressing HEK293T cells 
were determined by calculating the Km and V max. A total of 6 different E3S 
concentrations: 0, 0.15, 0.3, 0.5, 1.0 and 1.5 J.lM were tested using the optimised 
conditions described above. Uptake experiments were performed alongside the 
pcDNA control and control values subtracted. Values were fitted to the 
Michaelis-Menten equation as described in section 2.7.1 and the equation used 
to fit a Michaelis-Menten curve (figure 3.13). The Km was 0.105 ± 0.008J.lM 
and the V max 50.1 ± 10.9 pmol/mg proteinl3min. The protein did not 
demonstrate biphasic kinetics as described by some other groups (0.23J.lM & 
45J.lM, (Noe et al., 2007), (67 ± 31nM & 7 ± 2J.lM, (Tarnai et al., 2001); 
however, not all groups have detected biphasic properties (Cui et al., 200 I; 
Hirano et al., 2004; Miyagawa et al., 2009). In comparison with the findings of 
others, the Km found in this system may be the high affinity binding site. These 
kinetics will be used as a WT value for comparing with the kinetics of FLAG 
tagged and mutant isoforms. 
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Uptake of increasing concentrations of E3S were measured . The line is the 
Michaelis-Menten equation fitted to the Km and V max. Km = 0.105 ± 0.008f.1M 
V max = 50.1 ± 10.9 pmoVmgl3min. Each point is the mean ± SE of 5 individual 
experiments with 3 well replicates. 
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3.2.2.3 OATPIA2 and OATPIB3 transport results 
The optimised conditions established for OATPIB 1 were applied to OATPIA2 
and OATPI B3 transport experiments. Transport by OATPIA2 and OATPI B3 
in HEK293T cells was in contrast to OATPIBI very low (figure 3.14), and not 
significant from the pcDNA vector control. Various parameters were changed 
in an attempt to increase the low levels of expression. OATPIB 1 was used as a 
positive control in each optimisation experiment. 
3.2.2.3.1 Optimisation of OATP1A2 transport with sodium butyrate 
A few research groups have treated OA TP transiently transfected HEK293 celIs 
with sodium butyrate 24 hours prior to transport experiments, to increase 
protein expression (Taub et 01.,2011; Westholm et 01.,2010). It is welI 
established that sodium butyrate produces morphological and biological 
changes in celIlines, including protein induction (Palermo et 01., 1991). The 
concentration range used varies from 5mM (Pacyniak et 01.,2010) to 10mM 
(Konig et 01., 2000b). Experiments were performed with the addition of 10mM 
sodium butyrate to transfected HEK293T cells, 24 hours prior to uptake 
experiments. Sodium butyrate did not increase the transport by OATPIA2 nor 
OATPIB3, and the observed effect on OATPIBI was not significant (figure 
3.l5). 
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Figure 3.14 - Uptake of CH]E3S into pcDNAISLCOlA2, pcDNAISL OlBl, 
pcDNA/SLCOlB3 and pcDNA vector transfected HEK293T cells. Each bar is 
the mean ± SE of one experiment with 6 well replicates. *Unpaired t-test 
P<O.05 . 
134 
6 
NS 
I • - Sodium butyrate 
---.5 * • + Sodium butyrate 
~ 5 
'5 -e c. 4 
ell 
E :::::. 
0 
E 3 ,::, 
C 
.ill: 
~ 
§- 2 
~ 
:E' ... 
'-' 
0 
pcDNA control OATPIA2 OATPIBI OATPIB3 
Figure 3.15 - Uptake ofeH]E3S into pcDNA/SLC01A2, pcDNA/SLC01Bl, 
pcDNA/SLC01B3 and pcDNA vector transfected HEK293T celis, in the 
presence/absence of sodium butyrate . Each bar is the mean ± SE of one 
experiment with 6 well replicates. *Unpaired t-test; P<O.05 from pcDNA 
control. NS = No significance. 
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3.2.2.3.2 Optimisation of the linear time frame for OA TPIA2 transport 
A time course was performed to determine the time range at which OA TP 1 A2 
transport was in the linear phase. Uptake experiments were performed 
following 1,2,3,4,5 and 10 minute incubations with radioactivity. Figure 3.16 
shows that like OA TP 1 B 1, transport increased up to 5 minutes. However 
transport was marginally higher than the vector only control and significant 
only at the 5 minute time point. Further studies were performed using the 3 
minute incubation in radioactivity. 
3.2.2.3.3 Optimisation of OATPIA2 transport with increase in DNA 
concentration 
OATPIA2 transport was further investigated by increasing the concentration of 
SLCOJA2 DNA to which the cells were transfected. This was performed with 
the hypothesis that increasing the DNA concentration would increase protein 
expression. The DNA concentration per transfection reaction (recommended by 
the manufacturer; Lonza, Preston UK) was 5J,lg; this was increased to 7.5J,lg and 
10J,lg. The pcDNA vector controls were also transfected with equivalent 
concentrations of DNA. OATPIBI and its vector control were transfected as a 
positive control with 5J,lg DNA. Figure 3.17 shows that an increase in DNA 
concentration did not significantly increase transport for OA TP 1 A2. The 
addition of 10J,lg DNA just failed to reach significance (P=O.06) for increasing 
transport by OATPIA2. 
3.2.2.3.4 Optimisation of OATPIA2 transport by sub-cloning into the 
pel-neo vector 
An increase in OATPIA2 protein expression was further attempted by sub-
cloning the SLCOJA2 gene from pcDNA into another mammalian expression 
vector pCI-neo. pCI-neo is similar to pcDNA by containing a mammalian CMV 
promoter, however, pCI-neo also contains a chimeric intron derived from 
human p-globin and immunoglobulin genes. The insertion of introns flanking a 
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DNA insert has been shown to increase gene expression by up to 20-fold 
(Buchman and Berg, 1988), as the intron facilitates gene splicing. However 
gene expression is not always increased, owing to lack of recognition of the 
intron or inefficient splicing. SLCO IA2 was cloned into pCI-neo in an attempt 
to increase gene expression. Figure 3.18, however, confirmed that the presence 
of the intron in pCI-neo did not increase expression ofOATPlA2. Uptake of 
eH]E3S was not significantly increased in the OATPIA2 expressing cells 
compared with the vector control. 
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Figure 3.16 - Uptake of eH]E3S into pcDNAISL DlA2 and pcDNA vector 
transfected HEK293T cells following 1, 2, 3, 4, 5, and 10 minute incubat ions in 
radioactivity. Each point is mean ± SE of one experiment with 3 well replicates. 
*Unpaired t-test P<O.05. 
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and peDNA vector transfected HEK293T cells. pcDNAlSLC01A2 cells 
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3.2.3 Rat kidney membrane vesicle results 
Membrane vesicles prepared from rat kidney PT and DT were evaluated for 
endogenous eH]E3S transport by Oatplal and Oatp4cl. A control of eH]E3S 
+ 200~M unlabelled E3S was used. In the control, the unlabelled E3S competed 
with the radiolabelled substrate and inhibited transport ofthe radioactive 
substrate into the vesicle. Therefore the control values are a measure of the 
background radioactivity, and the difference between uptake observed in the 
control compared with that of the sample is a measure of the actual substrate 
uptake into vesicles. Oatplal is known to transport E3S with a Km between 1-
12~M (Eckhardt et aT., 1999; Wang et aT., 2008). Oatp4c 1 is known to transport 
E3S with a Km of21.5~M (Kuo et aT., 2012). Therefore a 200~M concentration 
of unlabelled E3S was considered high enough to completely inhibit any 
transport ofthe radio labelled substrate. 
Preliminary results show that uptake was significantly increased from the 
background control between 0-1 minute (figure 3.19 and mediated transport 
figure 3.20). However, the uptake did not significantly increase with time and 
there was a high background:signal ratio. This may be owing to a fast rate of 
uptake, whereby uptake is almost instantaneous, followed by passive diffusion 
out of the vesicles over time. 
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Figure 3.19 - Uptake of eH]E3S and control e H] E3 S + 200~M E3S into rat 
kidney membrane vesicles . Each point is the mean ± SE of2 individual 
experiments with 6 well replicates. *Unpaired t-test (P<O.05). 
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Figure 3,20 - Mediated uptake of eH]E3S into rat kidney membrane vesicles. 
Control eH]E3S + 200flM E3S values were subtracted. Each point is the mean 
± SE of2 individual experiments with 6 well replicates. *Unpaired t-test 
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3.3 Conclusion 
Two over-expression systems were evaluated for the expression of OA TPs; X 
laevis oocytes and HEK293T cells. Plasma membrane vesicles were also 
evaluated as an alternative tool for studying endogenous transport in primary 
tissue. 
The X laevis oocyte model is an established method for expressing transport 
proteins. The method was evaluated by measuring transport ofeH]E3S by 
OATPIA2, OATPIBI, OATPIB3 and OATP2BI expressing oocytes. Controls 
were first established by comparing the background uptake of radioactivity into 
non-injected and water injected controls. There was no significant difference 
between uptake into either control, and thus non-injected oocytes were used as 
negative controls. 
Initially OATPIA2 was assessed for transport while the gene was contained 
within its original vector, pBluescriptR. Transport levels were very low and not 
significant from controls. These results were validated using the transporter 
PepT! as a positive control, alongside OATPIA2 transport experiments. The 
low levels of transport were thought to be due to the vector, which was not 
designed for oocyte expression. Therefore all four SLCa genes were sub-cloned 
from their vectors into the X laevis expression vector pXT7. 
OATPIA2, OArPIB3 and OATP2Bl transported eH]E3S consistently over >6 
independent experiments. OATPIBI however only transported over 4 
experiments and transport was generally low in comparison with the other 
OA TPs. Therefore oocyte transport experiments with OA TP I B 1 were not 
continued. 
Over time however, transport demonstrated by the other OA TPs was variable, 
most likely owing to the variability in expression demonstrated by the oocytes. 
Many factors affected the oocytes, including the age and/or batch of frogs, 
adequate defolliculation of ovaries, accurate micro-injection and health of the 
oocytes post-injection. The oocyte system was therefore optimised in an 
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attempt to determine the best experimental conditions for OATP transport. The 
linear time frame for transport was assessed through a time course of 
incubations, from 30 minutes to 6 hours in radioactivity. Transport increased 
with time, but did not plateau within 6 hours. The linear time frame was 
estimated to be between 4-6 hours, although a longer time course would have 
been required to accurately determine this time. This however was not 
conducted as the increased incubation resulted in higher oocyte fatality. 
Transport experiments were also conducted over 3-4 days to determine if 
OA TP expression increased when incubated for an extra day. Transport was not 
significantly increased and again there was increased oocyte death. These 
optimisation experiments did not improve the variation observed. 
Cell lines have been used extensively for the characterisation of transport 
proteins, including OA TPs (Roth et al., 2011). The HEK293T cell model was 
utilised and OATPI B I displayed a high and consistent level of transport. The 
experimental conditions chosen for OA TP 1 B I-HEK293T expression were 
determined by optimising the transfection and substrate uptake experiments. 
Cells were grown up to 7 days post-transfection to determine the length oftime 
to which the cells retained the temporary plasmid. Transfection experiments 
with GFP showed that cells were still expressing the fluorescent protein 7 days 
post-transfection, providing a 7 day time frame for which to perform uptake 
experiments. The nucleofection method was optimised from 6 well plates as 
described in the manufacturer's instructions to 12 well plates, which allowed 
for more replicate samples and wells which were practical for viewing under 
the microscope. Once the transfection method was established the optimal 
incubation time for protein expression was established. 
Results showed that 24 hours did not provide the cells enough time to 
sufficiently express OA TP 1 B 1, however there was significant substrate 
transport at 48 and 72 hours. As maximal uptake was required, future 
experiments were performed 72 hours post-transfection. Other groups have also 
reported performing HEK293/0A TP transport experiments at 48 (Kobayashi et 
al., 2003) and 72 hours post-transfection (Sai et al., 2006). In order to ensure a 
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maximal level of substrate uptake, a time course was performed to determine 
the phase at which transport was linear. Transport was linear between 2-5 
minutes, therefore further experiments were conducted after 3 minute 
incubations in radioactivity. Using these experimental parameters, the Km and 
Vmax for OATPIBI were determined as 0.105 ± 0.008J.lM and 50.1 ± 10.9 
pmol/mg proteinl3min. 
Determination of these values validated the OA TP 1 B 1 transport and verified 
that the protein was functioning as described by other groups (0.23J.lM (Noe et 
aI., 2007), (0.21 ± 0.02J.lM, 25.6 ± 4.6 pmol/mg proteinl2min (Li et al., 2012). 
Determination of the Km also set the suitable range of concentrations for future 
experiments which were performed with the following concentrations of 
unlabelled E3S: 0, 0.05, 0.1, 0.5, 1.0, 1.5J.lM. In addition, these values provided 
an important control value for later experiments with mutant isoforms, whereby 
the change in Km and V max were assessed. 
OATPIA2 and OATPIB3 did not transport to a significant level from controls, 
despite several optimisation experiments. The reason for the low transport is 
surprising as both proteins have been expressed in HEK293 cells previously 
(Hu et al., 2008). Sodium butyrate was shown to increase gene expression in 
HEK293 cells when supplemented 24 hours before uptake experiments, 
however this was not the case for this model. Further optimisation experiments 
with an uptake time course, increasing concentrations of DNA during 
transfection and even sub-cloning into another vector did not significantly 
increase transport ofE3S by OATPIA2. OATP2B I transport in HEK293T cells 
was not analysed. 
Plasma membrane vesicles have been previously utilised for assessing 
endogenous membrane transport (Koopen et al., 1997; Meredith and Laynes, 
1996), but not for OATPs. Rat kidney cortex vesicles of PT and DT cells were 
assessed as a potential model for determining the endogenous uptake of 
substrates in the kidney. The substrate eH]E3S was used as it is a substrate for 
rat Oatplal and Oatp4cl. Vesicle eH]E3S uptake was significantly higher than 
146 
r ; ~ 
the background control in the first minute, suggesting that vesicular transport 
was occurring. However, transport was not significantly increased over time, 
as expected with an increased incubation in radioactivity. It is possible that 
transport into the vesicles was extremely rapid, followed by a decrease over 
time. Or it may be that some of the radioactivity was retained on the filter, as 
shown by the high fmol detected at the zero timepoint (-Bfmol). 
The vesicle system was not explored further for several reasons. The 
availability of rat kidney was limited, which would have limited the amount of 
experiments. In addition, the overlapping substrate specificities of transporters 
for uptake and efflux in the kidney cause limitations when detecting 
endogenous transport. Many transporters are present in the PT and DT apart 
from OATPs, including the OATs and ABCs. Some of these transporters also 
transport E3S, including Oat3, which is present on the basolateral PT 
membrane (Sweet e/ al., 2003). Therefore, the transport detected may have 
been the result of several transporters. Furthermore, gender differences occur 
between male and female kidney regulation. Oatplal has a sex-dependent 
renal clearance, with female rats demonstrating a faster clearance of compounds 
than males (Yang e/ al., 2009). Therefore both male and female rat kidneys 
would need to be analysed and compared. This gender difference has not been 
studied in the human homologues, making extrapolations from rat to human 
difficult. 
In summary, rat kidney membrane vesicles, X laevis oocytes and the HEK293T 
cell line were all evaluated as potential models for studying OATPs. OATPIBI 
transported significantly and consistently in HEK293T cells and thus this cell 
model was used for further experiments. The vesicle experiment had a number 
oflimitations and the oocyte system was not consistently reliable. Therefore the 
structural characteristics evaluated in chapters 4 and 5 were determined in 
OA TP 1 Bland compared to the WT type results generated here. 
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4 Investigation of the OATPIBI topology 
4.1 Introduction 
The structural knowledge of transmembrane proteins is lagging behind that of 
most other protein families owing to the difficulties with structure 
determination. The exact structural properties of the OATPs are therefore yet to 
be determined. 
The position of a protein within the membrane, along with the number and 
orientation of the TMs, is known as the topology (Wallin and von Heijne, 
1998). All members of the SLC superfamily contain multiple TMs (He et af., 
2009) and the OATPs have been previously predicted by topology prediction 
analysis to contain 12TMs with a large fifth extracellular loop (Chang et af., 
2005; Hagenbuch, 2003; Konig et af., 2000a; Li et af., 2012). The Nand C 
termini are putatively internal, facing the cytoplasmic space (Hanggi et af., 
2006; Meier-Abt et al., 2005). So far only rat Oatp I a I has been experimentally 
investigated as a potential 12TM protein (Wang et af., 2008) and the orientation 
of the Nand C termini was not elucidated. 
OA TP 1 B 1 was the isoform chosen to study the topology of the human OA TPs. 
OA TP 1 B 1 plays an important role in the transport of endogenous and 
xenobiotic compounds into the liver, and is implicated in many DDIs. Protein 
dysfunction and genetic variation are also implicated in disease and drug 
disposition (Niemi et af., 2011; van de Steeg et af., 2012). 
Therefore OATPIBI is an important candidate for which to determine the 
structure. Like all of the OA IPs, OA TP I B I has been predicted as a 12IM 
protein with a large extracellular loop and internal Nand C termini (Konig et 
af., 2000b), as well as the OATP superfamily signature at the border with TM6 
(Niemi et aZ., 20 11), but unlike some other OA IPs it does not contain a C 
terminal PDZ sequence (Wang et af., 2005a). OA TPI B I also contains 
glycosylation sites in extracellular loops 2 and 5 (N134, N503, N516) (Yao el 
148 
"f' 
,., 
.. , 
al., 2012), and the apparent molecular mass is reduced from 84 kDa to 58 kDa 
upon deglycosylation (Konig et al., 2000b). Several of the TMs are shown to be 
important for substrate binding (Gui and Hagenbuch, 2009; Li et al., 2012; 
Miyagawa et al., 2009), as are positive amino acids R57, K361 and R580 
(Weaver and Hagenbuch, 2010), which are predicted to line the putative pore of 
the protein (Meier-Abt et al., 2005). 
The topology of OA TPI B I was studied using a FLAG epitope tag and 
luminometry approach using the previously established OATP I B IIHEK293T 
system (section 3.2.3). FLAG epitope tags were inserted into putative 
extracellular and intracellular plus the Nand C terminal regions ofOATPIBl, 
as directed by topology prediction analysis. Sixteen topology prediction 
programs and 9 signal peptide prediction programs were used to evaluate the 
number ofTMs, orientation ofthe Nand C termini and presence of a signal 
peptide. Detection of the FLAG epitope was achieved by a quantitative 
luminometry experiment, using a FLAG antibody coupled to a 
chemiluminescent substrate. 
The hypothesis was that extracellular tags would be detected by luminometry as 
the epitope was exposed; intracellular tags would not be detectable unless cells 
were permeabilised. Therefore the topology could be inferred from these 
results. The luminometry method was validated using the established PeptTl-
FLAG transporter as positive control. Luminometry results were supported by a 
qualitative immunofluorescence method; the fluorescent cell membrane was 
visualised using confocal microscopy. Transport experiments were also 
performed on the FLAG mutants to ensure correct functioning of the mutant 
FLAG proteins. A new OATPI B 1 topological model is proposed, based on the 
luminometry findings. 
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4.2 Results 
4.2.1 OATPIBI topology prediction 
Topology modelling is an invaluable in silico approach to predicting the 
number and orientation ofTMs in a membrane protein. The results provide a 
framework with which to base experimental analyses. A collection of programs 
with different algorithms were chosen to predict the topology of OATPI B 1 
(table 4.1), to ensure the most accurate prediction from the results. The 
programs SOSUI (Hirokawa et al., 1998) and PRED-TMR (Pasquier et al., 
1999) use the hydropathy index and charge of the amino acid, whereas 
TMHMM (Krogh et al., 2001), Phobius (Kall et al., 2004), HMMTOP 
(Tusnadyand Simon, 2001a) and Philius (Reynolds et al., 2008) use the 
Hidden-Markov model as a statistical approach. TMpred (Hofman and Stoffel, 
1993) and TSeg (Kihara et al., 1998) compare the protein sequence with a TM 
protein database, using segment orientation and taxonomic classification in the 
analysis. ConPredII and TOPCONS use a consensus approach, predicting the 
structure based on the results of several programs. 
The prediction programs predicted between 11-12TMs, with 10 programs 
predicting 12TMs and 6 programs predicting II TMs (table 4.1). Of these, II 
programs predicted the positions of the termini (table 4.2). The programs 
predicting 12TMs all predicted the Nand C termini to be internal. This same 
analysis was also performed on OATPIA2, OATPIB3 and OATP2BI 
(appendix I-V). Interestingly, the results varied considerably, predicting 7-
9TMs, 9-12TMs, 8-13TMs respectively. The proteins were also mainly 
predicted to contain internal Nand C termini, however, there was more 
variation in the results. In particular, almost half of programs predicted 
OATP IA2 to contain extracellular termini. 
OATPIBI was also homology modelled on the MFS protein glycerol-3-
phosphate using the modelling program Phyre2 (Kelley and Sternberg, 2009). 
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OA TP 1 B3 has been modelled in a similar way (Meier-Abt et al., 2005) 
(discussed in section 1.3.4). The glycerol-3-phosphate transporter contains 
12TMs, internal Nand C termini and functions with a rocker-switch 
mechanism (Huang et al., 2003). The program modelled 65% ofOATPIBI 
residues with >90% confidence, displaying 12TMs and internal Nand C 
termini (figure 4.1). This modelling supports the consensus results from the 
topology prediction programs and the TM predictions are comparable (data not 
shown). However, this is not surprising as both analyses match the putative 
TMs to regions of hydrophobicity. A limitation of this method however, is that 
homology modelling is only able to model residues onto a known template. As 
only 65% of residues were modelled with high confidence, 35% could not be 
modelled, suggesting that these regions may form a different structure. 
Furthermore, the glycerol-3-phosphate transporter contains only one binding 
site, unlike OA TP 1 B 1 which may have two binding sites, as discussed 
previously (section 1.3.4) . 
The presence of an OA TPt B t signal peptide sequence was also investigated. A 
signal peptide is a region of up to 70 hydrophobic amino acids at the N-
terminus that is cleaved by signal peptidases, as part ofthe secretory pathway 
(Davis et al., 2006). Some membrane proteins do not have a signal peptide as 
one of the TMs acts as an anchor within the membrane, but is not cleaved 
(Davis et al., 2006). Signal peptides can be difficult to detect, as they can be 
mistaken for TMs owing to their hydrophobic nature (Kall et al., 2004). Little is 
known about the presence of signal peptides in OA TPs. A total of 9 signal 
peptide prediction programs were evaluated to assess the presence of an 
OATPtBl signal peptide sequence (table 4.3). It is likely that OATPIBI does 
not contain a signal peptide site as 6 programs did not report a signal sequence. 
The remaining 3 programs reported a signal sequence at cleavage site 44. 
Signal peptide analysis was also performed for OATPIA2, OATPIB3 and 
OATP2BI (appendix V). OATPIB3 and OATP2Bt did not contain a signal 
peptide sequence, with detection from only 3/9 and 119 programs respectively. 
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However 7/9 programs reported OATPIA2 to contain an N-terminal signal 
peptide sequence, with a cleavage site at amino acid position 16. 
Therefore the topology prediction analyses performed on OA TP I B I predicted a 
consensus of a 12TM protein with internal Nand C termini, which did not 
contain a signal peptide sequence. This supports previous prediction analysis 
conducted by other groups (Hagenbuch and Meier, 2004; Meier-Abt et al., 
2005). Experimental analysis was driven by these prediction results. 
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Table 4.1- Summary ofOATPIBI amino acid topology predictions 
Name of Length TMI TM2 TM3 TM4 TM5 TM6 
program ofTM 
ConPredlI 20 29-49 63-86 95-115 209-229 259-279 332-352 
(Araietal.,2004) 
SOSUI 23 29-51 64-86 96-118 206-228 257-279 337-359 
(Hirokawa et al., 
1998) 
TopPredll 20 28-48 71-91 96-116 165-185 211-231 262-282 
(von Heijne, 
1992) 
TMpred 21-28 25-48 65-88 96-121 169-196 207-230 259-279 
(Hofman and 
Stoffel, 1993) 
TMHMM 23 30-52 67-89 96-118 208-230 257-279 332-354 
(Krogh et aI., 
2001) 
TSeg 23-30 27-52 65-89 95-117 208-234 258-281 331-357 
(Kihara et aI., 
1998) 
MemBrain 13-29 28-49 73-87 96-115 169-181 208-232 257-278 
(Shen and Chou, 
2008) 
PHDhtm 6-23 29-45 74-88 98-113 175-180 211-231 259-277 
(Rost et aI., 1996) 
-~~ - --~ --- -
TM7 TM8 TM9 TMIO TMll TM12 
375-395 409-429 537-557 576-596 626-646 -
374-396 405-427 538-560 576-598 623-645 -
336-356 376-396 410-430 534-554 580-600 627-647 
332-356 376-397 410-430 536-560 570-595 624-647 
375-397 407-429 536-558 573-595 624-646 -
372-397 406-435 531-558 574-599 625-648 -
331-359 373-396 406-429 533-558 572-595 623-646 
332-356 378-396 410-428 536-558 577-594 628-645 
-~ 
-Vl 
~ 
Split 4.0 
(Juretic et aL, 
2002) 
Phobius 
_(](alletaL.2004) 
Philius 
(Reynolds et aL, 
2008) 
HMMTOP 
(Tusnady and 
Simon,2001b)_ 
TOPCONS 
(Bernsel et aL, 
2009) 
PRED-TMR 
(Pasquier et aL. 
1999) 
MEMSAT3 
(Jones, 20071 
SVMtm 
(Yuan etaL, 
2004) 
15-36 
19-26 
19-23 
17-27 
20 
17-21 
19-24 
14-21 
28-54 73-88 95-Il9 168·183 
29-48 68·89 96-Il7 170·195 
29-48 66·87 96·Il8 177·196 
29-48 65-87 96-113 170·194 
27-47 68·88 97-Il7 173-193 
29-48 65·84 96-113 207-226 
29-48 65·87 96-120 207-230 
29-48 72·86 98-114 168-182 
206-229 252-278 334-362 374-396 406-430 533-552 565-601 622·644 
207·230 258·279 337-356 376-395 407-428 534·560 572-595 624-646 
207·230 257-279 337-356 376-397 406-429 539·560 572-594 625-646 
207·230 257-279 324-347 374-397 410-429 536-560 569-593 624-647 
207·227 259·279 336-356 376·396 410-430 536·556 574-594 627-647 
254-271 339-360 376-397 410-429 534-552 577-595 624-644 -
I 
258·279 337-360 376-397 410-429 536-560 570-594 624-646 -
209-230 259-277 337-356 378-395 411-428 536-557 572-593 631·645 
~ u, ~ 
,. ... ""- -
Table 4.2 - Predicted Nand C terminal orientation for OATPIBI 
Name of program Number of N terminal C terminal 
I 
TMs position position 
ConPredII (Arai et al., 2004) 11 Internal External 
SOSUI (Hirokawa et al., 1998) 11 External Internal i 
TopPredII (von Hei.jne, 1992) 12 Internal Internal 
TMpred (Hofman and Stoffel, 1993) 12 Internal Internal 
TMHMM (Kroj!h et al., 2001) 11 Internal External 
TSee (Kihara et al., 1998) 11 Not predicted Not predicted 
MemBrain (Shen and Chou, 2008) 12 Not predicted Not predicted I 
PHDhtm (Rost et al., 1996) 12 Not predicted Not predicted -VI 
VI 
Split 4.0 (Juretic et al., 2002) 12 Internal Internal 
Phobius (KaU et ai, 2004) 12 Internal Internal 
Philius (Reynolds et al., 2008)- 12 Internal Internal 
HMMTOP (Tusnadv and Simon, 2001b) 12 Internal Internal 
TOPCONS (Bernsel et al., 2009) 12 Internal Internal 
PRED-TMR (pasquier et al., 1999) II Not predicted Not predicted 
MEMSA T3 (Jones, 2007) 11 External Internal 
~tm (Yuan et al., 2004) 12 Not predicted Not predicted 
Table 4.3 - Signal peptide and cleavage position predictions for OATPIBI 
Program Signal peptide? Cleavage position 
iPSORT (Bannai et al., 2002) No -
Phobius (Kall et al., 2004) Yes 44 
PrediSi (Hiller et al., 2004) Yes 44 
PSORT II (Nakai and Horton, 1999) No -
Sigcleave (von Heijne, 1986) No -
Si!!nalP 4.0 Jrdersen et al., 2011) Yes 44 
SIG-Pred (Bradford, 2001) No --VI SOSUIsi!!nal (Gomi et aL, 2004) No -
'" SPEPLip (Fariselli et al., 2003) No -
'/ 
'\ 
" 
Figure 4.1- Predicted tertiary structure ofOATPlBl, produced by homology 
modelling with the glycerol-3-phosphate transporter, using Phyre2 (Kelley and 
Sternberg, 2009) and rendered using PyMOL (DeLano, 2002). The TMs are 
depicted as rainbow coloured springs, extracellular and intracellular regions as 
fine lines. The Nand C termini are labelled. 
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4.2.2 Insertion of the OATPIBI FLAG epitope tags 
The topology prediction results (section 4.2.1) were used to map the 
internal/externalloops for insertion of the FLAG epitope tags. OATPI B I was 
predicted by the majority of programs to contain 12TMs with internal Nand C 
termini. The protein does not have a C terminal PDZ sequence (Wang el al., 
2005a), and the consensus from predictions was an absence of an N terminal 
signal peptide, facilitating the addition ofthe tag at the terminals of the protein. 
The range of the topology prediction results generated in section 4.2.1 was used 
to determine the amino acid range for each internaVexternalloop. Regions were 
predicted to be internal or external either side of the predicted TMs (table 4.4). 
The FLAG epitope (DYKDDDDK) was cloned into the amino acid sequence 
within or close to these regions at the positions described in table 4.4 (cloning 
described in section 2.2.14.4). The positions of the epitope tags are shown 
graphically in figure 4.2. A total of 13 individually tagged mutants were 
generated. 
Table 4.4 - Predicted OATPIBI amino acid regions for the internaVexternal 
loops and amino acid FLAG insertions 
FLAG Tag Predicted orientation Predicted amino Amino acid 
number acid region insertion of ta2 
1 Internal (N-terminus) 1-25 2 
2 External (between TM 1-2) 54-63 58 
3 Internal (between TM 2-3) 91-95 93 
4 External (between TM 3-4) 121-165 142 
5 Internal (between TM 4-5) 203-226 215 
6 External (between TM 5-6) 248-286 265 
7 Internal (between TM 6-7) 308-349 329 
8 External (between TM 7-8) 371-387 379 
9 Internal (between TM 8-9) 408-456 433 
10 External (between TM 9-10) 477-549 514 
11 Internal (between TM 10-11) 560-570 565 
12 External (between TM 11-12) 614-625 620 
13 Internal (C-terminus) 647-691 690 
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Figure 4.2 - Predicted topology ofOATPIBI displaying the locations of the inserted FLAG epitope tags. The model was rendered using 
TMRPres2D (Spyropoulos et aI., 2004). 
4.2.3 OATPIBI-FLAG transport results 
Transport experiments were performed on the 13 OA TP I B I-FLAG mutants 
(termed FI-F13 hereafter) to confirm that the epitope tag did not affect 
transport function. All transport experiments were performed with the FLAG 
tagged mutant, WT as positive control and pcDNA vector as negative control. 
WT uptake was significant from the pcDNA control for each mutant, validating 
the experiment (figure 4.3). OATPIBI-FI, F4 and F13 were consistently 
significant from the pcDNA control and uptake increased, but not significantly, 
from that of the WT. This suggests that OATPIBI-FI, F4 and F13 were 
functioning normally following the addition of the FLAG. The remaining 
FLAG mutants exhibited markedly reduced transport, suggesting that the 
position of the FLAG disrupted transport. 
Some of the FLAG mutants did exhibit significant transport in individual 
experiments, however it was variable. Figure 4.4 shows the individual uptake 
experiments for OATPIBI-F3, F6, FlO and FIt. The graphs show an 
increasing trend in uptake from the vector control and several independent 
experiments are significant. It also highlights the inter-assay variability, which 
masks the overall statistical significance. OATPI BI-F3 and FlO revealed some 
transport as 3/4 experiments were significant from the vector controls. 
OATPIBI-F6 and FII were much more variable, with F6 transporting a 
particularly low rate compared with the WT. It is likely that the position of the 
tag disrupted the function of these mutants. 
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Figure 4.3 - Uptake ofeH]E3S into pcDNAISLC01Bl-Fl-13, 
pcDNA/SLC01Bl WT and pcDNA vector transfected HEK293T cells. Each 
bar is the mean ± SE of3-6 experiments with 6 well replicates. *Unpaired t-
test; P<O.05 from the pcDNA control. 
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Figure 4.4 - Uptake ofeH]E3S into A) pcDNAISLCOIBI-F3, B) pcDNAlSLCOlBl-F6, C) pcDNAlSLCOlBl-FIO, D) 
pcDNAISLCOIBI-F11 and pcDNA transfected HEK293T cells. Each point is the mean ± SE of one experiment with 3 well 
replicates. *Unpaired t-test P<O.05. 
4.2.3.1 OATPIBI-FLAG transport kinetics 
Transport kinetics were performed on the FLAG mutants that demonstrated 
consistent uptake ofeH]E3S. This was OATPIB I-FI, F4 and F13. Data were 
obtained using the same experimental parameters as for the WT (section 
3.2.3.2.3). There were no significant differences between the Km values 
obtained for the FLAG mutants and the WT (summarised in table 4.6). The 
V max increased from the WT, though only significantly for OA TP I B I-F I. This 
is not surprising as in the previous uptake experiments OATPIBI-FI, F4 and 
FI3 eH]E3S uptake was increased, though not significantly, from the WT 
(figure 4.3). The values in table 4.6 were plotted as Michaelis-Menten curves 
using the Michaelis-Menten equation in figure 4.5. Transport kinetics were 
performed for F3 but data could not be generated as the uptake was variable and 
not significant from the control (data not shown). Kinetics for OATPIBI-FIO 
were performed once owing also to variability, resulting in a Km of 0.111 flM 
and Vmax of 133.9 pmol/mg proteinl3min (3 well replicates) (data not shown). 
This one experiment suggests that OATPIB I-FlO is transporting at a similar 
rate to the WT, though not consistently, as shown by the variable transport 
results. 
Table 4.5 - Michaelis-Menten Km and Vmax values from pcDNA/SLeOlBl WT 
(bold), pcDNA/SLCOlBl-FI, pcDNAlSLCOlBl-F4 and pcDNA/SLCOlBl-
FI3 transfected HEK293T cells. Each value is the mean:l: SE of 3-5 
independent experiments with 3 well replicates and the pcDNA uptake 
subtracted. *Unpaired t-test P<O.OS from WT 
OATP Km (11M) V mal (pmollmg 
protein/3min) 
OATPIBI-WT 0.105 :I: 0.008 50.1:1: 10.9 
OATPIBI-FI 0.OS4 :I: 0.019 103.8 ± 14.1 * 
OATPIBI-F4 0.159 ± 0.049 79.6± 6.S 
OATPIBI-F13 0.147 ± 0.071 97.7 ± 21.3 
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Figure 4.5 - E3S transport kinetics from A) pcDNAlSLC01Bl WT, B) 
pcDNAISLC01Bl-Fl, C) pcDNAISLC01Bl-F4 and D) pcDNAlSLC01Bl-F13 
transfected HEK293T cells. The line is the Michaelis-Menten equation fitted to 
the kinetic parameters in table 4.6. Each point is the mean ± SE of 3-4 
individual experiments with 3 well replicates and the pcDNA uptake subtracted. 
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4.2.4 Luminometry results 
4.2.4.1 Validation of the luminometry experiment 
The luminometry experiment was validated using the rabbit PepT 1 (Sic 15a 1) 
transport protein, containing a previously tested external FLAG tag (PepTl-
FLAG) (Panitsas et al., 2006). The SIc} 5a1 gene with the FLAG epitope was 
cloned into the pcDNA3.1IHygro(-) vector for expression in HEK293T cells 
(section 2.2.14). The construct was transfected simultaneously with the vector 
control. Surface expression ofPepTl-FLAG was detected using luminometry 
and values were significantly increased from the vector control (figure 4.6). 
This validated the luminometry method and led to subsequent analysis of 
OATP1Bl-FLAG surface expression. 
4.2.4.2 OATPIBI-FLAG luminometry results 
The 13 OATPIB1-FLAG mutants were analysed for surface expression using 
luminometry. OATPIBI-Fl and OATP1BI-F13 were the FLAG tagged Nand 
C termini respectively. FLAG tags attached to external loops could be detected 
by luminometry as the FLAG antibody would attach to the externally accessible 
epitope. Those that were internal would require cell permeabilisation for the 
antibody to reach the epitope. Figure 4.7 shows a summary of the luminescence 
data generated from each tagged mutant. OATPIBI-FI, F4 and F13 were 
consistently significant from the WT in at least 3 independent experiments, 
suggesting that tags in these regions were external. OA TP 1 B I-F4 and F 13 
however were not significant when the data were averaged owing to the inter-
assay variation. The remaining FLAG mutants were not significant from the 
WT. These results are supported by the immunofluorescence detection in 
section 4.2.5. 
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Figure 4.6 - Luminescence of pcDNAlSlcJ 5al-FLAG and pcDNA control 
transfected HEK293T cells. Each bar is the mean ± SE of one experiment with 
4 dish replicates. *Unpaired t-test P<O.05. 
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Figure 4.7 - Luminescence ofpcDNA/SLC01BJlFI-FI3 and 
pcDNA/SLC01Bl WT transfected HEK293T cells. Each bar is the mean ± SE 
of3-8 experiments with 3 dish replicates. *Unpaired t-test P<O.05. 
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4.2.5 OATP1Bl-FLAG immunofluorescence results 
Immunofluorescence was performed on HEK293T cells transfected with the 
pcDNAISLCOIBI-FLAG mutants as a qualitative epitope detection method. 
Cells were fixed to cover slips and incubated with a primary anti-FLAG and 
secondary-FITC antibody that detected the FLAG epitope. Cells were also 
incubated with the nucleic acid stain DAPI to visualise the nucleus. The 
presence of intact nuclei combined with the visualisation of cells under the 
bright field confirmed that fixation did not disrupt cellular morphology. 
Figures 4.8 and 4.9 display the confocal microscopy images recorded from each 
FLAG mutant, as well as the OA TP 1 B 1 WT control. The images are displayed 
as A) 405nm channel highlighting DAPI stained nuclei, B) 488nm channel 
highlighting the FITC labelled FLAG epitope and C) overlay of both images. 
OA TP 1 B I-F 1, F4 and F 13 displayed distinctive membrane specific 
fluorescence (figure 4.8), compared to the low level of background FITC 
fluorescence observed in the cytoplasm of the WT. However, only non-specific 
background was observed for OATPIB I-F2, F3, F5, F7, F8, F9, Fll and F12 
(figure 4.9). OA TP 1 B I-F 1 0 displayed areas of brighter fluorescence, but this 
was still restricted to the cytoplasm. This supports the luminometry data, as 
OA TP 1 B I-F 1, F4 and F 13 demonstrated significant luminescence, whereas the 
other mutants did not. 
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Figure 4.8 - continued on next page 
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Figure 4.8 - pcDNAlSLCOIBI WT and pcDNA/SLCOIBI-Fl , 
pcDNA/SLCOIBI-F4 and pcDNA/SLCOIBI-F13 transfected HEK293T cell 
immunofluorescence by confocal microscopy. A) DAPI (blue) localised to the 
nucleus (504nm) B) FITC (green) localised to the FLAG epitope (488nm) C) 
overlay of both images. Scale bar = 20~M. 
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Figure 4.9 - pcONAlSLCOlBl WT and pcONA/SLCOIBI-F2, F3, F5, F6, F7, 
F8, F9, FlO, F 11 , F 12 transfected HEK293T cell immunofluorescence by 
confocal microscopy. A) OAP] (blue) localised to the nucleus (504nm) B) 
FITC (green) localised to the FLAG epitope (488nm) C) overlay of both 
images. Scale bar = 20J.lM. 
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4.2.6 OATP-FLAG permeabilisation results 
FLAG mutants that did not exhibit significant luminescence but did exhibit low 
levels of transport were investigated as containing potential internal tags. 
OATPIBI-F3, F6, FlO and FII did not show significant luminescence but did 
exhibit some transport of eH]E3S (section 4.2.3), albeit not significant overall. 
These FLAG mutants were chosen for permeabilisation experiments to 
determine whether the epitope was on the internal side of the membrane. This 
was achieved by permeabilising the HEK293T cell membranes during cell 
fixation of the luminometry experiment. Permeabilisation allowed the antibody 
to enter the cells and attach to the epitope if present, as shown by a significant 
increase in luminescence. 
Permeabilised luminescence was normalised to non-permeabilised 
luminescence and significance was denoted using a one sample t-test. 
Normalised values were expressed as a percentage in figure 4.10. Results 
showed that luminescence increased, but not significantly, when the OA TP I B 1-
F3, F6, FlO and FII transfected cells were permeabilised. OATPIBI-FI 
exhibited significant luminometry and thus the OA TP I B I WT and OA TP I B 1-
Fl proteins were used as negative and positive controls, respectively. When 
these control cells were permeabilised, however, luminescence also increased 
(figure 4.10). An increase from the OATPIBI-Fl positive control was expected 
owing to the presence of transporters in the cytoplasm and organelles, however, 
there was a large signal from the OATPIBI WT negative control which did not 
contain any tagged protein, most likely due to non-specific binding of the 
antibody. The increase in luminescence following permeabilisation suggests 
that the cells were permeabilised adequately; however the increase from the 
permeabilised FLAG mutants was not significantly higher than the background 
observed in the controls. 
Immunofluorescence was also performed with permeabilised HEK293T cells 
transfected with pcDNNSLCOIBI-F3, pcDNNSLCOIBI-F6, 
pcDNAlSLCOlBl-FIO and pcDNNSLCOIBI-FII (figure 4.11). However 
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permeabilisation did not localise the antibody to the epitope on the membrane. 
Rather, large areas of non-specific fluorescence were observed. This, combined 
with presence of intact nuclei, suggests that cell perrneabilisation was effective, 
but that there was non-specific binding of the antibody. This supports the 
results obtained from the luminometry experiments performed with 
permeabilised cells. These FLAG mutants did not display a high and consistent 
level of transport, which may be owing to disruption of protein expression from 
addition of the tag. This would also explain why the luminometry and 
immunofluorescence following perrneabilisation did not indicate an internal 
tag. 
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Figure 4.10 -Luminescence following penneabilisation. Penneabilised values are nonnalised to non-penneabilised values and expressed as 
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Figure 4.11 - pcDNAISLCOIBI-F3, pcDNAISLCOIBI-F6, 
pcDNA/SLCOIB1-FIO and pcDNA/SLC01Bl-Fl1 transfected HEK293T cell 
immunofluorescence by confocal microscopy, with and without cell 
permeabilisation . A) DAPllocalised to the nucleus (504nm) B) FITC localised 
to the FLAG epitope (488nm) C) overlay of both images. Scale bar = 20IlM. 
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4.2.7 Summary ofOATPlBl transport and luminometry results 
Luminometry and transport experiments were performed with 3-6 replicates 
over at least 3 individual experiments. As discussed, there was some inter-assay 
variability, which masked the significance when the data were grouped 
together. To overcome this, the luminometry and uptake data for all FLAG 
mutants were normalised to the OA TP I B I WT in figure 4.12. 
The pcDNA control uptake was subtracted from the sample uptake and the 
values normalised to those of the OATPI BI WT. Similarly the sample 
luminometry values were normalised to those of the OATPIBI WT. Values 
were expressed as a percentage and significance was denoted using a one 
sample t-test. Figure 4.12 highlights the significant luminometry and uptake for 
OATPIBI-FI, F4 and F13, obserVed in individual experiments. OATPIBI-F6 
luminometry was also significantly increased from the OA TP I B 1 WT, though 
this is not supported by consistently significant transport and 
immunofluorescence experiments. OATPIBI-F2, F5, F6, F7, F8, F9, FIl and 
FI2 all displayed a significant decrease in transport from the OATPI B I WT. 
Furthermore, OATPIBI-F2, F5, F7, F8, F9, FII and FI2 showed no significant 
difference in luminometry. 
Therefore, the epitope tagged OATPIBI-FI, F4 and Fl3 proteins retained 
transport function and will be used to make extrapolations and form a new 
OATPIBI model. 
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Figure 4.12 - Summary of eH]E3S transport and luminometry results from 
pcDNA/SLCOIBI-FI-F13 transfected HEK293T cells. Values are normalised 
to the WT and expressed as a percentage. Each bar is the mean ± SE of 3-8 
experiments (luminometry = 3 dish replicates, transport = 6 well replicates). 
*P<O.05 increase from WT, #P<O.05 decrease from WT (Both one sample t-
tests) . 
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4.3 Conclusion 
There is currently little understanding of the topological structure of OA TPs. 
Knowledge of the structure is imperative to understanding how these proteins 
bind to and transport compounds. Therefore the topology of OA TP I B I was 
studied using topology prediction programs, epitope insertion, luminometry and 
immunofluorescence detection methods. 
The topology prediction programs predicted OATPIBI to contain between 11-
12 domains with internal Nand C termini. A 12TM model was chosen as more 
programs predicted 12TMs than II, in line with the predictions of other groups 
(Gui and Hagenbuch, 2009; Konig et ai., 2000b). This was supported by the 
novel homology modelling ofOATPIBI on the glycerol-3-phosphate 
transporter, which revealed a 12TM protein with internal Nand C termini. 
Interestingly, OATPIA2 was predicted to be a 7-9TM protein by all the 
topology programs, which is not in keeping with the other predictions, nor that 
the OA TPs are related to the MFS (Pao et ai., 1998). OA TP I B3 and OA TP2B I 
were predicted with some variation but up to 12TMs were predicted. OA TP I B3 
shares 80% amino acid identity with OA TP 1 B I and thus it would be expected 
that the topology predictions were similar. However more variation was 
demonstrated for OATPIB3, predicting between 9-12TMs rather than 11-12. 
These predictions suggest that there may be a larger degree of TM variability 
between OA TPs than previously recognised, and further experiments are 
required to confirm this topology. 
A signal peptide was not predicted for OATPIBI. A small number of programs 
predicted a cleavage site at position 44, however later luminometry results from 
the Nand C termini suggest that this is unlikely, as the tags at the Nand C 
terminal ends were not cleaved/did not disrupt protein functioning. It is 
interesting also to note that OA TP 1 A2 was predicted to contain a signal peptide 
site, whereas OATPIB3 and OATP2BI were not. Why OATPIA2 contains a 
potential cleavage site and the others do not remains to be elucidated. However 
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some topology programs predicted the first 20 amino acids ofOATPIA2 to be 
a TM, owing to their hydrophobic nature, so it is possible that the signal 
sequence predicted is in fact a TM. If so, this TM could be acting as an anchor, 
rather than a signal peptide. It is difficult for prediction programs to distinguish 
between a signal peptide sequence and a TM owing to their similarities in 
length and hydrophobicity, however several programs have adapted their 
algorithms to account for this (Kall et al., 2007; Reynolds et al., 2008). There is 
very little signal prediction data available for the OA TP family and further 
research is required. 
The FLAG epitope was cloned into the intracellular and extracellular regions of 
OA TP I B 1 based on the topology prediction results. A total of 13 tagged 
OA TP I B I proteins were generated; termed F I-F 13 .Transport experiments were 
performed on the FLAG mutants to ensure that inserting the epitope tag did not 
disrupt functioning. OATPIBI-FI (N terminal), F4 and F13 (C terminal) all 
transported eH]E3S significantly and consistently. OATPIBI-F3, F6, FlO and 
FII demonstrated some significant uptake but it was variable, as shown by the 
individual graphs. It is likely that the tag affected the functioning of these 
mutant proteins. The remaining FLAG mutants demonstrated very low 
transport, suggesting that insertion of the tag was detrimental to functioning or 
expression. Kinetic experiments were performed on OATPIBI-FI, F4, FlO and 
F13. The results showed that apart from the OATPIBI-FI Vmax, Km and Vmax 
were not significantly different from that of the WT. 
Luminometry experiments were performed on the 13 mutants to detect the 
epitope on the membrane. A significant increase in luminescence was observed 
for OATPIB I-FI, F4 and F13. FI and F13 as the Nand C termini were 
predicted to be internal. Interestingly, the luminometry results revealed the 
terminals to be external. OATPIBI-F4 was also predicted to be external and 
confirmed by luminometry. OATPIB I-F6 displayed significant luminometry 
but this was not supported by immunofluorescence and transport experiments. 
The remaining luminometry results were not significant, in line with the low 
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transport results. OATPIBI-F3, F6, FlO and FIl demonstrated a small amount 
of transport and thus it was hypothesised that these epitopes may have been 
internal. Cell permeabilisation experiments were performed on these tagged 
proteins to determine whether the tag was on the inside of the membrane. 
Luminescence increased following permeabilisation but was not significantly 
increased from that of the non-permeabilised cells. Furthermore, the controls 
demonstrated a large increase in luminescence following permeabilisation, 
suggesting that the increase is due to non-specific binding. 
Immunofluorescence experiments were performed in order to qualitatively 
validate the luminometry results. OATPIBI-FI, F4 and FI3 displayed 
membrane specific fluorescence, confirming the significant luminometry. The 
other FLAG mutants were comparable to the background fluorescence observed 
for the OA TP I B I WT, suggesting that the epitope was not detectable. 
Furthermore, immunofluorescence of the permeabilised cells transfected with 
OATPIBI-F3, F6, FlO and FIt resulted in a large amount of fluorescence 
within the cell, but not on the membrane. This fluorescence increase, combined 
with the increase in luminescence following permeabilisation suggests that the 
cells were permeabilised adequately; however it is likely that the fluorescence 
was due to non-specific binding of the antibody. 
These results reveal that the experimental evidence does not support the 
predicted topology for OATPtBI. The Nand C termini were predicted to be 
facing the intracellular space, however the epitope tags attached to the Nand C 
termini were detected as extracellular. The putative extracellular loop 2 
containing F4 was also detected as external. However for both OATP I B I-F I 
and F4 to be external, both TM2 and TM3 cannot exist, further contradicting 
the topology predictions. The epitope tags placed in the other predicted loops 
were not detectable by luminometry and/or did not function the same as the 
WT. 
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Further investigation is required to determine the exact number of TMs in 
OATPIBI, however this is the first experimental evidence to suggest that 
OA TP 1 Bland potentially the other human OA IPs have extracellular N and C 
termini. 
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5 Mutagenesis of the OATPIBI signature 
• regIon 
5.1 Introduction 
The OA TP superfamily signature is a highly conserved 13 amino acid sequence 
(D-X-RW-(I,V)-GAWW-XG-(F,L)-L), conserved across all known OATPs 
(Hagenbuch, 2003), the function of which is not known. A signature sequence 
is not uncommon among transporter families and sequences often playa pivotal 
role in the functioning of the transporter. For example, the ABC transporters 
contain the signature sequence 'LSGGQ' in their nucleotide binding domains, 
important for the ATP-hydrolysis required for driving transport (Ren et af., 
2004). The conserved nature of the OATP signature sequence suggests that it 
also plays a role in protein function. 
The signature sequences for the 11 human OA TPs are shown in table 5.1, 
highlighting the high degree of amino acid similarity within this region. This 
high degree of conservation and localisation within the protein family suggests 
an important role potentially for substrate binding, membrane targeting and/or 
membrane anchoring. 
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Table 5.1 - The human OA TPs with each signature sequence region . Highly 
conserved amino acids are in bold/yellow. Source: NCBI (Benson et ai., 2012) 
OATP Signature sequence Amino 
acid 
position 
OATPIA2 D T R W V G A W W F G F L 218 
OATP1Bl D S R W V G A W W L N F L 251 
OATPIB3 D S R W V G A W W L G F L 251 
OATPICI D P Q w V G A W W L G Y L 149 
OATP2Al D P R W I G A W W L G L L 250 
OATP2Bl D P R W V G A W W L G F L 269 
OATP3Al D P R W I G A W W G G F L 199 
OATP4Al S P L W V G A W W V G F L 303 
OATP4CI D P R W L G A W W I G F L 307 
OATP5AI D P R F I G N W W S G F L 340 
OATP6Al S P E W L W T W W I N F L 307 
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The signature sequence is predicted to be between the extemalloop 3 and TM6, 
as determined by the topology analysis performed in chapter 4. This is in line 
with previous predictions (Hagenbuch, 2003). 
The presence of the signature sequence at the interface between the TM and the 
extracellular loop suggests a potential role for stabilising or anchoring the 
protein in the membrane. This is supported by the presence of conserved 
tryptophan residues; residues which are relatively rare in proteins, normally 
constituting approximately 5% of the amino acid sequence (Lodish el al., 
2000). 
Tryptophans are more prevalent in transmembrane proteins than soluble 
proteins (Schiffer et al., 1992) and are often found in membrane proteins at the 
hydrophobic/hydrophilic interface of helices and TMs (Wallace and Janes, 
1999). In the OATPIBI sequence there are six tryptophan residues, three of 
which are present in the signature sequence. The preference oftryptophans for 
the interface has been linked to protein stability within the membrane; Clark 
and colleagues (Clark el al., 2003) mutated the tryptophans in the 
transmembrane protein diacylglycerol kinase, finding that tryptophan tilted the 
residues at the end of the helix, linking them to the helix backbone. This 
stability may be because of hydrogen bonding from the unique indole ring, 
whereby hydrogen bonds are formed with the lipid heads of the membrane, 
whilst the hydrophobic rings are immersed within the bilayer (Schiffer el al., 
1992). 
This hydrogen bonding was also found to be important for the correct folding of 
transmembrane gramicidin channels (Sun el al., 2008b). Aromatic amino acids 
such as tryptophan can also undergo stacking interactions with other aromatic 
residues. This stacking of one amino acid on another stabilises the protein, and 
may suggest why there are three tryptophan residues in close proximity within 
the sequence. 
A positively charged arginine is also found within the signature sequence and is 
highly conserved. Arginines and Iysines that flank the membrane play an 
important role in anchoring the TM within the membrane. Positive amino acids 
are thought to interact with the negatively charged phospholipid head groups, 
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stabilising the hydrophobic regions within the membrane (Lodish et al., 2000; 
Mandery et al., 2011). 
Therefore the presence of amino acids such as arginines and tryptophans and 
the localisation to the helixITM interface suggest that the signature sequence 
region is important for protein anchoring and/or folding. 
OA TP 1 B 1 was the chosen isoform to study the sequence with the OA TP 1 B 1-
HEK293T model previously established (chapter 3). Furthermore, the topology 
of OA TP 1 B 1 has been evaluated, revealing extracellular loop 2 (F4) to be 
extracellular (chapter 4). The epitope in this position did not disrupt transport 
and kinetic values were comparable. Therefore this OATP1BI-F4 mutant 
isoform provided a suitable system for investigating the surface expression of 
the signature sequence. 
The most conserved amino acids within the signature sequence were mutated 
conservatively to determine the importance of the charge and structure of the 
amino acid, for transport and surface expression. The mutations OATP1B1-F4-
D251E, R253K, W254F, W258/259F (double mutant) and N261A were 
introduced using SDM. Each mutant was expressed in HEK293T cells and the 
effect on transport investigated using the previously validated eH]E3S 
transport experiment. In addition, luminometry and immunofluorescence 
experiments were performed to evaluate the effects of the mutations on surface 
expression. Values for each experiment were compared to OATPIBI-F4 as the 
WT. 
The results from these experiments provided evidence for the importance of 
specific amino acids within the OA TP signature sequence for transport and 
surface expression. 
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5.2 Results 
5.2.1 OATPIBI signature mutagenesis and rationale 
The highly conserved OA TP 1 B 1 signature sequence was investigated using 
SDM. The topology predictions in section 4.2.1 were used to predict the 
location of the signature sequence in OATPIBI. The sequence was located 
between extemalloop 3 and TM6 (figure 5.2), in line with previous predictions 
(Hagenbuch, 2003). 
Mutations were introduced to the validated F4 externally tagged OA TP I B 1 
isoform to allow the quantification of surface expression following 
mutagenesis. Conservative mutations were made to 6 amino acids within the 
signature sequence ofOATPlBl (figure 5.1). These were D251E, R253K, 
W254F, W258/259F and N261A (mutagenesis method in section 2.2.14.5). 
Aspartic acid was mutated to glutamic acid (D251 E); both being negatively 
charged polar residues. Arginine, the only positively charged residue in the 
signature sequence, was mutated to the similarly positive and polar lysine 
(R253K). The tryptophans were mutated to phenylalanines; W254F and 
W258/259F as a double mutant. Phenylalanines and typtophans are non-polar 
with aromatic side chains, differing by the nitrogen containing indole ring of 
tryptophan and phenyl group of phenylalanine. Phenylalanine is also more 
hydrophobic than tryptophan but both are able to perform stacking interactions 
to stabilise the protein (Lieberman and Marks, 2012). 
Interestingly, the first three residues ofthe signature sequence are polar, 
followed by a stretch of non-polar residues, with the exception of asparagine 
(figure 5.1). This asparagine is also not very conserved among the other 
OATPs, which are mostly non-polar glycines (table 5.1). Therefore asparagine 
was mutated to investigate the role of this amino acid in the sequence. 
Asparagine, as the amide of aspartic acid, does not carry a charge. Therefore it 
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was mutated to alanine (N261A), a residue similarly without a charge and 
lacking a reactive side group, so as not to mask the potential function of 
asparagine . 
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OATPIBI Sequence ID S RI V G A W W 1N]r=-=-! 
1 1 1 \/ 1 
Mutation E KF FF A 
Figure 5.1 - OA TP I B I signature sequence with mutations and amino acid 
positions, polar amino acids highlighted in blue, non-polar in orange. 
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Figure 5.2 - Predicted topology of OATP 1 B 1 from the prediction results in section 4.2.1, displaying the location of FLAG 4 and the 
signature sequence region (orange). The model was rendered using TMRPres2D (Spyropoulos et aI. , 2004). 
5.2.2 OATPIBI signature mutant transport 
Transport experiments were conducted with mutant transfected HEK293T cells 
and the substrate eH]E3S (figure 5.3). Experiments were performed 
simultaneously with the pcDNA vector negative control and OATP1 B 1-F4 WT 
(WT F4) positive control. All WT F4 transport was significant from the pcDNA 
control, validating the experiment. N261A was the only mutant to show a 
significant increase in transport from the pcDNA control, and was not 
significantly different from the WT F4. Mutants D251 E, R253K, W254F and 
W258/259F were not significant from the negative control. This suggests that 
N261A was the only mutant to maintain significant transport function. 
Transport kinetics were performed on the mutants to ascertain whether the 
affinity for the substrate was changed (section 5.2.2.1). 
5.2.2.1 OATPIBI signature mutant transport kinetics 
Transport kinetics were performed on the signature sequence mutants to 
investigate a change in Km and/or V max following mutagenesis. Initial transport 
experiments revealed that N261A was the only mutant to show significant 
transport from the pcDNA control (section 5.2.2), the remaining mutants were 
not significant. 
Table 5.2 shows the Km and V max values obtained using the same experimental 
parameters as for the WT F4 (section 3.2.3.2.3). N261A transport kinetics were 
performed over three separate experiments and were not significantly different 
from the WT F4. Kinetic experiments with the remaining mutants were 
performed with one experiment owing to the low levels of transport. This small 
amount of data though not significant, does suggest that the Km was increased 
and V max slightly decreased from the WT F4. The values in table 5.2 were 
plotted as Michaelis-Menten curves using the Michaelis-Menten equation in 
figure 5.4. 
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Figure 5.3 - Uptake of eH]E3S into pcDNA negative control, 
pcDNA/SLC01Bl-F4 WT and pcDNNSLC01Bl-F4-D251E, 
• pcDNA control 
. WTF4 
• Mutant 
N261A 
pcDNA/SLCOl Bl-F4-R253K, pcDNAISLC01Bl-F4-W254F, 
pcDNA/SLC01Bl-F4-W258/259F and pcDNNSLC01Bl -F4-N261 transfected 
HEK293T cells. Each bar is the mean ± SE of3-5 experiments with 6 well 
replicates. *Unpaired t-test; P<O.05 from the pcDNA control. 
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Table 5.2 - Michaelis-Menten Km and Vmax values for pcDNAlSLCOlBl-F4 
WT (bold), pcDNAISLCOIBI-F4-D25IE, pcDNAlSLCOlBl-F4-R253K, 
pcDNAlSLCOlBl-F4-W254F, pcDNAlSLCOlBI-F4-W258/259F and 
pcDNAISLCOIBI-F4-N261A transfected HEK293T cells. Each value is the 
mean ± SE of 1-4 experiments with 3 well replicates and the pcDNA control 
subtracted. 
OATP Km (11M) V mn (pmollmg 
protein/3min) 
OATPIBI-F4 WT 0.159 ± 0.049 79.6 ± 6.S 
OATlBI-F4-D25IE 0.886 74.6 
OA TP 1 B I-F4-R253K 0.303 76.7 
OATPIBI-F4-W254F 0.772 76.7 
OA TP I B I-F4-W258/259F 0.424 76.6 
OATPIBI-F4-N261A 0.084 ± 0.033 47.0± 19.4 
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Figure 5.4 - continued on next page 
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Figure 5.4 - E3S Michaelis-Menten curves of A) pcDNA/SLC01Bl-F4 WT 
B) pcDNNSLC01Bl-F4-D251E, C) pcDNAISLC01Bl-F4-R253K, D) 
pcDNAISLC01Bl-F4-W254F, E) pcDNNSLC01Bl-F4-W258/259F and F) 
pcDNAISLC01Bl-F4-N261A transfected HEK293T cells. The line is the 
Michaelis-Menten equation fitted to the kinetic parameters in table 5.2. ach 
point is the mean of 1 experiment, except for N26 1 A where each point is the 
mean ± SE of 3 experiments and WT F4 which is the mean ± SE of 4 
experiments. All were performed with 3 well replicates. 
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5.2.3 OATPIBI signature mutant luminometry 
Luminometry experiments were conducted with the signature sequence 
OATPIBI F4 mutants to determine the change in surface expression. 
OATPIBI was used as the non-tagged WT negative control, OATPIBI-F4 as 
the WT positive control. The luminometry experiments were validated by the 
individually significant luminometry of OATPI B I-F4, however when averaged 
the values were not significant owing to variation between experiments (figure 
5.5). Similarly N261A was significantly increased from the negative control in 
individual experiments but was not significant when averaged. The remaining 
mutants were not significant from the negative control, confirming that surface 
expression was reduced. The variation between experiments was removed by 
normalising the luminometry and transport data in section 5.2.4. Luminometry 
results were supported by those of immunofluorescence experiments (section 
5.2.5). 
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Figure 5.5 - Luminescence ofpcDNNSLC01Bl negative control, 
pcDNAISLC01Bl-F4 WT and pcDNNSLC01Bl-F4-D25 I E, 
pcDNAISLCO 1 Bl-F4-R253K, pcDNAISLCOl Bl-F4-W254F, 
pcDNA/SLC01Bl-F4-W258/259F and pcDNNSLC01Bl-F4-N261 tran fected 
HEK293T cells. Each bar is the mean ± SE of 3 experiments with 3 dish 
replicates. 
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5.2.4 Summary of OATPIBI signature mutant transport and 
luminometry 
The luminometry and transport experiments displayed some inter-assay 
variation as observed for the OATPIBI-FLAG experiments in section 4.2. This 
was particularly apparent for R253K. R253K demonstrated some significant 
transport and luminometry which were not significant when the experiments 
were averaged. In order to highlight this, the three experiments have been 
shown individually as line graphs (figure 5.6). The data shows an increased 
trend from the negative control for both transport and luminometry, with one 
transport and two luminometry experiments significant from controls. This is 
contrasting with D251 E, W254F and W258/259F which demonstrated no 
significant results in individual experiments. Therefore this suggests that there 
was a small amount of transport and luminometry for R253K. 
All transport and luminometry data were normalised to the F4 WT (figure 5.7), 
to avoid masking the significance in the data by the variability. The pcDNA 
control eH]E3S uptake was subtracted from all eH]E3S sample uptake and the 
values normalised to those of the WT F4. Similarly the negative control non-
tagged OA TP 1 B 1 luminometry values were subtracted from sample 
luminometry values and values normalised to those of the WT F4. Significance 
was denoted using a one sample t-test and values were expressed as a 
percentage. 
The normalised data displays a significant decrease in transport and 
luminometry for D251E, W254F and W258/259F. R253K was not significantly 
reduced from the WT F4. N261 was not significantly different from the WT F4 
and was significant from controls, suggesting that this mutation did not affect 
the functioning of the protein. 
The transport and luminometry values for D251E, R253K, W254F and 
W258/259F were not significant from one another, suggesting a relatively equal 
reduction in transport and surface expression. Therefore transport was most 
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likely reduced because there were fewer transporters on the membrane. These 
results are supported by immunofluorescence experiments (section 5.2.5). 
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5.2.5 OATPIBI signature mutant immunofluorescence 
Immunofluorescence experiments were performed to qualitatively confirm the 
luminometry results displayed in section 5.2.3. The experiments were 
performed as previously described in section 4.2.5. To summarise, HEK293T 
cells expressing the protein were fixed to cover slips and incubated with a 
primary anti-FLAG and secondary-FIre antibody that detected the FLAG 
epitope. The nucleic acid stain DAP! was also used to visualise the DNA. 
Figure 5.8 displays the confocal microscopy images recorded from each 
mutant, as well as the OATPIBI-F4 positive control and OATPIBI negative 
control. The images are displayed as A) 405nm channel highlighting the DAP! 
stained nuclei, B) 488nm channel highlighting the FITe labelled FLAG epitope 
and C) overlay of both images. 
The N261A immunofluorescence results confirm the significant luminometry 
results as the FIre fluorescence detecting the FLAG epitope is membrane 
specific. The membrane is clearly defined as in the WT OATPIBI-F4 with 
little intracellular staining. The other mutants displayed fluorescence, 
suggesting that some protein was present, but this was completely throughout 
the cell, suggesting that the protein was not reaching the membrane. This 
supports the reduced luminometry values for these mutants. 
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Figure 5.8 - pcDNNSLCOIBl negative control, pcDNA/SLCOIBI-F4 WT, 
pcDNNSLCOIBI-F4-D25 IE, pcDNAISLCOIB1-F4-R253K, 
pcDNA/SLCOIBI-F4-W254F, pcDNA/SLCOIBI-F4-W258/259F and 
pcDNNSLCO 1 BI -F4-N261 A transfected HEK293T cell immunofluorescence 
by confocal microscopy. A) DAPI (blue) localised to the nucleus (504nm) B) 
FITC (green) localised to the FLAG epitope (488nm) C) overlay of both 
images. Scale bar = 20J.lM. 
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5.3 Conclusion 
All OATPs contain a 13 amino acid signature sequence, the function of which 
is not known (Hagenbuch, 2003). The signature sequence ofOATPlBI 
(DSRWVGA WWLNFL) was investigated by mutating 6 highly conserved 
residues, using SDM. These were D251E, R253K, W254F, W258/259F and 
N261A. These conservative mutations were made to highlight the importance 
of the structural features of the amino acid. The mutations were cloned into the 
F4 externally tagged OATPI B I, which maintained WT transport kinetics and 
allowed changes in surface expression to be investigated. 
Transport and luminometry results revealed that mutations D251E, W254F and 
W2581259F had dramatic effects on function and surface expression, reducing 
to less than 40% of the WT F4. R253K was reduced to approximately 50% of 
the WT F4 and displayed some significant transport and luminometry. The 
relatively equal reduction in transport and surface expression suggest that 
transport was reduced owing to fewer transporters present on the membrane. 
Transport kinetics, despite low experiment numbers and low transport, did 
show an increase in Km and small reduction in Vmax. N261A protein function 
was not significantly altered by the mutation. Immunofluorescence results 
supported the luminometry results, showing membrane specific fluorescence 
for N261 A but throughout the cell for the other mutants. The presence of 
fluorescence suggests that some protein was present in the cell, but the 
intracellular staining was most likely the result of the antibody binding to 
incorrectly folded or retained protein. 
Aspartic acid and glutamic acid are both negatively charged polar residues, 
therefore a substitution (D25IE) was not expected to affect the protein. 
However a significant decrease in transport and luminometry to background 
levels was observed. This may be owing to the differing spacial preferences of 
the two amino acids. Aspartic acid interacts with tryptophan more frequently 
than glutamic acid, possibly because of the slightly differing chain lengths 
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(Jonson and Petersen, 2001). Therefore mutating to glutamic acid may have 
changed the interactions with tryptophan within the sequence, disrupting the 
structure. 
Mutation of arginine to lysine (R253K) reduced transport and surface 
expression to approximately 50% ofthe WT F4, with a small amount of 
transport and luminometry. Positively charged arginine and lysine are thought 
to playa role in stabilising the membrane by interacting with negatively 
charged phospholipid head groups (Lodish et a/., 2000). The effects of this 
mutation on transport and surface expression suggest that a structurally 
different property of arginine is required for correct function. Arginine and 
lysine are both polar, positive amino acids, differing by their functional groups. 
The conformation of the guanidinium group of arginine is known to form more 
electrostatic interactions compared to the basic functional group of lysine. 
Arginine also has a higher pKa, potentially allowing for more stable ionic 
interactions (Sokalingam et al., 2012). It may be for these reasons that arginine, 
rather than lysine, is required in this position, but that the positively charged 
property of lysine possibly rescued some of the function. 
Tryptophan is a unique and versatile amino acid, exhibiting a large non-polar 
surface area, the capability for hydrogen bond formation from the indole N-II 
moiety and the greatest electrostatic potential for cation-1l" and other non-
covalent interactions (Sanchez et a/., 2011). It is for these properties that the 
highly conserved tryptophans present in the sequence may be essential for 
stabilising OATPIBI within the lipid bilayer. The reduction in function and 
surface expression from substituting tryptophan for phenylalanine (W254F, 
W258/259F) suggests that a feature within the tryptophan structure is required 
for the correct functioning of the signature sequence. This could be owing to 
the indole ring that only tryptophan possesses, previously shown as an 
important feature for hydrogen bonding and membrane stability (Sanchez el al., 
2011; Schiffer el a/., 1992). Westholm and colleagues however provide 
interestingly contrasting results (Westholm et a/., 2010). When the group 
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mutated the equivalent double tryptophans in rat OatplcI (W277/278F) to 
phenylalanines, the protein retained WT transport kinetics and surface 
expression by immunofluorescence. It was only when replaced with small, non-
aromatic alanines that function was abolished. This suggests that different 
OATPs may be folded or stabilised in the membrane slightly differently. 
The mutation of asparagine to alanine (N26IA) did not affect transport or 
surface expression. It may be that maintenance of a neutral charge at this 
position is sufficient to complete protein folding and function. Asparagine is 
able to perform hydrogen bond interactions with its side chain amide groups 
(Shimoni and GIusker, 1995), which is not possible with the hydrophobic side 
chain of alanine. Therefore hydrogen bonding is also unlikely to be required in 
this amino acid position. 
Mutating residues within the signature sequence region has had a profound 
effect on protein transport and surface expression. Of the six amino acids 
mutated conservatively, four were severely affected. The relatively equal 
decrease in surface expression combined with transport suggests that there were 
less transporters present or that the protein was folded incorrectly on the 
membrane. This is supported by the intracellular fluorescence observed from 
the immunofluorescence experiments. However the presence of structurally 
important residues such as tryptophans and the putative position at the 
helixlTM interface suggest a role in stabilising or anchoring the protein within 
the membrane. It is possible that this sequence is an internal non-cleaved 
membrane-anchor sequence or stop-transfer anchor sequence, ensuring that the 
protein is anchored within the membrane at the correct position following 
translocation from the ER. However transmembrane proteins that contain an 
anchor sequence often also contain a cleavable signal peptide (Cooper, 2000), 
which is not predicted for OA TP 1 B I. Further analysis would benefit from the 
investigation of L263 in the signature sequence, which is also conserved across 
all human OA TPs. 
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6 Discussion 
Membrane transport research has expanded significantly in the last decade; with 
the understanding that membrane transport contributes significantly to drug 
disposition. The OA TPs are one such family of membrane proteins responsible 
for the transport of many varied endogenous and xenobiotic compounds. The 
presence of OA TPs in the membranes of hepatocytes and renal cells highlights 
their influential role in the uptake of compounds for drug metabolism and 
excretion. Furthermore, the OA TPs have been linked to disease and clinically 
relevant DDIs, emphasising the importance for understanding the structure and 
function of these proteins. 
OATPs have been predicted to contain 12TMs with the Nand C termini facing 
the cytoplasmic space (Hagenbuch and Meier, 2004; Hanggi et al., 2006; Noe 
et al., 1997; Roth et al., 2011). N-glycosylation sites have been located in 
extracellular loops 2 and 5 (Lee et al., 2003; Wang et al., 2008; Yao et al., 
2012). The large extracellular loop 5 also contains cysteine residues linked by 
disulphide bonds, found to be essential for targeting to the cell surface in 
OATP2B 1 (Hanggi et al. 2006). In addition, several residues within TMs are 
important for substrate binding (Gui and Hagenbuch, 2009; Li el al., 2012; 
Miyagawa el al., 2009). The OATPs are characterised by a signature sequence 
region (D-X-RW-(I,V)-GAWW-XG-(F,L)-L) located at the border between 
extracellular loop 3 and TM6, which is conserved across all species 
(Hagenbuch and Meier, 2004), but the function is not known. Meier-Abt and 
colleagues (Meier-Abt el al., 2005) homology modelled OATP1B3 on two 
MFS proteins, revealing a pore like structure, to which substrates potentially 
translocate. Positive residues predicted to line the pore have been studied and 
are involved in transport (Glaeser el al., 2010; Weaver and Hagenbuch, 2010). 
The aim of this research was to further this structural knowledge by validating 
the topology predictions experimentally and elucidate the role of the signature 
sequence. 
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OATPIA2, OATPIB1, OATPIB3 and OATP2Bl are functionally influential 
transporters that are present in the liver and kidney, linked to disease and 
implicated in DDIs. Therefore any/all of these isoforms were relevant 
candidates for evaluating the OA TP structure/function. Several expression 
systems were investigated as potential models for studying these OA TPs, using 
the substrate E3S. The X laevis oocyte and HEK293T cell systems were 
evaluated as over-expression systems. X laevis oocytes are used routinely to 
express membrane proteins and significant transport ofE3S was observed for 
all four isoforms. However transport was variable, and so HEK293T cells were 
evaluated as an alternative cell culture model. OA TP I B 1 demonstrated 
consistent transport when expressed in HEK293T cells with an E3S Km and 
Vmax of 0.105 ± 0.008JlM and 50.1 ± 10.9 pmol/mg proteinl3min respectively. 
These values are in line with those published previously (0.23JlM (Noe et al., 
2007), (0.21 ± 0.02JlM, 25.6 ± 4.6 pmol/mg proteinl2min (Li et al., 2012). 
Primary membrane vesicles were also evaluated as a potential tool for 
measuring endogenous Oatplal and Oatp4cl mediated E3S transport. 
Transport was significant from the control in the first minute, then decreased 
over time, suggesting that transport was either very rapid and/or that the 
radioactivity was potentially retained on the filter. This system requires further 
optimisation to determine whether it would be a suitable model for measuring 
endogenous OA TP transport. 
The validated OA TP I B IIHEK293T cell system was used to further investigate 
the topology and OATP signature sequence region of the protein. There is very 
little supporting evidence for the topology of the OA TPs, the only previously 
studied OATP is rat Oatplal (Wang et al., 2008). The authors used two 
prediction programs; TMPRED and TMHMM, which predicted 12 and 10TM 
proteins respectively. An epitope tag was inserted in a region that was external 
in the 10TM model and internal in the 12TM model to differentiate between the 
two. The region was found to be external, suggesting that the 10TM model may 
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not be correct. However further experiments were not performed to definitively 
confirm the 12TM topology and the orientation of the Nand C termini. 
The topology ofOATPIBl was predicted from the results of 16 topology 
prediction programs, including TMHMM and MEMSA T3, which were found in 
an independent comparison to be the most accurate (Moller et al., 2001). 
Results predicted a consensus of 12TMs, internal Nand C termini and no 
presence of a signal peptide sequence. A 12TM topology was therefore 
investigated, using FLAG epitope tags which were inserted into the predicted N 
and C termini plus extracellular/intracellular regions of the protein. The epitope 
was detected quantitatively using luminometry and qualitatively using 
immunofluorescence. Transport experiments were conducted to confirm that 
mutant proteins retained function. Results revealed that the Nand C termini (Fl 
and F13) were external, as well as predicted extracellular loop 2 (F4). F6 
demonstrated significant luminometry but this was not supported by the 
immunofluorescence experiments and transport was significantly reduced. The 
remaining internal and external tags disrupted the function of the protein. 
Therefore the topology predictions did not match the experimental data. 
The lack of transport function from epitope insertion may be owing to the 
importance of the loops in protein folding; as the role ofthe 
intracellular/extracellular loops is not fully understood. Alternatively, the 
epitopes may have been inserted into TM regions of the protein. Topology 
prediction programs do have limitations which can often result in inaccurate 
predictions. Hydrophobic residues present in the external loops can skew the 
TM prediction results (Zhou and Zhou, 2003) predicting them as internal. 
Furthermore, fixed hydrophobicity thresholds present in programs such as 
TopPred can result in one or more TMs being missed because they are too 
small (Sonnhammer et al., 1998). Also, TMs can span the membrane 
differently. For example, TMsl-3 in rabbit PepTl do not span the membrane in 
a direct fashion, but are longer and potentially tilted (Meredith and Price, 2006). 
These domains could not be accurately predicted, nor epitope tagged because of 
this (Covitz et al., 1998). 
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Predicted transmembrane proteins can also form re-entrant loops, whereby a 
TM enters the membrane and re-emerges on the same side (Viklund et al., 
2006). Approximately 10% of all transmembrane proteins are predicted to 
contain a re-entrant loop, some of which have been identified experimentally 
(Slotboom et ai., 1999). However when the OATPIBI protein sequence was 
analysed using the re-entrant loop prediction programs Octopus (Viklund and 
Elofsson, 2008), ZPred (Gran seth et al., 2006) and PSI-Pred (Nugent and Jones, 
2009), none identified a re-entrant loop (data not shown). However the 
accuracy ofre-entrant loop prediction can be as low as 44% (Nugent and Jones, 
2009). It may be that some of these structural characteristics are present in 
OA TP I B 1, resulting in inaccurate predictions. 
A new OATPIBI topological model has been generated based on the 
luminometry data and recent literature (figure 6.1). In this model, the F4 region 
(predicted extracellular loop 2), Nand C termini are extracellular, as directed 
by the significant luminometry results. For both Fl and F4 to be extracellular, 
the protein is only able to span the membrane once. Therefore it is proposed 
that TM2 may be a re-entrant loop. In addition, FlO is in the putative large 
extracellular loop between TM9-10. The large size of the loop combined with 
the experimental evidence for OA TP I B I N-glycosylation sites (Yao et al., 
20 12)and disulphide bonding in OA TP2B 1 (Hanggi et al., 2006) (discussed 
below) suggest that this loop may be external. For FlO and F13 to be external, 
Fll may also be a re-entrant loop. 
This model is supported by other structural studies conducted with OA TP I B 1 
which match the model below (figure 6.1). OATPIBI N-glycosylation sites 
have recently been identified as N134 in the extracellular loop between TM3-4 
and N503 and N516 in the extracellular loop between TM9-10 (Yao et ai., 
2012). This strongly supports the likelihood that these loops are extracellular, 
owing to the extracellular nature of these sites. The amino acids ofTMlre-
entrant loop 2 are highly conserved between different OA TP members and four 
amino acids: D70, F73, E74 and G76 were found to be important for E3S 
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transport (Li et al., 2012). Furthennore, surface expression was not reduced, 
suggesting that these residues playa functional rather than structural role, in 
accordance with being within a TM. These residues also fall within re-entrant 
loop 2 of the adapted model. The signature sequence predicted by the topology 
analysis here and previously as being between external loop 3ITM6 
(Hagenbuch, 2003) is also located at the externaVTM6 interface in the model. 
As discussed previously, homology modelling ofOATPIB3 on the MFS 
transporters has been perfonned (Meier-Abt et a/., 2005), which revealed a 
number of positive residues that were solvent exposed. Ofthese, R57 is 
conserved between OA TPI B I and OATPI B3 and mutating the residue reduced 
transport function (Weaver and Hagenbuch, 2010). The homology modelling 
however was perfonned on 12TM MFS proteins with internal Nand C tennini, 
thus was predicted to be within extracellular loop 2. In this model this loop 
cannot be external as the N tenninus is external, therefore it is intracellular. The 
equally conserved amino acids K361 and R580 predicted to be involved in 
substrate interactions also displayed reduced transport upon mutation (Weaver 
and Hagenbuch, 2010). In the model, these residues are in the positions as 
predicted by the homology modelling; extracellular between TM7-8 and within 
re-entrant loop 11 respectively. There is also evidence to suggest that TM lOis 
important for substrate binding, as shown by chimeric proteins made with 
OATPIB3 (Gui and Hagenbuch, 2009). The authors isolated four amino acids 
in TM I 0 that were critical for the transport of various OA TP I B I substrates; 
L545, F546, L550 and S554. These also are located in TMIO of the model 
below. 
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Figure 6.1- Adapted OATPIBI topology model based on luminometry results. Amino acid positions for the internal/externalloops are 
displayed with FLAG epitope locations (red). TM2 and TMll are displayed as re-entrant loops. Previously studied OATPIBI structural 
features are highlighted in orange. 
The structural features studied in other OA TPs were also mapped onto 
OATPIBI to evaluate their conservation and location within the new topology 
(figure 6.2). The large putative extracellular loop in OA TP2B I contains 10 
cysteine residues (C489-C557), all found to be disulphide bonded (Hanggi el 
of., 2006). When OA TP2B I was aligned with OA TP I B I using CLUST AL W2 
(Larkin et 01.,2007) (data not shown), 7 of these cysteine residues were 
conserved (C489, C493, C495, C504, C516, C520, C557). The OATPISI 
extracellular loop (429-535) also contains 10 cysteine residues and overlaps 
with that ofOATP2BI, suggesting that OATPISI also contains disulphide 
bonded cysteines in this region. This knowledge of OA TP2S I, combined with 
the presence of OATPI B I N-glycosylation sites strongly suggests that the large 
putative extracellular loop is external. 
Rat Oatp I a I contains 3 experimentally verified N-glycosylation sites (Lee el 
01.,2003; Wang el 01.,2008). Of these three Oatplal N-glycosylation sites, one 
is conserved in OATPIBI: N124. This is located within the extracellular loop 
between TM3-4, in the same location as OATPIS I NI34 (Yao el 01.,2012). 
The model presented here serves to amalgamate the experimental findings 
described in this thesis with the previously reported structural knowledge. It 
may be that models such as those described here can be used in the future to aid 
in silico drug design, whereby a novel compound could be modelled on a 
computational binding site, potentially reducing the cost and time of drug 
discovery. Furthermore, developments in structural knowledge will provide 
important insights for the locations of functionally relevant SNPs. It is hoped 
that this will summarise and speculate on the current findings and drive further 
research. 
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Figure 6.2 - Adapted OATPI B 1 topology model based on luminometry results. Amino acid positions for the intemaVextemalloops are 
displayed with FLAG epitope locations (red). TM2 and TMll are displayed as re-entrant loops. Conserved OATP structural features are 
highlighted in orange. 
The highly conserved signature sequence of OA TP 1 B 1 
(DSRWVGGAWWLNFL) was investigated by SOM of the most highly 
conserved or unusual residues: 0251E, R253K, W254F, W258/259F and 
N261A. Mutations were introduced to the previously validated OATPIBI-F4 
which contained an external epitope tag and retained transport function. N261 A 
was the only mutant to retain surface expression and transport kinetics. 025 J E, 
R253K, W254 and W258/259F surface expression and transport were reduced. 
The reduction in surface expression, combined with the intracellular staining 
observed from the immunofluorescence, suggests that the mutation caused the 
protein to be retained and/or not folded correctly in the membrane. These 
results, combined with the position of the signature sequence at the interface of 
the helix and TM, suggest that the sequence may have a role in stabilising the 
protein in the membrane. This is supported by the presence of an arginine and 
three tryptophan residues, amino acids which are known to anchor proteins via 
their charge, hydrogen bonding and/or stacking interactions. 
This study has highlighted the effectiveness of luminometry methods for 
detecting surface expression and confirming the extracellular nature of different 
regions of a protein. It also is a useful tool for detecting the change in surface 
expression following the introduction of a mutation. Combined with 
immunofluorescence and transport detection methods, this approach provides a 
comprehensive analysis of structure/function effects in membrane transporters. 
The structural knowledge of OATPs is required to understand how these 
transporters are targeted to and folded in the membrane, as well as how they 
bind and translocate compounds. This knowledge has great significance when 
attempting to understand how DOls and drug toxicities arise from the 
competitive binding and inhibitory interactions between transporters and 
enzymes. Furthermore, understanding which residues are key to substrate 
binding or protein functionality will help understand how genetic variability in 
specific populations may affect drug disposition by the OA TPs. This 
understanding is also transferrable to the knowledge of how OA TP transport is 
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affected by disease, which has a broad relevance to many types of liver disease 
such as hepatitis, as well as cancer pathogenesis. With the advent of more 
sophisticated in silica prediction methods and advanced molecular biology and 
crystallography techniques, further investigation is required to study the 
intimate structure/function relationship ofthe OA TPs. 
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7 Future perspectives 
The specific future directions of this project are briefly described below. These 
include the optimisation of the primary membrane vesicle study, further 
OATPIBI topology determination, additional characterisation of the OATPIBI 
signature sequence and structural features identified during the course of this 
study which require further analysis. 
The rat plasma membrane vesicle method requires further optimisation to 
determine whether it would be a reliable approach for investigating endogenous 
transport. The preliminary experiments described above suggest that some 
uptake by the vesicles was occurring. This would need to be confirmed by 
further experiments to determine the linear time frame for transport and the 
transport kinetics. Also, transport experiments would need to be performed with 
freshly prepared vesicles as well as frozen, to determine whether freeze thawing 
reduces transport capability. There is some evidence that freeze thawing 
produces more inside out rather than right side out vesicles (Palmgren et al., 
1990). The high background radioactivity observed at the zero timepoint may 
also be attributed to radioactivity being retained on the filter, and may be 
reduced by increased washing steps. 
The topology ofOATPIBl was confirmed to have external Nand C termini by 
luminometric methods; however the exact number ofTMs was not elucidated 
owing to the disruption to function upon insertion of the epitope tags. Further 
investigations of the topology are required, which could include inserting the 
epitope tags elsewhere within the protein. The immunofluorescence technique 
in this case could be improved by the addition of a membrane specific marker, 
such as E-cadherin (Luo et al., 2003), which would co-localise with the FLAG 
antibody in the membrane. This would clarify the membrane specific 
fluorescence. Other approaches could include cysteine scanning or N-
glycosylation scanning mutagenesis. 
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Cysteine scanning mutagenesis is a strategy by which amino acid residues are 
substituted for cysteine residues. Chemical modifications of the introduced 
cysteine residues can provide information about the accessibility of a particular 
residue to the extracellular space, thereby locating the boundaries of the TM 
(Karlin and Akabas, 1998). This approach has been employed previously with 
transport proteins including the ABC transporters (Blott et al., 1999). Scanning N-
gJycosylation employs a similar strategy, by introducing acceptor sites a minimum 
of 12-14 amino acids from the putative TMs (Cheung and Reithmeier, 2007). 
Therefore the TMs could be located by determining the limits to which 
extracellular regions can be glycosylated. 
The topology predictions ofOATPIA2, OATPIB3 and OATP2Bl require 
experimental verification, using the luminometry approach described for 
OATPIBI. OATPIA2 is particularly of interest, as it is predicted to contain 
between 7-9TMs, which is not in accordance with the predictions for the other 
OA TPs, nor with the notion that the OA TPs are related to the MFS. The 
topological analysis ofOATPIA2 and OATP2Bl would however be more 
difficult than for OATPIBl, owing to the presence of a putative N terminal 
signal peptide sequence (OATPIA2) and C terminal PDZ sequence (OATPIA2 
and OA TP2B 1), that would be cleaved or disrupted by the epitope. The results 
from these investigations would reveal whether all OA TPs maintain a similar 
topology and contain external Nand C termini. 
The SDM of the OATPIBI signature sequence revealed that the majority of the 
conserved residues are required for membrane targeting and/or protein 
anchoring. The remaining 7 residues in the sequence also require mutating to 
investigate their structure/function role, as they are also relatively conserved 
and likely to support the surrounding residues. This would in particular involve 
L263 which is a highly conserved amino acid at the end of the sequence. 
Leucine is an aliphatic, highly hydrophobic amino acid, possibly buried within 
a TM. Leucine could be substituted for valine or isoleucine, as both are also 
aliphatic hydrophobic amino acids (Barnes and Gray, 2003). In addition, more 
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investigation is required to determine the exact position of the signature region 
at the helixffM interface. Cysteine scanning mutagenesis could also be 
employed for this purpose, and is particularly applicable for the signature 
sequence as it potentially spans an extracellular loop and aTM. 
There are many further specific functional and structural OA TP 1 B 1 questions 
that still require answers, some of which have not been studied at all. These 
include the experimental identification and characterisation of the disulphide 
bonded cysteine residues in the large extracellular loop of OA TP 1 B I, which 
have already been studied in OATP2B I. Seven of these cysteine residues in 
OATP2BI are conserved in OATPIBI and likely to be also disulphide bonded. 
Furthermore, serine phosphorylation sites have been identified and studied in 
Oatplal but require identification and analysis in OATPIBI. The features 
described here are also applicable to characterisation in the other human 
OATPs. 
The understanding of these structural features may help answer many of the 
general questions asked of OA TPs. For example, what is the driving force for 
transport? There is currently conflicting evidence for the mechanism of 
transport and driving force. Electro-neutral exchange, bicarbonate, glutathione 
and pH have all been implicated. 00 the OA TPs function as multimers; i.e. do 
several monomer sub-units come together to form a complex required for 
function? Other transporters do function as multimers, such as the transporters 
PepTl and the human copper transport Ctrl (Guo et al., 2004; Panitsas et al., 
2006). What is the exact 30 structure for OA TPs and how do they bind to 
substrates in the membrane? Further mutagenesis and advances in 
crystallography are required to answer this question. Furthermore, there are 
many questions to be answered as to how OATPs are regulated, such as why 
some OA TPs contain signal sequences whereas others do not. 
These structural features are all required to determine how substrates are bound 
and translocated, and in tum how this causes disease and harmful ODIs. ODIs 
are caused by a complex collection of interactions, including interactions with 
the CYPs and ABCs, as well as genetic variation and inhibition. Therefore a 
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wealth of transporter knowledge is required to uncover these complex 
mechanisms. The above mentioned strategies will advance this knowledge for 
this influential family of multi specific OA TP transporter proteins. 
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Appendix I: Summary of OA TPIA2 amino acid TM predictions by 16 topology prediction programs 
Name Length TMI TM2 TM3 TM4 TM5 TM6 TM7 TM8 
ofTM 
ConPredll 21 36-56 65-85 134-154 179-199 226-246 292-312 335-355 370-390 
(Arai et aL, 
20041 
SO SUI 22-23 1-23 35-57 64-86 130-152 178-200 226-248 297-319 336-357 
(Hirokawa et 
aL,1998) 
TopPredII 20 1-21 43-63 66-86 181-201 226-246 296-316 334-354 370-390 
(von Heijne, 
1992) 
TMpred 18-29 2-20 40-61 67-85 136-164 182-202 223-240 297-316 334-357 
(Hofman and 
Stoffel, 1993) 
TMHMM 23 35-57 67-89 174-196 224-246 297-319 334-356 368-390 -
(Krogh et aL, 
2001) 
TSeg 22-27 37-60 63-87 177-203 224-249 291-317 333-358 370-391 -
(Kihara et aL, 
19981 
MemBrain 13-56 6-21 45-59 68-87 136-148 175-199 224-245 291-319 333-356 
(Shen and 
..£hou, 2008) 
TM9 TMI0 TMll TM12 
- - - -
368-390 - - -
- - - -
362-388 - - -
I 
- - - -
- - - -
366-389 - - -
N 
U1 
........ 
PHDhtm 
(Rost et al, 
1996) 
Split 4.0 
(Juretie et al, 
2002) 
Phobius 
(Kall et al, 
20041 
Philius 
(Reynolds et 
al., 2008) 
HMMTOP 
(Tusnady and 
Simon, 2001 b) 
TOPCONS 
(Bernsel et al, 
2009) 
PRED-TMR 
(Pasquier et 
al,1999) 
MEMSAT3 
(Jones, 2007) 
SVMtm 
(Yuan etal, 
2004) 
2-29 
15-26 
18-27 
19-23 
20-23 
20 
18-22 
16-23 
14-21 
11-12 42-61 69-88 138-151 175-201 
45-60 65-88 133-149 176-200 223-246 
40-60 67-85 137-163 175-202 222-246 
36-58 66-85 176-198 223-246 297-318 
37-60 67-90 138-161 174-197 224-247 
3-23 39-59 69-89 140-160 175-195 
37-56 67-85 182-202 225-246 297-316 
37-59 66-82 174-196 225-246 297-319 
44-58 68-82 136-150 178-197 224-245 
223-245 291-319 336-358 367-390 - - -
293-319 334-359 368-391 - - - -
297-319 334-356 368-388 - - - -
334-356 369-389 - - - - -
285-307 334-357 370-390 - - - -
222-242 297-317 336-356 370-390 - - -
335-356 370-388 - - - - -
334-357 367-388 - - - - -
297-313 336-356 373-387 - - - -
N 
t.n 
ex) 
Appendix II: Summary of OATP IB3 amino acid TM predictions by 16 topology prediction programs 
Name Length TMI TM2 TM3 TM4 TMS TM6 TM7 TM8 
ofTM 
ConPredII 21 29-49 68-88 96-116 211-231 258-278 332-352 375-395 408-428 
(Arai et aL, 
2004) 
SOSUI 23 29-51 210- 256- 337-359 374-396 406-428 536-558 574-596 
(Hirokawa et 232 278 
a1.,1998) 
TopPredII 20 28-48 71-91 96-116 135-155 211-231 259-279 337-357 376-396 
(von Heijne, 
1992) 
TMpred 20-27 24-44 68-88 96-121 170-196 215-234 256-280 340-360 376-397 
(Hofman and 
Stoffel, 1993) 
TMHMM 23 30-52 67-89 96-118 208-230 255-277 332-354 375-397 407-429 
(Krogh et aL, 
2001) 
TSeg 22-29 28-52 65-89 95-116 210-236 257-281 331-358 373-397 406-431 
(Kihara et 
al,1998) 
MemBrain 13-29 28-49 73-87 96-115 169-181 208-232 257-278 331-359 373-396 
(Shen and 
Chou, 2008) 
PHDhtm 14-24 31-45 74-88 98-112 211-233 258-277 332-356 378-397 409-428 
(Rost et al, 
19961 
TM9 TMI0 TMll TM12 
534-554 575-595 625-645 -
624-646 - - -
410-430 542-562 576-596 627- I 
647 
411-430 534-560 570-595 624-
647 
534-556 576-595 624-646 -
532-558 574-598 522-650 -
406-429 533-558 572-595 623-
646 
536-559 577-594 628-646 -
N 
V1 
\,() 
lit 4.0 
(Juretic et 
61.,2002) 
Phobius 
(Kall et 6/., 
2004) 
Philius 
(Reynolds et 
al.,2008) 
HMMTOP 
(Tusnady 
and Simon, 
2001b) 
TOPCONS 
(Dernsel et 
al.,2009) 
PRED-TMR 
(Pasquier et 
a/.,1999) 
MEMSATJ 
(Jones, 2007) 
SVMtm 
(Yuan et aI., 
2004) 
14-29 28-57 
19-28 29-52 
19-24 27-48 
19-24 29-52 
20 27-47 
17-22 29-48 
17-24 29-48 
14-25 29-48 
73-87 94-114 168-183 
64-84 96-117 170-195 
66-87 96-118 177-196 
65-87 96-118 170-194 
68-88 97-117 173-193 
99-120 214- 254-271 
231 
96-120 207- 258-279 
231 
72-86 98-113 210-231 
207-232 253-277 334-358 374-395 403-429 533-548 566-595 619-
646 
207-235 255-279 337-356 376-397 404-425 534-558 570-591 624-
647 
207-231 257-279 337-359 376-397 405-426 538-560 576-595 625-
647 
207-230 257-279 324-347 374-397 410-429 534-558 571-595 626-
645 
208-228 259-279 336-356 376-396 410-430 540-560 573-593 625-
645 
339-360 376-397 402-421 534-556 577-595 624-645 - -
, 
337-360 376-397 404-426 534-558 578-595 624-647 - -
258-275 336-356 376-397 406-426 535-558 572-592 621-646 -
N 
0\ o 
Appendix III: Summary ofOATP2Bl amino acid TM predictions by 16 topology prediction programs 
Name Length TMI TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9 
ofTM 
ConPredII 21 47-67 90-1I0 117-137 187-207 226-246 276-296 371- 410- 442-
(Arai etaL, 391 430 462 
2004) 
SOSUI 23 44-66 117- 189-211 226-248 275-297 375-397 409- 441- -
(Hirokawa 139 431 463 
et aL, 1998) 
TopPredIl 21 49-69 88-108 1I7-137 156-176 186-206 225-245 272- 371- 411-
(von Heijne, 292 391 431 
1992) 
TMpred 16-27 50-68 91-112 117-138 188-214 225-244 277-298 371- 411- 441-
(Hofman 390 432 466 
and Stoffel, 
1993) 
TMHMM 23 88- 117- 192-214 227-249 275-297 372-394 409- 443- 565-
(Krogh et 110 139 431 465 587 
al., 2001) 
TSeg 21-32 48-68 118- 185-208 224-250 275-299 365-394 406- 438- 554-
(Kihara et 140 435 469 584 
aL,1998) 
MemBrain 14-29 48-69 94-108 117-136 186-199 226-250 276-296 366- 408- 440-
(Shen and 394 431 464 
Chou, 2008) 
PHDhtm 8-24 50-66 96-109 119-133 191-199 229-249 277-295 368- 412- 445-
(Rost et al., 392 431 463 
1996) 
- - ---
TMIO TMII TM12 TM13 
562- 595- 654- -
582 615 674 
- - - -
445- 559- 596- 653-
465 579 616 673 
562- 597- 656- -
578 622 672 
600- 651- - -
622 673 
653- - - -
676 
560- 599- 649- -
585 622 672 
561- 603- 655- -
585 621 671 
N 
0'1 .... 
lit 4.0 
(Juretie et 
al,2002) 
Phobius 
(Kall etaL, 
2004) 
Philius 
(Reynolds et 
al.,2008) 
HMMTOP 
(Tusnady 
and Simon, 
2001b) 
TOPCONS 
(Bernsel et 
al.,2009) 
PRED-TMR 
(Pasquier et 
al,1999) 
MEMSATJ 
(Jones, 
2007) 
SVMtm 
(Yuan et aL, 
2004) 
22-36 
19-28 
18-24 
17-24 
20 
17-22 
16-23 
14-24 
49-71 119-
142 
50-69 89-110 
51-69 89-108 
50-69 86-108 
48-68 89-109 
117- 188-
134 206 
50-69 88-108 
50-64 94-108 
185-212 223-250 272-297 370-395 399-
430 
117-138 188-213 225-253 273-297 372-
394 
117-138 188-211 225-249 275-297 372-
394 
117-134 188-212 225-248 275-298 371-
394 
117-137 186-206 225-245 276-296 372-
392 
229-249 272-292 372-394 411-432 445-
463 
117-134 186-206 225-249 276-297 372-
394 
119-133 187-201 226-248 276-294 371-
391 
438- 555- 593- 648- - -
471 591 628 675 
406- 444- 560- 608- 651- -
432 464 587 631 673 
408- 440- 560- 598- 652- -
432 463 583 622 673 
411- 441- 564- 596- 651- -
432 463 587 620 673 
411- 443- 560- 598- 653- -
431 463 580 618 673 
566- 597- 651- - - -
587 617 673 
411- 440- 564- 596- 651- -
432 463 587 612 673 
408- 442- 560- 601- 657- -
431 466 574 615 671 
N 
0\ 
N 
Appendix IV - Table of predicted Nand C terminal orientation for OATP IA2, OA TP 1 B3 and OA TP2B 1 
OATP1A2 OATP1B3 
Name of program Number of N terminal Number of N terminal 
TMs position TMs Position 
ConPredII JArai et al., 2004) 8 Internal 11 Internal 
SOSUI J!!irokawa et al., 1998) 9 External 9 External 
TopPredII (von Heijne, 1992) 8 External 12 Internal 
TMpred (Hofman and Stoffel, 1993) 9 Internal 12 Internal 
TMHMM (Kro~h et al., 2001) 7 Internal 11 Internal 
TSe~ (Kihara et al., 1998) 7 Not predicted 11 Not predicted 
MemBrain (Shen and Chou, 2008) 9 Not predicted 12 Not predicted 
PHDhtm (Rost et al., 1996) 9 Not predicted 11 Not predicted 
Split 4.0 (Juretic et al., 2002) 8 External 12 Internal 
Phobius (Kall et al., 2004) 8 External 12 Internal 
Philius (Reynolds et al., 2008) 7 Internal 12 Internal 
HMMTOP (Tusnady and Simon, 8 External 12 Internal 
2001b) 
TOPCONS (Bernsel et al., 2009) 9 Internal 12 Internal 
PRED-TMR (Pasquier et aL, 1999) 7 Not predicted 10 Not predicted 
MEMSAT3 (Jones, 2007) 7 Internal 11 External 
SVMtm (Yuan et al., 2004) 8 Not predicted 11 Not predicted 
OATP2B1 
Number of N terminal 
TMs Position 
12 Internal 
8 External 
13 Internal 
12 Internal 
11 External 
10 Not predicted 
12 Not predicted 
12 Not predicted 
11 External 
12 Internal 
12 Internal 
12 Internal 
12 Internal 
10 Not predicted 
12 Internal 
12 Not predicted 
N 
0\ 
W 
Appendix V - Table of signal peptide and cleavage position predictions for OATPIA2, OATPIB3 and OATP2Bl 
OATPIA2 OATPIB3 OATP2Bl 
• 
Program Signal Cleavage Signal Cleavage Signal Cleavage I 
peptide . position ~eptide position peptide position 
iPSORT (Bannai et al., 2002) No - No - No -
Phobius (Kall et al., 2004) Yes 16 Yes 44 No -
PrediSi (Hiller et al., 2004) Yes 16 Yes 351 No -
PSORT II (Nakai and Horton, 1999) No - No - No -
Si2c1eave (von Heijne, 1986) Yes 16 No - Yes 384 
Si2naiP 4.0 (petersen et aL, 2011) Yes 16 Yes 43 No -
SIG-Pred (Bradford, 2001) Yes 16 No - No -
SOSUIsignal (Gomi et al., 2004) Yes 16 No - No -
~fl.,ipJfariselli et al., 2003) Yes 16 No - No -
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